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General introduction 
 
 
 
1.1 Cardiovascular disease and atherosclerosis 
 
The primary cause of death in the Western world involves cardiovascular 
diseases (CVD) such as ischemic (coronary) heart disease, angina 
pectoris, and myocardial and cerebral infarction. In the Netherlands, CVD is 
the major cause of death accounting for 34% of the mortality rate [1]. The 
most important cause of CVD and thus death is the phenomenon called 
atherosclerosis, narrowing of the arteries as a result of arterial lipid 
deposition. 
Atherosclerosis is a progressive disease, characterized by the accumulation 
of lipids and fibrous elements (atherosclerotic plaque) in the arteries as a 
result of altered gene expression in the endothelium of the artery. 
Epidemiological studies have revealed numerous environmental and 
genetic risk factors for the initiation of atherosclerosis. These include 
smoking, consuming a high fat diet, low blood antioxidant levels, elevated 
blood pressure, diabetes, systemic inflammation, male gender, family 
history, and elevated blood lipid levels [2]. Upon local alteration of the 
endothelium, the expression of surface adhesion molecules and cytokines 
is induced, resulting in an increased adherence and subsequent migration 
of mononuclear cells (e.g. monocytes and lymphocytes) into the 
subendothelial space, where they then differentiate into macrophages and 
take up (modified) lipoproteins, forming foam cells (fatty streak) [3,4]. 
Subsequently, smooth muscle cells start to proliferate and migrate to form a 
fibrotic cap, consisting of extracellular matrix, collagen, and proteoglycans, 
that covers the lipid or necrotic core that is formed by excessive 
macrophage cell death (advanced fibrous lesion) [5]. A uniformly thick 
fibrous cap provides stability to the plaque resulting in a stable plaque. 
However, a thin and nonuniform cap may lead to instability of the plaque 
and rupture of the plaque, resulting in secondary hemorrhage and 
thrombosis, and possibly occlusion of the artery (complicated lesion) [6,7]. 
 
 
1.2 Lipoproteins and atherosclerosis 
 
Cholesterol is an important molecule for eukaryotic organisms, since it 
modulates membrane fluidity and is essential for steroid hormones 
synthesis. In mammals, a complex system regulates biosynthesis and 
transport of cholesterol between cells in the body. Cholesterol is 
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transported through the blood circulation by lipoproteins. Lipoproteins are 
water-soluble protein-lipid complexes, which consist of a hydrophobic core, 
containing triglycerides and cholesterol esters, and a hydrophilic 
monolayered shell, composed of phospholipids, free cholesterol, and 
specific proteins (apolipoproteins). Several different lipoproteins can be 
distinguished based upon their lipid and apolipoprotein composition, 
electrophoretic mobility, and size (Table 1) [8]. 
In more detail, chylomicrons, very low-density lipoprotein (VLDL), and low-
density liprotein (LDL) have apolipoprotein B (ApoB) as their primary 
protein, whilst apolipoprotein A-I (ApoA-I) is the major protein constituent of 
the high-density lipoprotein (HDL). Chylomicrons and VLDL are triglyceride-
rich lipoproteins, whilst LDL and HDL contain relatively high levels of 
cholesterol esters and phospholipids, respectively. Furthermore, the size of 
the different lipoproteins is inversely correlated to their density, with VLDL 
being the biggest lipoprotein and HDL the smallest lipoprotein. 
 
 
Table 1 
Physical properties and composition of human plasma lipoproteins 
 Chylomicrons VLDL LDL HDL 
Diameter (nm) 75-1200 30-80 19-25 5-12 
Density (g/ml) <0.96 0.96-1.006 1.019-1.063 1.063-1.210 
Mw (X 106 Da) 400 10-80 2.3 0.17-0.36 
Mobility1 origin Pre-β β α 
     
Lipid composition2     
Triglyceride 80-95 45-65 18-22 2-7 
Free cholesterol 1-3 4-8 6-8 3-5 
Cholesterol ester 2-4 6-22 45-50 5-20 
Phospholipid 3-6 5-20 18-24 26-32 
     
Apolipoproteins A-I, A-II, A-IV - - A-I, A-II, A-IV 
 B48 B100 B100 - 
 C-I, C-II, C-III C-I, C-II, C-III - C-I, C-II, C-III 
 E E - E 
1According to the electrophoretic mobility of plasma α- and β-globulins on agarose gel electrophoresis 
2The values given for composition are expressed as percentage of total weight 
 
 
Importantly, multiple studies have indicated a strong correlation between 
serum levels of the different lipoproteins and the incidence of 
atherosclerosis and cardiovascular diseases. In fasting participants with 
normal triglyceride levels (<4.52 mmol/L), a 1.03 mmol/L higher baseline 
total non-HDL or LDL cholesterol was associated with a 30% to 35% higher 
cardiovascular heart disease event rate [9]. Data from the Lipid Research 
Clinics Program Follow-up Study, a mortality study, have shown that the 
non-HDL cholesterol level is a good predictor of cardiovascular disease 
mortality [10]. Furthermore, in a 15.5-year prospective study the non-fasting 
serum triglyceride level predicted the incidence of coronary heart disease 
among Japanese men and women who possessed low mean values of total 
cholesterol [11]. These combined findings suggest a strong positive 
correlation between a high level of (small) ApoB-containing lipoproteins and 
the risk for cardiovascular diseases. In contrast, Miller et al. have observed 
a lower HDL level in subjects with existing clinical ischemic heart disease 
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9 
than in healthy subjects in the same population [12]. Several studies have 
indicated that there consists a strong negative correlation between serum 
HDL cholesterol levels and the risk for cardiovascular diseases. In 
accordance, a rise in HDL cholesterol levels leads to a reduction in the CVD 
risk at all plasma total cholesterol levels (Fig.1) [13]. 
 
Fig.1. Incidence of cardiovascular heart disease per 1000 subjects over a 6-year period according to 
total cholesterol and HDL cholesterol levels. 
 
 
 
1.3 Lipoprotein metabolism 
 
 
1.3.1 Chylomicron metabolism 
 
Dietary triglycerides and cholesterol esters that are hydrolysed in the 
intestine by pancreatic lipase and cholesteryl esterase, respectively, are 
absorbed by the intestinal epithelium and subsequently repackaged into 
chylomicrons. Lipid absorption is a complex process which involves 
coordinated gastric, intestinal, biliary and pancreatic function [14]. Nascent 
triglyceride-rich chylomicrons contain ApoB48, ApoA-I, and ApoA-IV as its 
primary aplipoproteins and are secreted into the lymph. Once secreted into 
the blood circulation, the chylomicrons loose ApoA-I and partly ApoA-IV, 
and acquire ApoC-I, ApoC-II, ApoC-III, and ApoE. In the circulation 
lipoprotein lipase (LPL) hydrolyses the triglycerides in the chylomicron core 
[15], which is accompanied by the transfer of phospholipids by phospholipid 
transfer protein and apolipoproteins to HDL [16]. This results in the 
formation of smaller triglyceride-depleted cholesterol ester-rich chylomicron 
remnants, which are rapidly cleared from the circulation by the liver. In the 
past, Mahley et al. have shown that initial rapid clearance by the liver 
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begins with sequestration of the remnants within the space of Disse, where 
apolipoprotein E secreted by hepatocytes enhances remnant binding and 
uptake. Heparan sulfate proteoglycans (HSPG), which are also abundant in 
the space of Disse, mediate this enhanced binding. Next, the remnants 
undergo further processing in the space of Disse by hepatic and lipoprotein 
lipases, which may also serve as ligands mediating remnant uptake. The 
final step, endocytosis by the hepatocytes, appears to be mediated, at least 
in part, by the LDL receptor and by the LDL receptor-related protein (LRP1). 
In addition, cell-surface HSPG are suggested to play a critical role in 
remnant uptake, not only in the important initial sequestration or capture 
step in the space of Disse, but also as an essential or integral component of 
the HSPG-LRP1 pathway (reviewed by Mahley and Ji [17]). Recently, Out 
et al. have shown that scavenger receptor class B type I (SR-BI) on liver 
parenchymal cells predominantly mediates the hepatic association of 
chylomicron remnants, since the association of chylomicron remants is 
>70% reduced in SR-BI deficient mice as compared to controls [18]. 
Subsequently, several recognition sites for ApoE, such as the LDL receptor 
and the LDL receptor-related protein (LRP1) that are present on the 
parenchymal cells mediate the whole particle uptake/internalization of the 
chylomicron remnants. However, the exact mechanism of the interaction 
between the primary association of chylomicron remnants by SR-BI and the 
subsequent secondary uptake via the ApoE-mediated LDL receptor/LRP1 
process is still under investigation. 
 
 
1.3.2 VLDL and LDL metabolism 
 
VLDL is produced in the liver from cholesterol and triglycerides derived from 
de novo synthesis or lipoprotein uptake [19,20]. Human nascent VLDL 
contains a single copy of ApoB100 as well as newly synthesized ApoE and 
ApoC’s. Upon its secretion into the circulation triglyceride-rich VLDL 
particles, like chylomicrons, acquire additional ApoE and ApoC. The 
triglycerides in the core of VLDL are subject to lipolysis by LPL [21], 
resulting in the formation of VLDL remnants, which can in part be cleared 
via the same mechanism as proposed for chylomicron remnants. The part 
of the VLDL remnants that is not cleared via the LDL receptor/LRP1 
pathway can be further processed and converted into LDL. LDL only 
contains the apolipoprotein ApoB100, which serves specifically as a ligand 
for recognition by the LDL receptor. Importantly, a fraction of the LDL 
formed is not taken up by liver but is used as a source of cholesterol for the 
synthesis of membranes and steroids in cells of steroidogenic tissues. 
Moreover, a fraction of the LDL becomes modified in the circulation and is 
subsequently removed via uptake by macrophage scavenger receptors 
(reviewed by Van Berkel et al [22]). 
 
1.3.3. HDL metabolism 
 
HDL is produced primarily by the liver through an interaction of lipid-poor 
ApoA-I with the ATP-binding cassette transporter A1 (ABCA1), which 
mediates lipidation of ApoA-I, resulting in the formation nascent pre-β HDL 
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particles [23]. The nascent HDL particles subsequently take up free 
cholesterol from peripheral cells via an ABC mediated efflux system, which 
are converted to cholesterol esters by lecithin:cholesteryl acyltransferase 
(LCAT), leading to the formation of small spherical HDL3. HDL3 is 
subsequently converted into large α-migrating mature HDL2 by acquirement 
of phospholipids and apolipoproteins that are released during lipolysis of 
triglycerides in chylomicrons or VLDL. The mature circulating HDL is then 
transported back to the liver, where it is bound to SR-BI with high affinity. 
Upon binding, SR-BI mediates the uptake of cholesterol esters into the liver 
without internalisation and degradation of the HDL particle (selective 
cholesterol ester uptake) [24]. The complete process of peripheral 
cholesterol efflux to HDL and subsequent transport and uptake of HDL 
cholesterol esters by the liver is called reverse cholesterol transport [25,26] 
and is considered to be a very important anti-atherogenic system in the 
body. A second route of hepatic HDL cholesterol clearance is through the 
enrichment of HDL with ApoE by either extrahepatic tissues or in the 
circulation and the subsequent whole particle uptake via the LDL 
receptor/LRP1 uptake system [27]. The third route of HDL cholesterol 
delivery to the liver is via the transfer of cholesterol esters from HDL to 
VLDL and LDL by cholesteryl ester transfer protein (CETP) [28] and 
subsequent hepatic uptake of these lipoproteins as described earlier. 
Importantly, rodents do not express CETP, which excludes this pathway for 
HDL cholesterol removal in these animals. 
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Fig.2. Schematic representation of the pathways involved in human lipoprotein metabolism. 
Chapter 1 
 
 
12 
1.4 Hepatic lipid metabolism 
 
The liver plays an essential role in the removal of lipid from the blood 
circulation by mediating the uptake of lipoproteins [29,30]. Subsequently, 
cholesterol can be secreted into the bile or converted to bile acids coupled 
to excretion into the bile [31,32]. The liver primarily aims to control its intra-
hepatic cholesterol homeostasis, by maintaining an appropriate balance 
between the regulatory free cholesterol and the more inert cholesterol ester 
pool. Several key processes are involved in the intra-hepatic cholesterol 
balance. These include: 1) the uptake free and esterified cholesterol from 
the lipoproteins, VLDL, LDL, and HDL, and 2) the de novo synthesis of free 
cholesterol from acetyl-CoA, which induce an increase in the intra-hepatic 
free cholesterol level, and 3) the esterification of free cholesterol for storage 
in the inert cholesterol ester pool, 4) the efflux of cholesterol to ApoA-I for 
the production of nascent HDL, 5) the catabolism of cholesterol to bile acids 
for excretion into the bile, and 6) the direct biliary efflux of free cholesterol 
(Fig.3). Importantly, each process is mediated through a complex 
interaction between different proteins, which all have their specific role in 
the process. 
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Fig.3. Pathways involved in the maintenance of the intra-hepatic cholesterol balance. 
C = free cholesterol; BA = bile acids. 
 
General introduction 
 
 
13 
1.4.1 Genes involved in increasing the hepatic free cholesterol level 
 
Hepatic uptake of cholesterol from lipoproteins via the LDL receptor, the 
LDL receptor-related protein, and scavenger receptor BI is an important 
mechanism via which the liver can increase its intra-hepatic cholesterol 
level. In addition, de novo synthesis of cholesterol via the action of the 
enzyme HMG-CoA reductase is a second important mechanism through 
which the liver is able to increase its intra-hepatic cholesterol level. 
 
 
1.4.1.1 Low-density lipoprotein receptor (LDL receptor) 
 
The LDL receptor is the prototype lipoprotein receptor of the LDL receptor 
family, which is highly expressed in tissues that utilize lipoproteins, such as 
the liver and adrenals [33]. The mature LDL receptor protein is a 160 kDa 
protein, which is formed in the Golgi from the 120 kDa LDL receptor 
precursor protein synthesized in the endoplasmatic reticulum [30]. At a 
cellular level, hepatic LDL receptors are confined to the basolateral 
(sinusoidal) surface of the parenchymal liver cells on microvilli and not to 
the apical (bile canalicular) surface [34]. Upon expression on the cell 
surface, the LDL receptor binds cholesterol-rich lipoproteins that contain 
ApoB and/or ApoE and mediates their endocytic uptake [35]. Particles 
internalised via the LDL receptor are subject to lysosomal degradation in 
which the apolipoproteins are broken down into amino acids while the lipids 
are released from the lysosomes into the cytosol. The uptake of lipoproteins 
by the LDL receptor serves a dual role in lipid metabolism. It delivers 
essential lipids required for the maintenance of cellular functions, and it 
regulates the concentration of cholesterol-rich lipoproteins in the blood. The 
importance of the latter function is underscored by pathological 
abnormalities observed in patients with LDL receptor gene defects. These 
patients suffer from a syndrome called familial hypercholesterolemia (FH), 
which is associated with increased serum cholesterol levels and premature 
atherosclerosis and coronary heart disease [36,37]. 
 
 
1.4.1.2 Low-density lipoprotein receptor-related protein (LRP1) 
 
LRP1 (a.k.a. α2-macroglobulin receptor) is a largely conserved high 
molecular weight (Mw=600 kDa) multifunctional receptor of the LDL 
receptor family that is expressed in many different tissues and on numerous 
cell types, such as fibroblasts, smooth muscle cells, 
monocytes/macrophages, and in particular in liver parenchymal cells [38-
40]. LRP1 is a heterodimer composed of a 515 kDa extracellular and an 85 
kDa membrane-anchored subunit [41]. Both subunits are generated by 
proteolytic cleavage from a 600 kDa precursor and remain non-covalently 
associated to form the mature receptor on the cell surface. Like the LDL 
receptor, LRP1 is confined to the basolateral surface of the parenchymal 
liver cells and not to the apical surface. LRP1 has diverse biological roles, 
since it is able to recognize numerous ligands, including ApoE-enriched 
remnant lipoproteins, LPL, α2-macroglobulin-protease complexes, 
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plasminogen activator-inhibitor complexes, and tissue-type plasminogen 
activator [42,43]. Evidence that LRP1 is involved in the in vivo clearance of 
ApoE-containing lipoprotein remnants came from studies using transgenic 
mice deficient for LRP1 or receptor-associated protein (RAP), a chaperone 
protein and a strong inhibitor of ligand binding to LRP1 [44,45]. 
Furthermore, these studies demonstrated that in vivo chylomicron remnant 
uptake proceeds by a dual hepatic lipoprotein receptor system consisting of 
the LDL receptor and LRP1. Either receptor is able to assure virtually 
normal chylomicron remnant clearance when the other receptor pathway is 
defective. Furthermore, in dual receptor deficient mice (LDL receptor/LRP1 
double knockout mice) the initial capture of chylomicron remnants by the 
liver is not affected. 
 
 
1.4.1.3 Scavenger receptor class B type I (SR-BI) 
 
SR-BI (a.k.a CD36 and lysosomal integral membrane protein-II analogous-1 
[CLA-1]) is expressed in many tissues and cell types, including brain, lung, 
intestine, placenta, smooth muscle cells, macrophages, and endothelial 
cells. However, its highest expression has been detected in tissues that 
need cholesterol for bile acid (liver) and steroid hormone (adrenals) 
synthesis [46-50]. SR-BI is an 82 kDa cell surface membrane protein that 
consists of a heavily N-linked glycosylated and fatty acylated protein 
backbone, containing a large extracellular loop, two transmembrane 
domains, and short cytoplasmic N-terminal and C-terminal domains [51]. 
Under normal conditions, SR-BI in the liver is predominantly expressed on 
the sinusoidal membrane of parenchymal cells. However, SR-BI protein 
expression has also been detected in liver endothelial and Kupffer cells 
(tissue macrophages) [52], and on the canalicular membrane of 
parenchymal cells [53]. SR-BI in the plasma membrane has been 
suggested to facilitate lipid transport, since SR-BI it able to mediate the 
selective uptake of cholesterol esters from HDL, the process in which 
cholesterol esters from the HDL core are taken up without the endocytic 
uptake and degradation of the HDL particle/protein. Direct evidence for a 
role of SR-BI in the selective uptake was obtained from studies using 
genetically manipulated mice. Mice deficient in SR-BI accumulated 
cholesterol-rich HDL particles that are heterogenous in size and are 
enriched with ApoE, resulting from a hampered cholesterol ester uptake. In 
addition, these mice have a decreased hepatic biliary cholesterol secretion 
rate and their adrenal glands are depleted of cholesterol [54,55]. Moreover, 
on a Western type diet SR-BI deficient mice have an increased 
susceptibility to atherosclerosis as compared to their wild-type littermates 
[56], suggesting that the SR-BI mediated selective uptake of cholesterol 
esters from HDL is an essential atheroprotective process. 
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1.4.1.4 HMG-CoA reductase 
 
In addition to the uptake of cholesterol from lipoproteins, the liver can also 
increase its intra-hepatic cholesterol level via de novo synthesis of 
cholesterol from acetyl coenzyme A (acetyl-CoA). The biosynthesis of 
cholesterol (C27) from acetyl-CoA involves the formation of several carbon 
intermediates, including 3-hydroxy-3-methyl-glutaryl CoA (HMG-CoA; C6), 
mevalonate (C6), isopentenyl phosphate (C5), and squalene (C30). The rate-
limiting step in cholesterol biosynthesis is the formation of mevalonate from 
HMG-CoA by the cytosolic enzyme HMG-CoA reductase. HMG-CoA 
reductase is therefore considered to be the key rate-limiting enzyme in 
cholesterol biosynthesis. HMG-CoA reductase is a 97 kDa endoplasmatic 
reticulum glycoprotein, anchored 7-fold in this membrane.  Expression of 
HMG-CoA reductase has been detected in many organs where cholesterol 
is being synthesized, such as the intestine [57]. However, the major site for 
cholesterol biosynthesis in mammals is the liver. Importantly, the expression 
and activity of HMG-CoA reductase is rapidly reduced by sterols and 
metabolites derived from mevalonate (negative feedback pathway) [58]. 
Furthermore, the essential role of HMG-CoA reductase in cholesterol 
biosynthesis has been evaluated using specific HMG-CoA reductase 
inhibitors. Treatment of both rats and mice with these inhibitors resulted in a 
>90% decrease in hepatic sterol synthesis, suggesting an essential role for 
HMG-CoA reductase in hepatic cholesterol biosynthesis [59,60]. Since 
inhibition of HMG-CoA reductase activity significantly affects cholesterol 
biosynthesis rates, specific inhibitors of HMG-CoA reductase have been 
developed for the primary treatment of dyslipidemia and atherosclerosis. 
The most potent inhibitors are the statins, which in multiple studies have 
proven to be effective in lowering serum total and LDL cholesterol (up to 
40%) and triglycerides [61], thereby considerably reducing the risk for and 
incidence of atherosclerosis and thus CVD death. 
 
 
1.4.2 Genes involved in decreasing the hepatic free cholesterol level 
 
The esterification of free cholesterol to cholesterol esters, the conversion of 
cholesterol to bile acids and the direct efflux of cholesterol to the serum or 
bile are important mechanism via which the liver can decrease its intra-
hepatic cholesterol level. Several proteins involved in these processes have 
been identified. These include acyl-CoA:cholesterol acyltransferases, 
cholesterol 7α-hydroxylase, ATP-binding cassette transporter (ABC) A1, 
ABCG5, and ABCG8. 
 
 
1.4.2.1 Acyl-CoA:cholesterol acyltransferase (ACAT) 
 
The ACAT gene family consists of several enzymes involved in cholesterol 
ester synthesis. ACAT1 and ACAT2 function intracellularly to convert free 
cholesterol to cholesterol esters using an acyl coenzyme A (acyl-CoA) 
substrate. The tissue distribution of ACAT1 and ACAT2 is quite different, 
with ACAT2 being confined to sites of lipoprotein particle secretion in liver 
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hepatocytes and mucosal cells in the intestine, whereas ACAT1 is present 
in most tissues, with a relatively high expression in cells and tissues that 
store cholesterol esters in cytoplasmic lipid droplets such as macrophages 
of hyperlipidemics and adrenal cortical cells [62,63]. Both ACAT1 and 
ACAT2 are membrane-bound enzymes, which have multiple 
transmembrane domains, with the N-terminus of the enzyme residing in the 
cytosol and the C-terminus of the enzyme being situated in the ER lumen 
[64]. The structures and topology of ACAT1 and ACAT2 are still quite 
different (only about 60% similar in regions of the putative transmembrane 
domains), indicating that functional differences between the enzymes might 
be caused by differences in structure/topology. The important role for 
ACAT1 and ACAT2 in cholesterol ester synthesis has become evident from 
specific knockout animals. ACAT2 deficiency results in a reduction in 
cholesterol ester synthesis in the small intestine and liver, which in turn 
limits intestinal cholesterol absorption, hepatic cholesterol gallstone 
formation, and the accumulation of cholesterol esters in the plasma 
lipoproteins [65]. Total ACAT1 deficiency in LDL receptor deficient mice led 
to marked alteration in cholesterol homeostasis and extensive deposition of 
unesterified cholesterol in the skin and brain [66,67]. 
 
 
1.4.2.2 Cholesterol 7α-hydroxylase (CYP7A1) 
 
In addition to the conversion of free cholesterol to cholesterol esters, the 
intra-hepatic free cholesterol content can be decreased through catabolism 
of cholesterol to bile acids. CYP7A1 is a microsomal cytochrome P450 that 
catalyzes the first step in bile acid synthesis. In agreement with its function 
in bile acid formation, CYP7A1 is only expressed in the liver [68], the organ 
involved in the conversion of cholesterol to bile acids. The intracellular 
distribution profile of CYP7A1 is quite similar to the one found for HMG-CoA 
reductase, with a confined expression of both enzymes in the smooth, 
ribosome-poor, endoplasmatic reticulum. The critical role for bile acid 
synthesis and thus CYP7A1 in the maintenance of cholesterol homeostasis 
has become clear from studies using transgenic mice. CYP7A1 gene 
knockout mice, as young adults on a regular chow diet, are 
hypercholesterolemic due a concomitant decrease in the expression of 
hepatic LDL receptors [69]. In contrast, mice with transgenic 
overexpression of human CYP7A1 had decreased plasma cholesterol 
levels on a regular chow diet [70]. Importantly, recent data have also 
indicated an important role for CYP7A1 in the maintenance of cholesterol 
homeostasis in humans; individuals with a homozygous deletion mutation in 
CYP7A1 resulting in loss of the active site and enzyme function 
(L413fsX414) have high LDL cholesterol levels, double the normal hepatic 
cholesterol content, and a markedly deficient rate of bile acid excretion [71]. 
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1.4.2.3 ATP-binding cassette transporter A1 (ABCA1) 
 
ABCA1 is a 240 kDa protein belonging to a large family of conserved 
transmembrane proteins that use ATP as a source to transport a wide 
variety of substrates across cellular membranes [72]. ABC transporters 
consist of two 6-helix transmembrane domains that serve as a pathway for 
the translocation of substrates across membranes and two nucleotide-
binding domains that bind ATP and provide the energy for substrate 
transport [73,74]. ABCA1 is ubiquitously expressed, with highest expression 
levels in placenta, fetal tissues, lung, adrenal glands, brain, and liver. In the 
liver, ABCA1 is expressed on the sinusoidal membrane of parenchymal 
cells and on Kupffer cells [75]. The recognition that mutations in the human 
ABCA1 gene are the underlying molecular defect in HDL deficiency 
syndromes such as Tangiers disease [76-78] has contributed substantially 
to the understanding of the function of ABCA1. In addition, targeted 
disruption of ABCA1 in mice results in a virtual absence of HDL cholesterol 
[79,80], whilst overexpression of ABCA1 in mice increases HDL levels 
[81,82]. The liver expresses high levels of ABCA1 [75] and secretes lipid-
free and lipid poor ApoA-I [83], the primary protein constituent of HDL, 
suggesting that the liver itself mediates the formation of HDL. 
 
 
1.4.2.4 ATP-binding cassette transporters ABCG5 and ABCG8 
 
ABCG5 and ABCG8 are, in contrast to ABCA1, half-size ABC proteins 
belonging to the ABCG or White subfamily of ABC transporters that are 
intended to dimerize to form active membrane transporters [84]. Among the 
half-size molecules ABCG proteins have a peculiar domain organization 
characterized by the nucleotide-binding domain (ATP-binding cassette) at 
the N-terminus followed by six transmembrane-spanning domains. ABCG5 
and ABCG8 are both highly expressed in small intestine and liver. In the 
liver, mature ABCG5 and ABCG8 are expressed on the apical plasma 
membrane [84]. Exit of the proteins from the endoplasmic reticulum (ER) 
requires co-expression of both ABC half-transporters [85,86], suggesting 
that formation of a heterodimer is necessary to target ABCG5 and ABCG8 
to the apical plasma membrane. Recently, studies using genetically 
modified mice have been conducted to elucidate the role of the twinned 
transporters ABCG5 and ABCG8. Transgenic mice that overexpress both 
human proteins display markedly elevated biliary cholesterol secretion 
rates, increased fecal neutral sterol excretion, and markedly reduced 
plasma phytosterol levels [87]. It was therefore suggested that ABCG5 and 
ABCG8, upon their expression on the apical membrane in the liver, function 
as an export pump for neutral sterols (e.g. cholesterol) to the bile, whilst 
ABCG5 and ABCG8 in the intestine play an important role in reducing 
intestinal absorption. Recently, several mutations and a number of 
polymorphisms have been identified in ABCG5 and ABCG8 in humans. 
Strikingly, mutations in either ABCG5 or ABCG8 have been related to the 
occurrence of a rare autosomal recessive disorder, called ß-sitosterolemia 
[88]. The disease is characterized by enhanced trapping of cholesterol and 
other sterols, including plant and shellfish sterols, within the intestinal cells 
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and the inability to concentrate these sterols in the bile. As a consequence 
affected individuals have strongly increased plasma levels of plant sterols, 
for example, ß-sitosterol, campesterol, stigmasterol, avenosterol, and 5-
saturated stanols, whereas total sterol levels remain normal or are just 
moderately elevated. Despite the almost normal total plasma sterol levels, 
the disease shares several clinical characteristics with homozygous familial 
hypercholesterolemia. Patients suffer from tendon and tuberous xanthomas 
at an early age, premature development of atherosclerosis, and coronary 
artery disease [89]. 
 
 
1.5 Regulators of genes involved in lipid metabolism 
 
The observation that several hepatic proteins are crucial factors involved in 
the different pathways of hepatic lipid metabolism, and thereby total body 
lipid homeostasis, has inspired scientists to intensively search for regulators 
of these factors on a transcriptional basis. Importantly, regulation of genes 
on a transcriptional level is primarily controlled by transcription factors, 
which are nuclear receptors that, upon activation, are able to bind to 
specific sequences in DNA resulting in a changed expression of their target 
genes. In the past, medicinal chemists and pharmacologists have not 
ventured into the field of transcription regulation due to the fear that drugs 
that interfere with transcription regulation may not be selective or 
efficacious. However, the past 5 years have seen some exciting 
developments in the field of signal transduction in general, and transcription 
regulation in particular with the discovery of a specific group of nuclear 
hormone receptors, the orphan receptors. Like all nuclear receptors, the 
orphan receptors share a common domain structure that includes a highly 
conserved DNA binding domain (DBD) with two zinc fingers and a ligand 
binding domain (LBD) (Fig.4A) [90]. The DBD interacts with specific DNA 
sequences known as response elements. The LBD, located in the carboxyl 
terminal of the protein, serves as the docking site for ligands and also 
contains dimerization motifs and transcriptional activation domains. The 
binding of a ligand to the LBD results in a conformational change in the 
receptor that facilitates interaction with accessory proteins and activation of 
target gene expression. However, prior to DNA binding and gene activation, 
these so-called orphan nuclear receptors need to form a receptor-dimer 
complex with a common heterodimeric partner, namely the retinoic X 
receptor (RXR) [91], which is bound and activated by 9-cis-retinoic acid 
(Fig.4B). In addition, this novel subfamily of transcription factors has been 
proven to be very important in disease (reviewed by Gurnell and Chatterjee 
[92]), since its members have been identified as critical players in 
carbohydrate metabolism, inflammation, reproduction, and nutritional status 
(Table 2). Interestingly, several orphan nuclear receptors have also been 
suggested to play a role in the regulation of (hepatic) lipid metabolism. 
These include the liver X receptor, farnesoid X receptor, peroxisome 
proliferator-activated receptor, and pregnane X receptor. 
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Fig.4. A) Structural and functional organisation of the nuclear receptor superfamily. Nuclear receptors 
consist of six domains (A–F) based on regions of conserved sequence and function. The evolutionarily 
conserved regions C and E are indicated as boxes, and a black bar represents the divergent A/B, D and F 
regions. The N-terminus (A/B region) contains one autonomous transcriptional activation function (AF-1). 
The highly conserved C region harbours the DNA-binding domain that confers sequence-specific DNA 
recognition. The ligand-binding domain (E region) is a highly structured domain comprising a ligand-
dependent activation function (AF-2). The activation domains (ADs) contain transcriptional activation 
functions that can activate transcription when fused to a heterologous DNA-binding domain. B) Nuclear 
receptors form heterodimeric complexes with RXR and affect target gene transcription. Upon binding 
their specific ligands, nuclear receptors heterodimerize with 9-cis retinoic acid (9-cis RA)-activated RXR. 
This complex subsequently binds to hormone response elements (HREs) in the promoter of the nuclear 
receptor target gene leading to transactivation/transrepression. 
 
 
Table 2 
Nuclear receptors, their ligands, and associated functions and diseases 
Receptor HRE Natural ligand Synthetic ligand Biological function Disease 
VDR DR-3 Vitamin D3 Calcipotriene Calcium absorption Osteoporosis 
TR DR-4 T3 GC-1 Basal metabolic rate Graves disease, 
Thyroid cancer 
RARα,β,γ DR-2 
DR-5 
All-trans RA TTNPB Vitamin A signalling, 
body health 
Cancer, 
dermatology 
PPARα DR-1 Palmitic acid Fenofibrate Triglyceride Hyperlipidemia, 
heart disease 
PPARγ DR-1 PGJ2 Rosiglitazone Fat storage Diabetes 
PPARδ DR-1 EPA GW501516 Fatty acid metabolism, 
VLDL production 
Hyperlipidemia 
RXRα,β,γ DR-1 9-cis RA LG100268 Essential heterodimer 
partner 
Cancer, insulin 
resistance 
LXRα,β DR-4 24(S),25-EPC T1317 Cholesterol 
homeostasis 
Heart disease 
FXR IR-1 CDCA Fexaramine Bile acid metabolism Cholestasis 
PXR DR-3 LCA Hyperforin Drug and hormone 
detoxification 
Drug-drug 
interaction 
CAR DR-5 Androstanol TCPOBOP Drug and hormone 
detoxification 
Drug-drug 
interaction 
HRE, hormone response elements; DR, direct repeat; IR, inverted repeat; T3, 3,5,3'-triiodo-L-thyronine; RA, 
retinoic acid; PGJ2, prostaglandin J2; EPA, eicosapentanoic acid; 24(S),25-EPC, 24(S),25-epoxycholesterol; 
CDCA, chenodeoxycholic acid; LCA, lithocholic acid; TTNPB ([(E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-
tetramethyl-2-naphthylenyl)-1-propenyl]benzoic acid]; TCPOBOP, 1,4-bis[2-(3,5-
dichloropyridyloxy)]benzene. 
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1.5.1 Liver X receptor (LXR) 
 
The LXR subfamily consists of two members, LXRα and LXRβ. Both 
subtypes are expressed in the enterohepatic system, but each has a 
distinct pattern of expression in other tissues. Whereas LXRβ is ubiquitously 
expressed, LXRα expression is restricted to tissues rich in lipid metabolism, 
such as brown and white adipose tissue, intestine, kidney, and liver [93]. 
Upon activation by naturally occurring oxysterols derived from tissue-
specific cholesterol metabolism (e.g. 22(R)-hydroxycholesterol, 24(S)-
hydroxycholesterol, and 24(S),25-epoxycholesterol), LXR forms the obligate 
heterodimer with RXR [94]. Subsequently, the RXR-LXR heterodimer is 
able to bind a DNA hormone response element (termed an LXRE) that 
consists of two hexanucleotide repeats separated by 4 nucleotides (DR4) in 
the promoter and/or distal enhancers of its target genes, resulting in a 
stimulation of target gene expression [95]. Due to the rapid generation of 
LXR deficient mice and specific (synthetic) activators of LXR, several target 
genes of LXR involved in liver lipid metabolism have currently been 
identified. In rodents, LXR has been shown to control the regulatory 
cascade of bile acid synthesis by activating CYP7A1 transcription through 
an LXRE in the CYP7A1 promoter [96]. In addition, the expression of the 
ABC transporters involved in cholesterol efflux to the serum (ABCA1) and 
bile (ABCG5/G8) has been shown to be strongly regulated by LXR 
activators [97,98]. Furthermore, LXR is able to induce the gene expression 
of the HDL receptor SR-BI in hepatocytes and preadipocytes [99]. 
Moreover, LXRs regulate the esterification and storage of cholesterol by an 
indirect means that involves the coordinate regulation of another important 
lipid metabolic pathway, fatty acid synthesis. Under high cholesterol 
conditions, LXRs stimulate transcription of sterol regulatory element-binding 
protein 1c (SREBP-1c), the master regulator of genes involved in fatty acid 
synthesis [100]. Increased SREBP-1c protein results in increased cleavage 
of this membrane-bound basic helix-loop-helix transcription factor and the 
transcription of a number of fatty acid-synthesizing enzymes, including 
stearoyl-CoA desaturase 1 (SCD1) [101]. SCD1 is an enzyme responsible 
for the 9-cis desaturation of stearoyl-CoA and palmitoyl-CoA, converting 
them to oleoyl-CoA and palmitoleoyl-CoA, respectively. Increased oleoyl-
CoA, the preferred substrate for ACAT, enables increased esterification of 
cholesterol for storage. Since LXR is able to stimulate the expression of 
genes involved in different cholesterol and fatty acid synthesis/metabolism 
pathways, LXR can thus be considered a very important regulator of 
hepatic lipid homeostasis. 
 
 
1.5.2 Farnesoid X receptor (FXR) 
 
In contrast to the ubiquitous expression of LXR, expression of FXR is 
restricted to the enterohepatic system, kidneys, and adrenals [102]. Upon 
activation by its endogenous ligands, primary (e.g. chenodeoxycholic acid) 
and secondary (e.g. lithocholic acid and deoxycholic acid) bile acids, FXR 
forms an obligate heterodimer with RXR and binds to an inverted 
hexanucleotide repeat spaced by one nucleotide (IR1) in the promoter of its 
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target genes [103]. From multiple in vitro and in vivo studies it has become 
clear that FXR is the key factor that regulates bile acid homeostasis. In 
more detail, it maintains bile acid homeostasis by inducing the hepatic 
expression of genes involved in the export of bile acids such as the bile salt 
efflux pump (BSEP) [104], and by inhibiting the genes responsible for bile 
acid synthesis and uptake, CYP7A1 and sodium taurocholate cotransporter 
polypeptide (NTCP), respectively, through stimulation of the nuclear 
receptor small heterodimer partner (SHP) [105,106]. Interestingly, FXR has 
recently also been implicated in the regulation of serum triglyceride 
metabolism, since it is able to induce the hepatic expression of an activator 
(ApoC-II) [107] and to reduce the hepatic expression of an inhibitor (ApoC-
III) of LPL activity [108]. However, FXR’s main function is to serve as a bile 
acid sensor and regulator of bile acid synthesis, since FXR deficient mice 
develop cholestasis and severe liver damage [109]. In this light, recent 
studies have indicated that FXR is a promising therapeutic target for 
treating or preventing cholesterol gallstone disease. 
 
 
1.5.3 Peroxisome proliferator-activated receptor (PPAR) 
 
The PPAR subfamily consists of three members, PPARα, PPARγ, and 
PPARδ (also called PPARβ), which all bind fatty acids and fatty acid 
metabolites [110]. The different PPARs all heterodimerize with RXR and are 
able to bind the same DNA hormone response elements (termed PPREs) 
that consists of two hexanucleotide repeats separated by 1 nucleotide 
(DR1) in the promoter of their target genes. In the liver, PPARα is the most 
abundantly expressed PPAR subtype. Research has indicated that in the 
liver PPARα is able to regulate the expression of genes encoding 
peroxisomal, microsomal and some mitochondrial fatty acid metabolizing 
enzymes such as fatty acyl-CoA oxidase (ACO) [111] and enoyl-CoA 
hydratase (Ech-1)/3-hydroxyacyl-CoA dehydrogenase (HCDH) [112]. Thus 
PPARα is a strong activator of beta and omega fatty acid oxidation in 
mitochondria and peroxisomes, and microsomes, respectively. Since the 
PPARγ and PPARδ are not abundantly expressed in liver, the definite role 
of these nuclear receptors in liver lipid homeostasis has yet to be 
determined. However, from studies using genetically modified mice it has 
become evident that PPARδ activation is able to compensate for PPARα 
deficiency in skeletal muscle [113], which opens up the possibility that, in 
the liver, PPARδ might also have a role in the regulation of fatty acid 
oxidation. PPARγ is mainly expressed in adipose tissue where it 
coordinates the expression of many hundreds of genes responsible for 
establishment of the mature adipocyte phenotype, resulting in the 
development of adipose tissue [114]. Strikingly, treatment of mice with 
thiazolidinediones (TZDs), synthetic ligands of PPARγ, has been shown to 
decrease hepatic glucose production and increase glycogen synthesis in 
diabetic animals by increasing hepatic glucokinase expression [115], 
suggesting an important role for PPARγ in the regulation of glucose 
homeostasis. 
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1.5.4 Pregnane X receptor (PXR) 
 
PXR (also called PAR/SXR) is the most recently established member of the 
orphan nuclear receptor subfamily. It is highly expressed in liver, and to a 
minor extent, in colon and small intestine. The name PXR is based on the 
fact that the receptor is activated by various natural and synthetic 
pregnanes [116]. However, progesterone, glucocorticoids, and multiple 
drugs (e.g. phenobarbital) are also able to activate PXR. In agreement with 
its orphan function PXR also heterodimerizes with RXR upon activation, 
resulting in DNA binding to DNA hormone response elements that consists 
of two hexanucleotide repeats separated by 3 nucleotides (DR3) in the 
promoter of its target genes. The observation that the PXR expression in 
tissues correlates with the CYP3A expression [117] has led to the 
assumption that PXR might be a regulator of CYP3A1 expression. In 
accordance, studies have shown that PXR activation increases the 
expression of CYP3A4 [118] and CYP3A7 [119] through binding to a PXR 
response element in their promoters. Importantly, CYP3A4 is the 
predominant expressed CYP expressed in human liver, constituting up to 
60% of total hepatic P450 protein. CYP3A4 is involved in the metabolism of 
an extensive range of endogenous steroids and xenobiotics, making a 
significant contribution to the termination of the action of steroid hormones, 
elimination of foreign chemicals, and activation of several potent 
carcinogens [120]. It has been estimated that in excess of half of all 
therapeutic drugs are metabolized in full or part by this enzyme. Since PXR 
is a strong regulator of CYP3A4, the current vision on the role of PXR in the 
liver is that of xenosensor. Interestingly, recent data have also indicated an 
important role for PXR in the protection of the liver against bile acid toxicity, 
since litocholic acid (a toxic bile acid) is able to activate PXR, resulting in 
stimulation of the expression of several bile acid-metabolizing CYPs, bile 
acid transporters, and sulfotransferases that serve to detoxify bile acids 
such as lithocholic acid [121]. 
 
 
1.6 Outline of the Thesis 
 
In the first part of the thesis the role of scavenger receptor class B type I 
(SR-BI) in lipid metabolism was studied. In Chapter 2, the relative 
importance of SR-BI in the removal of cholesterol esters from HDL was 
quantified in vivo. Recently, Out et al. have established a novel role for SR-
BI in postprandial triglyceride metabolism [18]. In Chapter 3 additional 
studies are described on the role of SR-BI in chylomicron remnant 
metabolism in which adenoviral hepatic overexpression of SR-BI was used 
to determine the effect on chylomicron remnant metabolism. Finally, we 
also show that SR-BI, in addition to its role in lipoprotein metabolism, is 
important for the maintenance of adequate fasting glucose levels (Chapter 
4). 
The second part of the thesis focuses on the role of nuclear receptors in 
regulation of hepatic gene expression. In Chapter 5, the effect of a 
Western-type diet was studied on serum and hepatic lipid composition and 
the expression of genes involved in hepatic lipid metabolism in C57Bl/6 
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mice to gain insight into the nuclear receptor-mediated response of the liver 
to atherogenic diet feeding. In addition, the effect of a natural FXR agonist, 
taurocholic acid, on hepatic gene expression and atherosclerosis in ApoE 
deficient mice was explored in Chapter 6. Importantly, the liver consists of 
several different cell types with specific localizations and functions. 
Therefore, in Chapter 7 the expression of nuclear receptors and ABC 
transporters involved in hepatic lipid metabolism was studied in rat 
parenchymal, endothelial and Kupffer cells. In addition, the hepatic cell type 
specific regulation of genes involved in lipid metabolism by nuclear 
receptors on an atherogenic diet was investigated in Chapter 8. 
Furthermore, the initial nuclear receptor-mediated response of liver 
parenchymal cells to an increase in serum lipid levels by a Western type 
diet was studied in LDL receptor deficient mice using microarray technology 
(Chapter 9). 
 
 
1.7 References 
 
1. Statistics Netherlands CBS (2002) 
2. Lusis AJ (2000) Atherosclerosis. Nature 407, 233-41 
3. Munro JM, van der Walt JD, Munro CS, Chalmers JA, Cox EL (1987) An 
immunohistochemical analysis of human aortic fatty streaks. Hum Pathol. 
18, 375-80 
4. Walker LN, Reidy MA, Bowyer DE (1986) Morphology and cell kinetics of 
fatty streak lesion formation in the hypercholesterolemic rabbit. 
Am.J.Pathol. 125, 450-459 
5. Ross R (1990) Mechanisms of atherosclerosis--a review. Adv Nephrol 
Necker Hosp. 19, 79-86 
6. Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis 
of coronary artery disease and the acute coronary syndromes (1). N Engl J 
Med. 326, 242-50 
7.  Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 
1990s. Nature. 362, 801-9 
8.  Ginsberg HN (1998) Lipoprotein physiology. Endocrinol Metab Clin North 
Am. 27, 503-19 
9.  Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie GP Jr, Isaacsohn JL, 
Wassertheil-Smoller S, Wilson AC, Stamler J (1996) Serum lipids and 
incidence of coronary heart disease. Findings from the Systolic 
Hypertension in the Elderly Program (SHEP). Circulation. 94, 2381-8 
10.  Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik 
PS, Bush TL (2001) Non-high-density lipoprotein cholesterol level as a 
predictor of cardiovascular disease mortality. Arch Intern Med. 161, 1413-9 
11.  Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, 
Iida M, Komachi Y (2001) Serum triglycerides and risk of coronary heart 
disease among Japanese men and women. Am J Epidemiol. 153, 490-9 
12.  Miller GJ, Miller NE (1975) Plasma-high-density-lipoprotein concentration 
and development of ischaemic heart-disease. Lancet. 1, 16-9 
13.  Assmann G, Schulte H, von Eckardstein A, Huang Y (1996) High-density 
lipoprotein cholesterol as a predictor of coronary heart disease risk. The 
PROCAM experience and pathophysiological implications for reverse 
cholesterol transport. Atherosclerosis. 124, S11-20 
14.  Green PH, Riley JW (1981) Lipid absorption and intestinal lipoprotein 
formation. Aust N Z J Med. 11, 84-90 
Chapter 1 
 
 
24 
15.  Fielding CJ, Renston JP, Fielding PE (1978) Metabolism of cholesterol-
enriched chylomicrons. Catabolism of triglyceride by lipoprotein lipase of 
perfused heart and adipose tissues. J Lipid Res. 19, 705-11 
16.  Jonas A, Kezdy KE, Williams MI, Rye KA (1988) Lipid transfers between 
reconstituted high density lipoprotein complexes and low density 
lipoproteins: effects of plasma protein factors. J Lipid Res. 29, 1349-57 
17.  Mahley RW, Ji ZS (1999) Remnant lipoprotein metabolism: key pathways 
involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. 
J Lipid Res. 40, 1-16 
18.  Out R, Kruijt JK, Rensen PC, Hildebrand RB, de Vos P, Van Eck M, Van 
Berkel TJ (2004) Scavenger receptor BI plays a role in facilitating 
chylomicron metabolism. J Biol Chem. 279, 18401-6 
19.  Gibbons GF (1990) Assembly and secretion of hepatic very-low-density 
lipoprotein. Biochem J. 268, 1-13 
20.  Spring DJ, Chen-Liu LW, Chatterton JE, Elovson J, Schumaker VN (1992) 
Lipoprotein assembly. Apolipoprotein B size determines lipoprotein core 
circumference. J Biol Chem. 267, 14839-45 
21.  Goldberg IJ (1996) Lipoprotein lipase and lipolysis: central roles in 
lipoprotein metabolism and atherogenesis. J Lipid Res. 37, 693-707 
22.  Van Berkel TJ, Van Eck M, Herijgers N, Fluiter K, Nion S (2000) Scavenger 
receptor classes A and B. Their roles in atherogenesis and the metabolism 
of modified LDL and HDL. Ann N Y Acad Sci. 902, 113-26 
23.  Schmitz G, Langmann T (2001) Structure, function and regulation of the 
ABC1 gene product. Curr Opin Lipidol. 12, 129-40 
24.  Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M (1996) 
Identification of scavenger receptor SR-BI as a high density lipoprotein 
receptor. Science. 271, 518-20 
25.  Eisenberg S (1984) High density lipoprotein metabolism. J Lipid Res. 25, 
1017-58 
26.  Davis RA, Helgerud P, Dueland S, Drevon CA (1982) Evidence that 
reverse cholesterol transport occurs in vivo and requires lecithin-
cholesterol acyltransferase. Biochim Biophys Acta. 689, 410-4 
27.  Wilson HM, Patel JC, Russell D, Skinner ER (1993) Alterations in the 
concentration of an apolipoprotein E-containing subfraction of plasma high 
density lipoprotein in coronary heart disease. Clin Chim Acta. 220, 175-87 
28.  Tall AR, Sammett D, Vita GM, Deckelbaum R, Olivecrona T (1984) 
Lipoprotein lipase enhances the cholesteryl ester transfer protein-mediated 
transfer of cholesteryl esters from high density lipoproteins to very low 
density lipoproteins. J Biol Chem. 259, 9587-94 
29.  Glomset JA (1980) High-density lipoproteins in human health and disease. 
Adv Intern Med. 25, 91-116 
30.  Brown MS, Goldstein JL (1986) A receptor-mediated pathway for 
cholesterol homeostasis. Science. 232, 34-47 
31.  Pieters MN, Schouten D, Bakkeren HF, Esbach B, Brouwer A, Knook DL, 
van Berkel TJ (1991) Selective uptake of cholesteryl esters from 
apolipoprotein-E-free high-density lipoproteins by rat parenchymal cells in 
vivo is efficiently coupled to bile acid synthesis. Biochem J. 280, 359-65 
32.  Frimmer M, Ziegler K (1988) The transport of bile acids in liver cells. 
Biochim Biophys Acta. 947, 75-99 
33.  Hussain MM, Strickland DK, Bakillah A (1999) The mammalian low-density 
lipoprotein receptor family. Annu Rev Nutr. 19, 141-72 
34.  Pathak RK, Yokode M, Hammer RE, Hofmann SL, Brown MS, Goldstein 
JL, Anderson RG (1990) Tissue-specific sorting of the human LDL receptor 
in polarized epithelia of transgenic mice. J Cell Biol. 111, 347-59 
General introduction 
 
 
25 
35.  Russell DW, Brown MS, Goldstein JL (1989) Different combinations of 
cysteine-rich repeats mediate binding of low density lipoprotein receptor to 
two different proteins. J Biol Chem. 264, 21682-8 
36.  Goldstein JL, Brown MS (1979) The LDL receptor locus and the genetics of 
familial hypercholesterolemia. Annu Rev Genet. 13, 259-89. 
37.  Tolleshaug H, Goldstein JL, Schneider WJ, Brown MS (1982) 
Posttranslational processing of the LDL receptor and its genetic disruption 
in familial hypercholesterolemia. Cell. 30, 715-24 
38.  Moestrup SK, Gliemann J, Pallesen (1992) Distribution of the alpha 2-
macroglobulin receptor/low density lipoprotein receptor-related protein in 
human tissues. Cell Tissue Res. 269, 375-82 
39.  Zheng G, Bachinsky DR, Stamenkovic I, Strickland DK, Brown D, Andres 
G, McCluskey RT (1994) Organ distribution in rats of two members of the 
low-density lipoprotein receptor gene family, gp330 and LRP/alpa 2MR, 
and the receptor-associated protein (RAP). J Histochem Cytochem. 42, 
531-42 
40.  Moestrup SK, Kaltoft K, Petersen CM, Pedersen S, Gliemann J, 
Christensen EI (1990) Immunocytochemical identification of the human 
alpha 2-macroglobulin receptor in monocytes and fibroblasts: monoclonal 
antibodies define the receptor as a monocyte differentiation antigen. Exp 
Cell Res. 190, 195-203 
41.  Herz J, Kowal RC, Goldstein JL, Brown MS (1990) Proteolytic processing 
of the 600 kd low density lipoprotein receptor-related protein (LRP) occurs 
in a trans-Golgi compartment. EMBO J. 9, 1769-76 
42.  Moestrup SK (1994) The alpha 2-macroglobulin receptor and epithelial 
glycoprotein-330: two giant receptors mediating endocytosis of multiple 
ligands. Biochim Biophys Acta. 1197, 197-213 
43.  Strickland DK, Kounnas MZ, Argraves WS (1995) LDL receptor-related 
protein: a multiligand receptor for lipoprotein and proteinase catabolism. 
FASEB J. 9, 890-8 
44.  Willnow TE, Armstrong SA, Hammer RE, Herz J (1995) Functional 
expression of low density lipoprotein receptor-related protein is controlled 
by receptor-associated protein in vivo. Proc Natl Acad Sci U S A. 92, 4537-
41 
45.  Martins IJ, Hone E, Chi C, Seydel U, Martins RN, Redgrave TG (2000) 
Relative roles of LDLr and LRP in the metabolism of chylomicron remnants 
in genetically manipulated mice. J Lipid Res. 41, 205-13 
46.  Miquel JF, Moreno M, Amigo L, Molina H, Mardones P, Wistuba II, Rigotti 
A (2003) Expression and regulation of scavenger receptor class B type I 
(SR-BI) in gall bladder epithelium. Gut. 52, 1017-24 
47.  Kolleck I, Schlame M, Fechner H, Looman AC, Wissel H, Rustow B (1999) 
HDL is the major source of vitamin E for type II pneumocytes. Free Radic 
Biol Med. 27, 882-90 
48.  Cai SF, Kirby RJ, Howles PN, Hui DY (2001) Differentiation-dependent 
expression and localization of the class B type I scavenger receptor in 
intestine. J Lipid Res. 42, 902-9 
49.  Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, 
Chapman J, Fruchart JC, Tedgui A, Najib-Fruchart J, Staels B (2000) CLA-
1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated 
by activators of peroxisome proliferator-activated receptors. Circulation. 
101, 2411-7 
50.  Hirano K, Yamashita S, Nakagawa Y, Ohya T, Matsuura F, Tsukamoto K, 
Okamoto Y, Matsuyama A, Matsumoto K, Miyagawa J, Matsuzawa Y 
(1999) Expression of human scavenger receptor class B type I in cultured 
human monocyte-derived macrophages and atherosclerotic lesions. Circ 
Res. 85, 108-16 
Chapter 1 
 
 
26 
51.  Krieger M (1999) Charting the fate of the "good cholesterol": identification 
and characterization of the high-density lipoprotein receptor SR-BI. Annu 
Rev Biochem. 68, 523-58 
52.  Fluiter K, van der Westhuijzen DR, van Berkel TJ (1998) In vivo regulation 
of scavenger receptor BI and the selective uptake of high density 
lipoprotein cholesteryl esters in rat liver parenchymal and Kupffer cells. J 
Biol Chem. 273, 8434-8 
53.  Sehayek E, Wang R, Ono JG, Zinchuk VS, Duncan EM, Shefer S, Vance 
DE, Ananthanarayanan M, Chait BT, Breslow JL (2003) Localization of the 
PE methylation pathway and SR-BI to the canalicular membrane: evidence 
for apical PC biosynthesis that may promote biliary excretion of 
phospholipid and cholesterol. J Lipid Res. 44, 1605-13 
54.  Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M (1997) A 
targeted mutation in the murine gene encoding the high density lipoprotein 
(HDL) receptor scavenger receptor class B type I reveals its key role in 
HDL metabolism. Proc Natl Acad Sci U S A. 94, 12610-5 
55.  Mardones P, Quinones V, Amigo L, Moreno M, Miquel JF, Schwarz M, 
Miettinen HE, Trigatti B, Krieger M, VanPatten S, Cohen DE, Rigotti A 
(2001) Hepatic cholesterol and bile acid metabolism and intestinal 
cholesterol absorption in scavenger receptor class B type I-deficient mice. 
J Lipid Res. 42, 170-80 
56.  Van Eck M, Twisk J, Hoekstra M, Van Rij BT, Van der Lans CA, Bos IS, 
Kruijt JK, Kuipers F, Van Berkel TJ (2003) Differential effects of scavenger 
receptor BI deficiency on lipid metabolism in cells of the arterial wall and in 
the liver. J Biol Chem. 278, 23699-705 
57.  Luskey KL (1986) Structure and expression of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase. Ann N Y Acad Sci. 478, 249-54 
58.  Nakanishi M, Goldstein JL, Brown MS (1988) Multivalent control of 3-
hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonate-derived 
product inhibits translation of mRNA and accelerates degradation of 
enzyme. J Biol Chem. 263, 8929-37 
59.  Fears R, Richards DH, Ferres H (1980) The effect of compactin, a potent 
inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on 
cholesterogenesis and serum cholesterol levels in rats and chicks. 
Atherosclerosis. 35, 439-49 
60.  Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I, Tanaka M, 
Masuda H, Tarumi C, Watanabe Y, et al. (1986) CS-514, a competitive 
inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-
selective inhibition of sterol synthesis and hypolipidemic effect on various 
animal species. Biochim Biophys Acta. 877, 50-60 
61.  Rackley CE (1996) Monotherapy with HMG-CoA reductase inhibitors and 
secondary prevention in coronary artery disease. Clin Cardiol. 19, 683-9 
62.  Chang CC, Huh HY, Cadigan KM, Chang TY (1993) Molecular cloning and 
functional expression of human acyl-coenzyme A:cholesterol 
acyltransferase cDNA in mutant Chinese hamster ovary cells. J Biol Chem. 
268, 20747-55 
63.  Cases S, Novak S, Zheng YW, Myers HM, Lear SR, Sande E, Welch CB, 
Lusis AJ, Spencer TA, Krause BR, Erickson SK, Farese RV Jr (1998) 
ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. Its 
cloning, expression, and characterization. J Biol Chem. 273, 26755-64 
64.  Lin S, Cheng D, Liu MS, Chen J, Chang TY (1999) Human acyl-
CoA:cholesterol acyltransferase-1 in the endoplasmic reticulum contains 
seven transmembrane domains. J Biol Chem. 274, 23276-85 
65.  Buhman KK, Accad M, Novak S, Choi RS, Wong JS, Hamilton RL, Turley 
S, Farese RV Jr (2000) Resistance to diet-induced hypercholesterolemia 
and gallstone formation in ACAT2-deficient mice. Nat Med. 6, 1341-7 
General introduction 
 
 
27 
66.  Yagyu H, Kitamine T, Osuga J, Tozawa R, Chen Z, Kaji Y, Oka T, Perrey 
S, Tamura Y, Ohashi K, Okazaki H, Yahagi N, Shionoiri F, Iizuka Y, 
Harada K, Shimano H, Yamashita H, Gotoda T, Yamada N, Ishibashi S 
(2000) Absence of ACAT-1 attenuates atherosclerosis but causes dry eye 
and cutaneous xanthomatosis in mice with congenital hyperlipidemia. J Biol 
Chem. 275, 21324-30 
67.  Accad M, Smith SJ, Newland DL, Sanan DA, King LE Jr, Linton MF, Fazio 
S, Farese RV Jr (2000) Massive xanthomatosis and altered composition of 
atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol 
acyltransferase 1. J Clin Invest. 105, 711-9 
68.  Jelinek DF, Andersson S, Slaughter CA, Russell DW (1990) Cloning and 
regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in 
bile acid biosynthesis. J Biol Chem. 265, 8190-7 
69.  Erickson SK, Lear SR, Deane S, Dubrac S, Huling SL, Nguyen L, Bollineni 
JS, Shefer S, Hyogo H, Cohen DE, Shneider B, Sehayek E, 
Ananthanarayanan M, Balasubramaniyan N, Suchy FJ, Batta AK, Salen G 
(2003) Hypercholesterolemia and changes in lipid and bile acid metabolism 
in male and female cyp7A1-deficient mice. J Lipid Res. 44, 1001-9 
70.  Miyake JH, Doung XD, Strauss W, Moore GL, Castellani LW, Curtiss LK, 
Taylor JM, Davis RA (2001) Increased production of apolipoprotein B-
containing lipoproteins in the absence of hyperlipidemia in transgenic mice 
expressing cholesterol 7alpha-hydroxylase. J Biol Chem. 276, 23304-11 
71.  Pullinger CR, Eng C, Salen G, Shefer S, Batta AK, Erickson SK, Verhagen 
A, Rivera CR, Mulvihill SJ, Malloy MJ, Kane JP (2002) Human cholesterol 
7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic 
phenotype. J Clin Invest. 110, 109-17 
72.  Higgins CF (1992) ABC transporters: from microorganisms to man. Annu 
Rev Cell Biol. 8, 67-113 
73.  Sarkadi B, Muller M, Hollo Z (1996) The multidrug transporters--proteins of 
an ancient immune system. Immunol Lett. 54, 215-9 
74.  Smit LS, Wilkinson DJ, Mansoura MK, Collins FS, Dawson DC (1993) 
Functional roles of the nucleotide-binding folds in the activation of the 
cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci U 
S A. 90, 9963-7 
75.  Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, Chimini G, 
Kaminski WE, Schmitz G (1999) Molecular cloning of the human ATP-
binding cassette transporter 1 (hABC1): evidence for sterol-dependent 
regulation in macrophages. Biochem Biophys Res Commun. 257, 29-33 
76.  Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu 
L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, 
Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, 
Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, 
Genest J Jr, Hayden MR (1999) Mutations in ABC1 in Tangier disease and 
familial high-density lipoprotein deficiency. Nat Genet. 22, 336-45 
77.  Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, 
Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, 
Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G. The 
gene encoding ATP-binding cassette transporter 1 is mutated in Tangier 
disease. Nat Genet. 22, 347-51 
78.  Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, 
Brewer HB, Duverger N, Denefle P, Assmann G (1999) Tangier disease is 
caused by mutations in the gene encoding ATP-binding cassette 
transporter 1. Nat Genet. 22, 352-5 
79.  Orso E, Broccardo C, Kaminski WE, Bottcher A, Liebisch G, Drobnik W, 
Gotz A, Chambenoit O, Diederich W, Langmann T, Spruss T, Luciani MF, 
Rothe G, Lackner KJ, Chimini G, Schmitz G (2000) Transport of lipids from 
Chapter 1 
 
 
28 
golgi to plasma membrane is defective in tangier disease patients and 
Abc1-deficient mice. Nat Genet. 24, 192-6 
80.  Christiansen-Weber TA, Voland JR, Wu Y, Ngo K, Roland BL, Nguyen S, 
Peterson PA, Fung-Leung WP (2000) Functional loss of ABCA1 in mice 
causes severe placental malformation, aberrant lipid distribution, and 
kidney glomerulonephritis as well as high-density lipoprotein cholesterol 
deficiency. Am J Pathol. 157, 1017-29 
81.  Singaraja RR, Bocher V, James ER, Clee SM, Zhang LH, Leavitt BR, Tan 
B, Brooks-Wilson A, Kwok A, Bissada N, Yang YZ, Liu G, Tafuri SR, Fievet 
C, Wellington CL, Staels B, Hayden MR (2001) Human ABCA1 BAC 
transgenic mice show increased high density lipoprotein cholesterol and 
ApoAI-dependent efflux stimulated by an internal promoter containing liver 
X receptor response elements in intron 1. J Biol Chem. 276, 33969-79 
82.  Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD, Cain 
WJ, Fruchart-Najib J, Neufeld ED, Remaley AT, Brewer HB Jr, 
Santamarina-Fojo S (2001) ABCA1 overexpression leads to 
hyperalphalipoproteinemia and increased biliary cholesterol excretion in 
transgenic mice. J Clin Invest. 108, 303-9 
83.  Windmueller HG, Herbert PN, Levy RI (1973) Biosynthesis of lymph and 
plasma lipoprotein apoproteins by isolated perfused rat liver and intestine. 
J Lipid Res. 14, 215-23 
84.  Schmitz G, Langmann T, Heimerl S (2001) Role of ABCG1 and other 
ABCG family members in lipid metabolism. J Lipid Res. 42, 1513-20 
85.  Graf GA, Yu L, Li WP, Gerard R, Tuma PL, Cohen JC, Hobbs HH (2003) 
ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and 
biliary cholesterol excretion. J Biol Chem. 278, 48275-82 
86.  Graf GA, Li WP, Gerard RD, Gelissen I, White A, Cohen JC, Hobbs HH 
(2002) Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 
permits their transport to the apical surface. J Clin Invest. 110, 659-69 
87.  Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, Hobbs 
HH (2002) Overexpression of ABCG5 and ABCG8 promotes biliary 
cholesterol secretion and reduces fractional absorption of dietary 
cholesterol. J Clin Invest. 110, 671-80 
88.  Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, 
Shan B, Barnes R, Hobbs HH (2000) Accumulation of dietary cholesterol in 
sitosterolemia caused by mutations in adjacent ABC transporters. Science. 
290, 1771-5 
89.  Salen G, Horak I, Rothkopf M, Cohen JL, Speck J, Tint GS, Shore V, Dayal 
B, Chen T, Shefer S (1985) Lethal atherosclerosis associated with 
abnormal plasma and tissue sterol composition in sitosterolemia with 
xanthomatosis. J Lipid Res. 26, 1126-33 
90.  Parker MG (1990) Structure and function of nuclear hormone receptors. 
Semin Cancer Biol. 1, 81-7 
91.  Rastinejad F (2001) Retinoid X receptor and its partners in the nuclear 
receptor family. Curr Opin Struct Biol. 11, 33-8 
92.  Gurnell M, Chatterjee VK (2004) Nuclear receptors in disease: thyroid 
receptor beta, peroxisome-proliferator-activated receptor gamma and 
orphan receptors. Essays Biochem. 40, 169-89 
93.  Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ 
(1995) LXR, a nuclear receptor that defines a distinct retinoid response 
pathway. Genes Dev. 9, 1033-45 
94.  Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ (1996) An 
oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. 
Nature. 383, 728-31 
General introduction 
 
 
29 
95.  Willy PJ, Mangelsdorf DJ (1997) Unique requirements for retinoid-
dependent transcriptional activation by the orphan receptor LXR. Genes 
Dev. 11, 289-98 
96.  Chiang JY, Kimmel R, Stroup D (2001) Regulation of cholesterol 7alpha-
hydroxylase gene (CYP7A1) transcription by the liver orphan receptor 
(LXRalpha). Gene. 262, 257-65 
97.  Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards 
PA, Tontonoz P (2000) Control of cellular cholesterol efflux by the nuclear 
oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A. 97, 12097-102 
98.  Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ 
(2002) Regulation of ATP-binding cassette sterol transporters ABCG5 and 
ABCG8 by the liver X receptors alpha and beta. J Biol Chem. 277, 18793-
800 
99.  Malerod L, Juvet LK, Hanssen-Bauer A, Eskild W, Berg T (2002) Oxysterol-
activated LXRalpha/RXR induces hSR-BI-promoter activity in hepatoma 
cells and preadipocytes. Biochem Biophys Res Commun. 299, 916-23 
100.  Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan 
B, Brown MS, Goldstein JL, Mangelsdorf DJ (2000) Regulation of mouse 
sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol 
receptors, LXRalpha and LXRbeta. Genes Dev. 14, 2819-30 
101.  Tabor DE, Kim JB, Spiegelman BM, Edwards PA (1999) Identification of 
conserved cis-elements and transcription factors required for sterol-
regulated transcription of stearoyl-CoA desaturase 1 and 2. J Biol Chem. 
274, 20603-10 
102.  Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, 
Lustig KD, Mangelsdorf DJ, Shan B (1999) Identification of a nuclear 
receptor for bile acids. Science. 284, 1362-5 
103.  Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA 
(2000) Identification of the DNA binding specificity and potential target 
genes for the farnesoid X-activated receptor. J Biol Chem. 275, 10638-47 
104.  Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, 
Suchy FJ (2001) Human bile salt export pump promoter is transactivated 
by the farnesoid X receptor/bile acid receptor. J Biol Chem. 276, 28857-65 
105.  Chiang JY, Kimmel R, Weinberger C, Stroup D (2000) Farnesoid X 
receptor responds to bile acids and represses cholesterol 7alpha-
hydroxylase gene (CYP7A1) transcription. J Biol Chem. 275, 10918-24 
106.  Denson LA, Sturm E, Echevarria W, Zimmerman TL, Makishima M, 
Mangelsdorf DJ, Karpen SJ (2001) The orphan nuclear receptor, shp, 
mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. 
Gastroenterology. 121, 140-7 
107.  Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, Gonzalez 
FJ, Willson TM, Edwards PA (2001) Farnesoid X-activated receptor 
induces apolipoprotein C-II transcription: a molecular mechanism linking 
plasma triglyceride levels to bile acids. Mol Endocrinol. 15, 1720-8 
108.  Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, 
Fruchart JC, Gonzalez FJ, Staels B (2003) Farnesoid X receptor agonists 
suppress hepatic apolipoprotein CIII expression. Gastroenterology. 125, 
544-55 
109.  Moschetta A, Bookout AL, Mangelsdorf DJ (2004) Prevention of cholesterol 
gallstone disease by FXR agonists in a mouse model. Nat Med. 10, 1352-8 
110.  Auwerx J (1992) Regulation of gene expression by fatty acids and fibric 
acid derivatives: an integrative role for peroxisome proliferator activated 
receptors. The Belgian Endocrine Society Lecture 1992. Horm Res. 38, 
269-77 
111.  Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green 
S (1992) The mouse peroxisome proliferator activated receptor recognizes 
Chapter 1 
 
 
30 
a response element in the 5' flanking sequence of the rat acyl CoA oxidase 
gene. EMBO J. 11, 433-9 
112.  Marcus SL, Miyata KS, Zhang B, Subramani S, Rachubinski RA, Capone 
JP (1993) Diverse peroxisome proliferator-activated receptors bind to the 
peroxisome proliferator-responsive elements of the rat 
hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but 
differentially induce expression. Proc Natl Acad Sci U S A. 90, 5723-7 
113.  Muoio DM, MacLean PS, Lang DB, Li S, Houmard JA, Way JM, Winegar 
DA, Corton JC, Dohm GL, Kraus WE (2002) Fatty acid homeostasis and 
induction of lipid regulatory genes in skeletal muscles of peroxisome 
proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for 
compensatory regulation by PPAR delta. J Biol Chem. 277, 26089-97 
114.  Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA (1994) Peroxisome 
proliferator-activated receptor (PPAR) gamma: adipose-predominant 
expression and induction early in adipocyte differentiation. Endocrinology. 
135, 798-800 
115.  Kim HI, Ahn YH (2004) Role of peroxisome proliferator-activated receptor-
gamma in the glucose-sensing apparatus of liver and beta-cells. Diabetes. 
53, S60-5 
116.  Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, 
McKee DD, Oliver BB, Willson TM, Zetterstrom RH, Perlmann T, Lehmann 
JM (1998) An orphan nuclear receptor activated by pregnanes defines a 
novel steroid signaling pathway. Cell. 92, 73-82 
117.  Zhang H, LeCulyse E, Liu L, Hu M, Matoney L, Zhu W, Yan B (1999) Rat 
pregnane X receptor: molecular cloning, tissue distribution, and xenobiotic 
regulation. Arch Biochem Biophys. 368, 14-22 
118.  Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA 
(1998) The human orphan nuclear receptor PXR is activated by 
compounds that regulate CYP3A4 gene expression and cause drug 
interactions. J Clin Invest. 102, 1016-23 
119.  Pascussi JM, Jounaidi Y, Drocourt L, Domergue J, Balabaud C, Maurel P, 
Vilarem MJ (1999) Evidence for the presence of a functional pregnane X 
receptor response element in the CYP3A7 promoter gene. Biochem 
Biophys Res Commun. 260, 377-81 
120.  Forrester LM, Henderson CJ, Glancey MJ, Back DJ, Park BK, Ball SE, 
Kitteringham NR, McLaren AW, Miles JS, Skett P, et al. (1992) Relative 
expression of cytochrome P450 isoenzymes in human liver and association 
with the metabolism of drugs and xenobiotics. Biochem J. 281, 359-68 
121.  Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, 
LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller 
BH, Kliewer SA (2001) The nuclear receptor PXR is a lithocholic acid 
sensor that protects against liver toxicity. Proc Natl Acad Sci U S A. 98, 
3369-74 
 
 
 
33 
2 
 
 
Scavenger receptor class B type I is solely 
responsible for the selective uptake of cholesteryl 
esters from HDL by the liver and the adrenals in 
mice 
 
Menno Hoekstra, Ruud Out, John A.A. Spijkers, J. Kar Kruijt, Miranda Van 
Eck, I. Sophie T. Bos, Jaap Twisk, and Theo J.C. Van Berkel 
 
Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Gorlaeus 
Laboratories, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands 
 
 
Journal of Lipid Research 2004; 45(11):2088-2095 
 
 
Scavenger receptor class B type I (SR-BI) has been identified as a 
functional HDL binding protein that can mediate the selective uptake of 
cholesteryl ester (CE) from HDL. To quantify the in vivo role of SR-BI in the 
process of selective uptake, HDL was labeled with cholesteryl ether ([3H] 
CEt-HDL) and 125I-tyramine cellobiose ([125I]TC-HDL) and injected into SR-
BI knockout (KO) and wild-type (WT) mice. In SR-BI KO mice, the 
clearance of HDL-CE from the blood circulation was greatly diminished 
(0.043 ± 0.004 pools/h for SR-BI KO mice vs. 0.106 ± 0.004 pools/h for WT 
mice), while liver and adrenal uptake were greatly reduced. Utilization of 
double-labeled HDL ([3H]CEt and [125I]TC) indicated the total absence in 
vivo of the selective decay and liver uptake of CE from HDL in SR-BI KO 
mice. Parenchymal cells isolated from SR-BI KO mice showed similar 
association values for [3H]CEt and [125I]TC in contrast to WT cells, indicating 
that in parenchymal liver cells SR-BI is the only molecule exerting selective 
CE uptake from HDL.  
Thus, in vivo and in vitro, SR-BI is the sole molecule mediating the selective 
uptake of CE from HDL by the liver and the adrenals, making it the unique 
target to modulate reverse cholesterol transport. 
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2.1 Introduction 
 
In both mice [1,2] and humans [3] there is a strong inverse relation between 
the blood levels of HDL and the development of atherosclerosis. The 
atheroprotective effect of HDL is ascribed to its role in reverse cholesterol 
transport (RCT), as first proposed by Glomset [4], in which HDL accepts 
cholesterol from peripheral cells, including those in the arterial wall, and 
delivers it to the liver for biliary secretion [reviewed in Refs. 4–10]. In 
addition, HDL can deliver its cholesteryl ester (CE) to the adrenals and 
testis or ovary for steroid hormone synthesis [11,12]. At both the liver and 
steroidogenic tissues, cholesterol delivery occurs via selective cellular 
uptake of HDL-CE without stoichiometric degradation of HDL protein 
[13,14]. Acton and coworkers [15] provided the first evidence that 
scavenger receptor class B type I (SR-BI) can mediate the selective uptake 
of HDL-CE in Chinese hamster ovary cells stably transfected with mouse 
SR-BI. Furthermore, treatment of the adrenocortical cell line Y1-BS1 with 
antibodies directed against mouse SR-BI resulted in a dramatic decrease in 
the selective uptake of HDL-CE (16).  
In vivo, the expression levels of rat and mouse SR-BI mRNA and protein 
are highest in liver and steroidogenic tissues (adrenal gland, testis, and 
ovary) [17,18], all tissues that display selective uptake of HDL-CE. We 
showed earlier [19] that changes in SR-BI expression in rat liver, induced by 
estradiol treatment or a high-cholesterol diet, correlated with changes in the 
selective uptake of HDL-CE in vivo, supporting a function of SR-BI in 
mediating the selective uptake of HDL-CE. Adenovirus-mediated hepatic 
overexpression of SR-BI in mice on both sinusoidal and canalicular 
surfaces of hepatocytes resulted in the virtual disappearance of plasma 
HDL and a substantial increase in biliary cholesterol [20]. A similar 
decrease in plasma HDL cholesterol levels was found in transgenic mice 
overexpressing SR-BI under the control of the apolipoprotein A-I promoter 
[21]. These studies indicated that SR-BI expression in the liver can regulate 
blood HDL metabolism and influence cholesterol secretion into bile. Studies 
with transgenic mice with liver-specific overexpression of SR-BI showed 
increased total and selective uptake of HDL-CE by the liver compared with 
nontransgenic controls [22,23]. In addition, in SR-BI attenuate (att) mice 
with an SR-BI promoter mutation resulting in decreased expression of the 
receptor, the hepatic uptake of HDL-CE was decreased accordingly [24]. 
Further evidence for the role of SR-BI in RCT was provided by studies in 
SR-BI knockout (KO) mice. These animals displayed impaired biliary 
cholesterol secretion [25,26] and increased plasma cholesterol 
concentration in large apolipoprotein A-I-containing particles, together with 
low adrenal gland cholesterol content [27,28).  
Although the aforementioned studies are consistent with a regulatory role of 
SR-BI in HDL metabolism, there is no report that addresses the quantitative 
contribution of SR-BI in vivo to the selective uptake of HDL-CE by the liver 
and the adrenals. By using SR-BI KO mice in the present study, we made a 
quantitative comparison of the metabolism of HDL-CE in SR-BI KO and 
wild-type (WT) mice to assess the contribution of SR-BI to the serum decay 
and hepatic and adrenal uptake of HDL-CE. The data obtained are 
compared with data for holo-particle uptake, determined by analyzing the 
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fate of 125I-tyramine-cellobiose-labeled HDL ([125I]TC-HDL) in the animals, to 
assess whether additional HDL binding proteins perform selective CE 
uptake from HDL. In addition, studies with isolated parenchymal liver cells 
from WT and SR-BI KO mice demonstrate the quantitative importance of 
SR-BI for the high level of selective uptake of HDL-CE by these cells. 
 
 
2.2 Experimental Procedures 
 
 
2.2.1 Materials 
Egg yolk phosphatidylcholine was from Fluka (Buchs, Switzerland). 
Cholesteryl [1,2(n)-3H]oleoyl ether ([3H]CEt), cholesteryl[1,2(n)-3H] ester 
([3H]CE), and 125I (carrier free in NaOH) were obtained from Amersham 
(Piscataway, NJ). The PL phospholipids kit, the CHOD-PAP (cholesterol 
oxidase-peroxidase aminophenazone) kit, and the GPO-PAP 
(glycerolphosphate oxidase-peroxidase aminophenazone) kit were from 
Roche Diagnostics (Mannheim, Germany). Hypnorm and Thalamonal were 
from Janssen Pharmaceutica (Titusville, NJ), and ketamine was from Bela-
Pharm (Vechta, Germany). Ethylmercurithiosalicylate (thimerosal), BSA 
(fraction V), and collagenase type IV were from Sigma-Aldrich (St. Louis, 
MO). DMEM was from BioWhittaker (Walkersville, MD). All other chemicals 
were of analytical grade.  
 
 
2.2.2 Animals 
 
Heterozygous (+/-) SR-BI mice on a 129(agouti)/C57BL/6 background were 
kindly provided by Dr. Monty Krieger (Massachusetts Institute of 
Technology). The offspring of these mice was analyzed by polymerase 
chain reaction as described [27] for the presence of the targeted or WT SR-
BI alleles. Experiments were carried out with homozygous mutant (SR-BI-/-) 
progeny. The WT (SR-BI+/+) littermates were used as controls. All animals 
used were between 8 and 10 week old males. Animals were maintained on 
a 12 h light/dark cycle and had unlimited access to regular chow diet (SRM-
A; Hope Farms, Woerden, The Netherlands) and water. Animal welfare was 
in accordance with institutional guidelines.  
 
 
2.2.3 Phospholipid liposome preparation 
 
Unilamellar liposomes were prepared from egg yolk phosphatidylcholine 
and labeled with [3H]CEt or [3H]CE as described [29].  
 
 
2.2.4 Isolation and labeling of lipoproteins 
 
Human HDL and LDL were isolated from blood of healthy subjects by 
differential ultracentrifugation as described by Redgrave, Roberts, and West 
[30] and dialyzed against PBS with 1 mM EDTA. HDL (1.063<d<1.21) was 
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labeled with [3H]CEt or [3H]CE via exchange from donor particles as 
reported previously [31]. Donor particles were formed by sonication of egg 
yolk phosphatidylcholine supplemented with 50 µCi of either [3H]CE of 
[3H]CEt. Sonication was carried out with a MSE soniprep 150 for 40 min 
(amplitude, 12 µm) at 52°C under a constant stream of argon in a 0.1 M 
KCl, 10 mM Tris, 1 mM EDTA. 0.025% NaN3 buffer, pH 8.0. Donor particles 
with a density of 1.03 g/ml were isolated by density gradient centrifugation. 
HDL was labeled by incubating HDL with donor particles (mass ratio of HDL 
protein/particle phospholipid = 8:1) in the presence of human lipoprotein-
deficient serum as the CE transfer protein source (1:1, v/v) for 8 h at 37°C 
in a shaking-water bath under argon. Ethylmercurithiosalicylate (thimerosal; 
20 mM) was added to stimulate CE transfer and to inhibit phospholipid 
transfer and lecithin:cholesterol acyltransferase activity. Radiolabeled HDL 
was then isolated by density gradient ultracentrifugation.  
The specific activity varied between 5 and 8 dpm/ng protein. For some 
experiments, HDL was doubly labeled with [125I]TC. Synthesis and 
subsequent radioiodination of TC were performed as described earlier [32]. 
Coupling of [125I]TC to HDL was done as described by Bijsterbosch, Ziere, 
and Van Berkel [33]. To 50 µl of 0.3 mM [125I]TC were successively added 
20 µl of 0.75 mM cyanuric chloride in acetone and 10 µl of 3.0 mM NaOH. 
After 20 s, 20 µl of 2.25 mM acetic acid was added. The resulting activated 
ligand was added to 1–2 mg of HDL in 1 ml of 20 mM sodium tetraborate 
buffer, pH 9.0, containing 0.12 M NaCl and 1 mM EDTA. After 30 min at 
room temperature, the reaction was quenched by the addition of an equal 
volume of 0.2 M NH4HCO3. Unbound label was removed by exhaustive 
dialysis against phosphate-buffered saline (10 mM sodium phosphate 
buffer, pH 7.4, containing 150 mM NaCl and 1 mM EDTA). Less than 1% of 
the labeled material was trichloroacetic acid soluble. The specific activity 
was 20–30 cpm/ng protein. Before use, the radiolabeled HDL was checked 
for hydrolysis of the CE label and for its composition and physical properties 
[29]. Hydrolysis of the CE was <5%. Labeled HDL was used only when 
there were no differences in physical behavior and composition compared 
with the unlabeled HDL.  
LDL was dialyzed against PBS with 10 µM EDTA and, where indicated, 
oxidized by exposure to CuSO4 as described [34].  
 
 
2.2.5 Plasma decay, organ association, and liver cell distribution 
 
A dose of 200 µg (apolipoprotein) ± 1.2 x 106 dpm (plasma decay and organ 
association) or 500 µg (apolipoprotein) ± 3 x 106 dpm (liver cell distribution) 
of [3H]CEt-HDL (total volume of 100 or 250 µl) was injected into the tail vein 
of WT and SR-BI KO mice. At 3 min after injection, a blood sample was 
drawn to verify the injected dose. At the indicated time points, blood 
samples were drawn to measure serum decay. For analysis of organ 
association, the liver, adrenals, and various other organs (stomach, 
intestines, thymus, pancreas, spleen, kidneys, thyroid, heart, aorta, veins, 
lungs, lymph nodes, muscles, skin, adipose tissue, bones, and reproductive 
organs) were isolated for radioassay at 1, 2, 4, and 24 h after tracer 
injection. The organs were weighed, solubilized, and counted for 3H 
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radioactivity in a Packard liquid scintillation unit and for 125I in a counter 
(Packard). Correction was made for the radioactivity in the blood present in 
the organs at the time of sampling as determined by injection of screened 
[125I]BSA. The values are in µl/g organ (means ± SEM; n = 4): liver, 84.7 ± 
8.9; heart, 68.1 ± 2.9; lung, 125.9 ± 13.2; stomach, 22.9 ± 3.2; kidney, 135.2 
± 7.2; adrenal, 110.2 ± 9.5; spleen, 64.6 ± 9.1; small intestine, 46.3 ± 9.0; 
large intestine, 35.2 ± 3.0; skin, 13.1 ± 3.4; muscle, 13.7 ± 2.5; and bone, 
30.1 ± 5.2. When double-labeled HDL was used, the [3H]CEt radioactivity 
was measured in a Packard β counter with a double label program. Within 
the used 3H/125I activity ratios the percentage recovery for 3H is 100 ± 2%. 
Computer analysis using an interactive curve peeling program was applied 
to fit a least-squares multiexponential curve to each set of serum decay 
data and to calculate fractional catabolic rates (FCRs) according to the 
model of Matthews [35]. The uptake by liver parenchymal, endothelial, and 
Kupffer cells was determined at 2 h after injection. After a liver lobule was 
tied off (total liver sample), the parenchymal liver cells were isolated as 
indicated under “In vitro studies with freshly isolated hepatocytes”. The 
endothelial and Kupffer cells were collected from the parenchymal cell 
supernatant by centrifugation for 10 min at 500 g and separated further via 
centrifugal elutriation as described [36]. The purity of each fraction was 
examined via a staining reaction for peroxidase activity followed by light 
microscopy. The purity was 80–90% and >95% for Kupffer cells and 
endothelial cells, respectively. The total liver sample and the cell isolations 
were solubilized and analyzed for protein content and radioactivity.  
 
 
2.2.6 Protein determination 
Protein was determined according to Lowry et al. [37] with BSA as the 
standard.  
 
 
2.2.7 In vitro studies with freshly isolated hepatocytes 
 
Between 10 and 11 AM, WT (SR-BI+/+) and SR-BI KO (SR-BI–/–) mice 
were anesthetized by subcutaneous injection with a mixture of 1.5% (w/v) 
ketamine, 8.5% (v/v) Thalamonal, and 1.5% (v/v) Hypnorm in PBS at a 
dose of 5–7.5 ml/kg. Collagenase perfusion (0.06% (w/v) collagenase) of 
the liver was then performed for 12 min as described [38]. Liver cells were 
collected by mincing the liver in ice-cold Hank's buffer containing 0.3% (w/v) 
BSA followed by filtration through nylon gauze to remove large debris. 
Three subsequent washing steps (10 min, 50 g, 4°C) with ice-cold Hank's 
buffer were performed to separate the parenchymal cells (pellet) from the 
endothelial and Kupffer cells (supernatant). The pellet consisted of pure 
parenchymal cells as judged by light microscopy. Cell viability was 
examined by trypan blue exclusion and was 80–90% in every case. After 
resuspension in oxygenated DMEM supplemented with 2% (w/v) BSA (pH 
7.4), 1 mg of parenchymal cell protein was incubated with the indicated 
amounts of ligand at 37°C for 3 h in a final volume of 0.5 ml. During the 
incubation, the cells were shaken at 150 rpm and briefly oxygenated every 
hour. The viability of the cells remained greater than 80% during these 
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incubations. Subsequently, the cells were washed twice with wash buffer 
(0.15 M NaCl, 2.5 mM CaCl2, and 50 mM Tris-HCl, pH 7.4) containing 0.2% 
(w/v) BSA and once with the same buffer without BSA, after which the cells 
were lysed in 0.1 N NaOH and protein content and radioactivity were 
measured 
 
 
2.3 Results 
 
 
2.3.1 Serum decay and liver and adrenal association 
 
Upon injection of [3H]CEt-HDL into WT mice, 51.7 ± 3.1% of the injected 
label was removed from the blood during the first 4 h. In SR-BI KO mice, a 
severely delayed clearance was noted (Fig.1). In WT mice, the liver uptake 
of CEt from HDL increased gradually up to 4 h after injection. At this time 
point, 31.3 ± 4.9% of the injected dose (ID) was recovered in the liver 
(Fig.1). This indicates that, in agreement with data obtained in rats [30], 
also in mice the liver is responsible for the majority of the removal of CEt 
from HDL. In SR-BI KO mice, the liver uptake of CEt from HDL was greatly 
diminished: at 4 h after injection, only 3.3 ± 0.8% of the ID accumulated in 
the liver, indicating an almost 90% inhibition of liver uptake in the absence 
of SR-BI (P<0.05). Serum decay kinetics and the rate at which the liver 
accumulated CEt tracer were determined in both WT and SR-BI KO mice. 
The activity of the liver was expressed as organ FCR per gram of tissue. 
This represents the fraction of the plasma pool of the traced HDL 
component cleared per hour per gram of tissue. The serum decay rate and 
the liver FCR of the [3H]CEt-HDL were higher in WT mice compared with 
SR-BI KO mice. In WT mice, the serum FCR was 0.106 ± 0.004 pools/h 
(n=4); serum FCR was 0.043 ± 0.004 pools/h in SR-BI KO animals (n = 4; 
P=0.002). The liver FCR was 38.7 ± 6.6 x 10–3 serum pools/h/g in WT mice 
vs. 4.8 ± 0.80 x 10–3 serum pools/h/g in KO mice (P=0.036). These values 
indicate a severely delayed capacity for CE uptake in the SR-BI KO mice. 
We observed earlier that SR-BI deficiency induced a 1.8-fold increase in 
total serum cholesterol levels [28]. Interestingly, this increase in total 
cholesterol levels was mainly the result of a 3.2-fold increase in free 
cholesterol, and CEs were only increased by 1.3-fold. Rigotti et al. [27] 
reported that apolipoprotein A-I levels were not different between WT and 
SR-BI KO mice. Correction for the HDL-CE pool size indicates that the 
HDL-CE mass influx into the liver was reduced from 22.0 ± 3.8 µg HDL-
CE/h in WT mice to 4.1 ± 0.7 µg HDL-CE/h in SR-BI KO animals. To verify 
the possible presence of a selective CE decay and uptake in the absence of 
SR-BI, we injected double-labeled HDL, whereby the protein moiety was 
additionally labeled with [125I]TC (Fig.2, Table 1). In WT mice, the decay 
rate of [3H]CEt was higher than that of [125I]TC, indicative of selective CE 
removal from serum. In contrast, the decay rates of [3H]CEt-HDL and 
[125I]TC-HDL in SR-BI KO mice were identical, reflecting the absence of a 
selective CE removal pathway in these animals. The liver uptake values of 
[3H]CEt-HDL were similar to those for single CE-labeled HDL (30.3 ± 1.2% 
for WT mice and 4.4 ± 0.9% for KO mice), whereas the uptake values for  
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Fig.1. Serum decay, liver association, and adrenal association of HDL labeled with 
cholesteryl ether ([3H]CEt-HDL) in wild-type (WT) and scavenger receptor class B type I 
(SR-BI) knockout (KO) mice. A dose of 200 µg (apolipoprotein; 1.2 x 106 dpm) of [3H]CEt-
HDL was injected into the tail vein of WT (open symbols) and SR-BI KO (closed symbols) 
mice. At the indicated time points, the animals were killed, serum was collected, and liver and 
adrenal biopsies were taken. The tissue samples were weighed, combusted in a Hewlett-
Packard 306 sample oxidizer, and counted for radioactivity. Serum decay and liver and adrenal 
association were calculated. Correction was made for the radioactivity in the blood present in 
the organs at the time of sampling (see “Experimental Procedures”). For serum and liver, data 
are expressed as percentage of injected dose (ID), whereas for the adrenal, association values 
are expressed as percentage of ID/mg wet weight x 103. Values are means±SEM of four 
animals for each time point. 
 
Fig.2. Serum decay of double-labeled [3H]CEt-HDL 
and HDL labeled with tyramine-cellobiose 
([125I]TC-HDL) in WT and SR-BI KO mice. A dose 
of 200 µg (apolipoprotein) was injected into the tail 
vain of WT [open circles ([3H]CEt-HDL) and open 
triangles ([125I] TC-HDL)] and SR-BI KO [closed circles 
([3H]CEt-HDL) and closed triangles ([125I]TC-HDL)] 
mice. At the indicated time points, blood was taken 
and radioactivity was determined as described in 
Materials and Methods. The data are expressed as 
percentage of ID ± SEM of four animals at each time 
point. 
 
 
 
Table 1 
Liver and adrenal association of [3H]CEt-HDL and [125I]TC-HDL at 4 h after injection into 
SR-BI KO mice and WT mice 
 [3H]CEt-HDL [125I]TC-HDL 
Tissue WT mice SR-BI KO mice WT mice SR-BI KO mice 
Liver 
(% ID) 30.3 ± 1.8     4.4 ± 0.9 
(a) 4.8 ± 0.6 5.4 ± 0.4 
Adrenals 
(%ID/mg wet weight x 103) 45.3 ± 5.0 6.3 ± 1.7 6.1 ± 1.6 3.1 ± 0.2 
HDL labeled with tyramine-cellobiose ([125I]TC-HDL) and cholesteryl ether ([3H]CEt-HDL) was 
injected into the tail vein of wild-type (WT) and SR-BI knockout (KO) mice. At 4 h after 
injection, the animals were killed, serum was collected, and liver and adrenals were taken. 
Tissue samples were weighed, solubilized, and together with the serum samples assayed for 
3H or 125I counts. Correction was made for the contribution of serum to the measured organ-
associated radioactivity (see Experimental Procedures). Data are expressed as percentage of 
injected dose (ID) for liver and as percentage of ID/mg wet weight x 103 for the adrenals. The 
values are means±SEM of five to eight animals. 
a Significant difference for [3H]CEt-HDL (P<0.05) between WT and KO mice. The WT [125I]TC-
HDL values did not differ significantly from the KO [3H]CEt-HDL values or the KO [125I]TC-HDL 
values. 
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[125I]TC (4.8 ± 0.6% for WT mice and 5.4 ± 0.4% for KO mice) indicated that 
no residual selective uptake of CE from HDL was observed in SR-BI KO 
mice. Because the observed liver uptake did not account fully for the serum 
decay, the distribution of radioactivity over extra-hepatic tissues was also 
analyzed at various time points after injection; the data for 24 h are given in 
Table 2. It was found that the majority of the extra-hepatic label was present 
in skin (15–18%), bones (6–8%), muscle (3%), and intestine (4%), whereas 
the other tissues contained <1% for each tissue. The total recovery of label 
was between 80% and 90% for both WT and KO mice in every case. There 
was no significant difference in extra-hepatic distribution between WT and 
SR-BI KO animals except for the adrenals. The major differences in adrenal 
uptake occurred during the first 4 h after injection (Fig.1), during which the 
uptake in WT mice increased to 45.3 ± 5.0% of the ID/mg wet weight x 103, 
whereas uptake was only 6.3 ± 1.1% of the ID/mg wet weight x 103 in the 
SR-BI KO mice (Table 1). 
 
 
Table 2 
Percent radioactivity in tissues determined 24 h after injection of [3H]CEt-HDL in WT and 
SR-BI KO mice 
Organ WT mice SR-BI KO mice 
Liver 46.9 ± 2.4 14.8 ± 1.2 
Heart 0.4 ± 0.1 0.7 ± 0.2 
Lung 0.7 ± 0.1 0.7 ± 0.2 
Stomach 0.6 ± 0.2 0.6 ± 0.2 
Kidney 0.6 ± 0.1 0.4 ± 0.2 
Adrenal 0.5 ± 0.1 0.2 ± 0.1 
Spleen 0.7 ± 0.2 1.0 ± 0.2 
Small intestine 4.0 ± 0.3 3.3 ± 0.2 
Large intestine 2.5 ± 0.3 2.0 ± 0.2 
Skin 14.7 ± 2.4 18.1 ± 4.8 
Muscle 4.1 ± 0.3 3.7 ± 0.4 
Bone 8.2 ± 0.6 9.3 ± 1.9 
Serum 4.9 ± 0.7 32.0 ± 1.0 
Recovery 88.8% 86.8% 
[3H]CEt-HDL was injected into the tail vein of WT and SR-BI KO mice. At 24 h after injection, 
the animals were killed, serum was collected, and tissues were removed. Tissues were 
assayed for 3H counts, and correction was made for the contribution of serum to the measured 
organ-associated radioactivity (see Experimental Proceudres). The values are means±SEM of 
four animals in each group 
 
 
2.3.2 In vivo liver cell distribution 
 
At 2 h after injection of [3H]CEt-HDL, parenchymal, endothelial, and Kupffer 
cells were isolated from the livers of WT and SR-BI KO mice to examine the 
potential roles of SR-BI in the process of CEt uptake by these various cell 
types. For total liver, there was an 81.6% lower association of CEt in SR-BI 
KO animals compared with WT mice (13.1 ± 1.3% and 71.3 ± 3.6% of the 
ID/mg protein x 10–3 for KO and WT mice, respectively) (Fig.3). It can be 
calculated that in the WT liver, parenchymal cells were responsible for 88% 
of the [3H]CEt uptake from HDL, when taking into account the contribution 
of these cells to total liver mass. The absence of SR-BI from the liver 
parenchymal cells resulted in an 87% decrease of CEt uptake (62.4 ± 1.1% 
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uptake of the ID/g protein x 10–3 in WT parenchymal cells vs. 8.0 ± 0.6% 
uptake of the ID/mg protein x 10–3 in SR-BI KO parenchymal cells). For liver 
endothelial cells, no significant difference was observed. In the Kupffer cell 
fraction from SR-BI KO mice, the uptake of CEt from HDL was 51.5% lower 
compared with WT mice (69.6 ± 13.9% and 143.4 ± 7.5% of the ID/mg 
protein x 10–3, respectively). Because parenchymal liver cells are the 
predominant cell type in the liver (92.5%), the diminished uptake of CEt by 
the SR-BI KO liver is mainly the consequence of the absence of SR-BI in 
the parenchymal liver cells and is only to a minor extent caused by the SR-
BI deficiency in the Kupffer cells. 
 
 
Fig.3. In vivo distribution of [3H]CEt-
HDL in parenchymal, liver endothelial, 
and Kupffer cells in WT and SR-BI KO 
mice at 2 h after injection. A dose of 500 
µg (apolipoprotein; 3 x 106 dpm) of [3H] 
CEt-HDL was injected into the tail vein of 
WT (open bars) and SR-BI KO (closed 
bars) mice. At 2 h after injection, a liver 
lobule was tied off and the liver was 
perfused at 37°C. Parenchymal cells (PC), 
endothelial cells (EC), and Kupffer cells 
(KC) were further isolated at 4°C. The total 
liver sample and the cell isolations were 
solubilized and counted for radioactivity. 
Values are means±SEM of four isolations 
in both groups. *P<0.05 and ** P<0.005 
between WT and KO mice (unpaired 
Student's t-test). 
 
 
 
 
2.3.3 In vitro parenchymal liver cell association 
 
Parenchymal liver cells from WT and SR-BI KO mice were isolated and 
incubated for 3 h at 37°C with different concentrations of HDL doubly 
labeled with [3H]CE and [125I]TC. As described by Pittman et al. [39], values 
for CE association are expressed in terms of apparent particle uptake (i.e., 
from the amount of 3H-labeled tracer associated with the cells, the amount 
of HDL protein apparently taken up is calculated). In WT parenchymal liver 
cells, the CE association increased with increasing ligand concentration and 
exceeded the association to SR-BI KO cells by 3- to 5-fold (Fig.4). In SR-BI 
KO parenchymal liver cells, at every ligand concentration used, the 
association of HDL-derived [3H]CE was similar to the [125I]TC association, 
indicating that SR-BI KO parenchymal liver cells performed no residual 
selective CE uptake from HDL (Fig.4). With [3H]CEt-HDL, similar data were 
obtained as with the [3H]CE label. 
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Fig.4. Concentration dependence of HDL 
labeled with cholesteryl ester ([3H]CE-HDL) 
and [125I]TC-HDL association to isolated 
parenchymal liver cells from WT and SR-BI 
KO mice. Parenchymal liver cells from WT 
(open symbols) and SR-BI KO (closed 
symbols) mice were incubated for 3 h at 37°C 
with the indicated concentrations of HDL 
doubly labeled with [3H]CE (circles) and [125I]TC 
(triangles) in DMEM with 2% BSA. The 
association of [3H]CE is expressed as apparent 
uptake [i.e., the amount of HDL protein that 
would deliver the measured amounts of [3H]CE 
(39)], whereas for [125I]TC the association is 
expressed in ng HDL/mg cell protein. Values 
are means±SEM of four cell isolations from 
both groups. The [125I]TC values for WT and 
SR-BI KO mice are graphically similar in the 
plots and do not differ significantly from the 
[3H]CE-HDL values in the SR-BI KO mice 
(Student's t-test). 
 
 
 
2.3.4 Effect of LDL and oxidized LDL on selective uptake of [3H]CE 
from HDL 
 
Previously, we had shown that oxidized LDL (oxLDL) is a very potent 
inhibitor of HDL-CE association with rat parenchymal liver cells. Based on 
these inhibition characteristics, we suggested that SR-BI mediates the 
efficient uptake of HDL-CE by these cells [28]. In the present study, the 
availability of SR-BI KO mice enabled us to determine if this assumption is 
true. Incubation of freshly isolated WT and SR-BI KO mouse parenchymal 
liver cells with 10 µg/ml [3H]CE-HDL for 3 h at 37°C resulted in an 
association of 476.3 ± 37.8 ng/mg cell protein for WT cells and a 5-fold 
lower association of 89.5 ± 18.9 ng/mg cell protein for SR-BI KO cells 
(Fig.5). The efficiency of modified LDL to compete for this [3H]CE-HDL 
association was examined by including the indicated amounts of unlabeled 
native or oxidized LDL in the incubation (Fig.5). Addition of native LDL only 
marginally decreased the cell association (18% in WT cells and 20% in SR-
BI KO cells at the highest concentration of 100 µg/ml). Competition with 
oxLDL at a concentration of 100 µg/ml resulted in a 73% reduction of 
[3H]CE-HDL cell association to WT cells. With an oxLDL concentration as 
low as 25 µg/ml, a 52% decrease was achieved (Fig.5). In contrast, in the 
SR-BI KO parenchymal liver cells, oxLDL did not efficiently decrease the 
association of [3H]CE-HDL. This indicates that apparently oxLDL is a very 
efficient inhibitor of the SR-BI-mediated selective uptake of CE from HDL 
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Fig.5. Effect of increasing 
concentrations of LDL or oxidized 
LDL (oxLDL) on the association of 
[3H]CE-HDL to WT and SR-BI KO 
mouse parenchymal liver cells. 
Parenchymal liver cells from WT (open 
symbols) and SR-BI KO (closed 
symbols) mice were incubated for 3 h at 
37°C with 10 µg/ml [3H]CE-HDL and the 
indicated concentrations of LDL 
(squares) or oxLDL (circles) in DMEM 
with 2% BSA. The association is 
expressed as apparent uptake [i.e., the 
amount of HDL protein that would deliver 
the measured amounts of [3H]CE (39)]. 
Values are means ± SEM of four cell 
isolations. Where error bars are not 
visible, they fall within the symbols. 
 
 
2.4 Discussion 
 
Selective delivery of CE from HDL to the adrenals and the liver is important 
for the supply of substrate for steroid hormone synthesis and the 
maintenance of lipid homeostasis, respectively. Based on the following 
evidence, SR-BI is suggested to be a functional receptor for HDL: i) SR-BI 
is highly expressed in the steroidogenic organs and the liver in rats [17] and 
mice [18]; ii) SR-BI can bind HDL via interaction with its apolipoproteins 
[40]; and iii) SR-BI can mediate the selective uptake of HDL-CE [15]. In the 
present work, we used SR-BI KO mice to assess the quantitative role of 
SR-BI in the selective uptake of CE from HDL in vivo by comparing the 
uptake in these animals with that in WT mice. Our data show that, in the 
intact animal, the initial rate at which CE is taken up from HDL by the liver 
and the adrenals is greatly diminished in SR-BI KO animals compared with 
WT animals. Calculation of the liver FCR for WT and KO animals indicated 
that CE uptake from HDL by the liver occurred eight times faster in WT 
animals. This shows the quantitative importance of SR-BI as a rate-limiting 
factor in the process of selective uptake of CE from HDL by the liver. It is 
consistent with the finding that in SR-BI KO mice biliary cholesterol 
secretion is impaired [25,26] and that plasma HDL cholesterol 
concentrations are increased by 125% [27]. In agreement with the rate-
determining role of SR-BI in the selective CE uptake from HDL, it has been 
reported that overexpression of SR-BI in vivo resulted in a dramatic 
decrease in plasma HDL cholesterol levels [20–22] and increased total and 
selective uptake of HDL-CE by the liver [22] compared with nontransgenic 
controls. Furthermore, our data are consistent with the decreased CE 
uptake from HDL by the liver observed in SR-BI att mice, which have an 
attenuated expression of the SR-BI receptor [24]. Analysis of the organ 
distribution of [3H]CE at various times after injection indicated that in 
addition to the liver, only the uptake by the adrenals is impaired in the 
absence of SR-BI. This is in accordance with the previously reported low 
adrenal gland cholesterol content in homozygous SR-BI KO mice [27]. 
Comparison of the uptake values obtained for [3H]CE and [125I]TC, a 
nondegradable and accumulating label located in the protein moiety of 
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HDL, indicates that in SR-BI KO mice the residual CE uptake can be 
ascribed to HDL holo-particle association and/or uptake. This implies not 
only that SR-BI is the determining factor for the selective uptake of CE from 
HDL but also that no additional routes for the selective uptake of CE from 
HDL are active in vivo. Our data obtained with SR-BI KO animals compared 
with WT mice thus form the final proof that SR-BI is solely responsible for 
the selective uptake of CE from HDL in the blood circulation by the liver and 
the adrenals.  
Recently, in a preliminary report, Rinninger's group [41] came to the same 
conclusion by studying the kinetics of autologous HDL in SR-BI KO mice.  
The liver does contain, in addition to the parenchymal cells, endothelial and 
Kupffer cells. We have shown previously [19] that, in rats, SR-BI protein is 
expressed in both the parenchymal and Kupffer cells. Treatment with 
estradiol or a high-cholesterol diet led to downregulation of SR-BI protein 
expression in the parenchymal cells and resulted in an upregulation of SR-
BI protein expression in the Kupffer cells. These changes in SR-BI protein 
expression correlated with changes in the ability of these cells to perform 
selective uptake of CE from HDL [19]. In the present study, isolation of 
parenchymal, endothelial, and Kupffer cells at 2 h after in vivo 
administration of [3H]CEt-HDL revealed that in the SR-BI KO mice CEt-HDL 
uptake is greatly impaired in parenchymal cells but in liver endothelial cells 
no difference in uptake of CEt from HDL was observed. Kupffer cells from 
SR-BI KO mice showed a 2-fold decrease in CE uptake from HDL 
compared with WT mice. These data obtained in mice are consistent with 
our earlier data for the rat. Because the parenchymal liver cells account for 
92.5% of total liver protein, we conclude that the SR-BI-mediated selective 
uptake of CE from HDL by the liver is mainly exerted by the parenchymal 
cells.  
In view of the major role of the parenchymal liver cells in the removal of CE 
from HDL, additional in vitro studies were performed with these cells from 
WT and SR-BI KO mice. Pioneering studies by Glass and coworkers 
[11,14] have shown that the uptake route of HDL-CE by liver parenchymal 
cells is characterized by the selective uptake of the CE without 
simultaneous uptake of the holo-particle. We have shown previously that 
the selective uptake of HDL-CE by rat parenchymal liver cells can be 
blocked efficiently by oxLDL [29] and also that changes in SR-BI protein 
expression, induced by a high-cholesterol diet or estradiol treatment, 
correlated with changes in the selective uptake of HDL-CE in vitro [19]. Our 
present data with isolated parenchymal liver cells from SR-BI KO mice 
indicate that the uptake of HDL-CE is greatly diminished compared with WT 
parenchymal liver cells and also that inhibition by oxLDL of the selective 
uptake process no longer occurs. This indicates that, similar to the in vivo 
observations, SR-BI expression is essential for the efficient uptake of CE 
from HDL. In addition, the present data support our earlier suggestion [29] 
that the inhibition of CE uptake from HDL by oxLDL indicates that SR-BI is 
mainly responsible for the selective uptake process. By simultaneous 
measurement of [3H]CE uptake and [125I]TC uptake (reflecting holo-particle 
uptake) from HDL in parenchymal cells from SR-BI KO mice, we conclude 
that these cells, in contrast to WT parenchymal liver cells, no longer exert 
selective CE uptake from HDL. These data are consistent with the in vivo 
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uptake values and indicate that for this major liver cell type SR-BI is 
essential for the selective uptake of CE from HDL. Furthermore, the data 
indicate that the parenchymal liver cells do not contain additional receptor 
systems that can facilitate this unique uptake route.  
In conclusion, both our in vivo and in vitro data prove that SR-BI is mainly 
responsible for the efficient and selective uptake of HDL-CE by the liver and 
the adrenals, making it an important target for pharmaceutical interference 
with the RCT process.  
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The function of scavenger receptor class B type I (SR-BI) in mediating the 
selective uptake of HDL cholesteryl esters is well established. In SR-BI-
deficient mice, we recently observed a delayed postprandial triglyceride 
(TG) response, suggesting an additional role for SR-BI in facilitating 
chylomicron (CM) metabolism. Here, we assessed the effect of adenovirus-
mediated hepatic overexpression of SR-BI (Ad.SR-BI) in C57BL/6J mice on 
serum lipids and CM metabolism. Infection of 5 x 108 plaque-forming units 
per mouse of Ad.SR-BI significantly decreases serum cholesterol (>90%), 
phospholipids (>90%), and TG levels (50%), accompanied by a 41.4% 
reduction (P<0.01) in apolipoprotein B-100 levels. The postprandial TG 
response is 2-fold lower in mice treated with Ad.SR-BI compared with 
control mice (area under the curve = 31.4 ± 2.4 versus 17.7 ± 3.2; P<0.05). 
Hepatic mRNA expression levels of genes known to be involved in serum 
cholesterol and TG clearance are unchanged and thus could not account 
for the decreased plasma TG levels and the change in postprandial 
response.  
We conclude that overexpression of SR-BI accelerates CM metabolism, 
possibly by mediating the initial capture of CM remnants by the liver, 
whereby the subsequent internalization can be exerted by additional 
receptor systems such as the LDL receptor and LDL receptor-related 
protein 1 (LRP1). 
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3.1 Introduction 
 
Scavenger receptor class B type I (SR-BI) binds HDLs and mediates the 
selective uptake of cholesteryl esters (CEs) from HDL without concomitant 
uptake of HDL protein [1]. The major apolipoproteins from HDL 
(apolipoprotein A-I (ApoA-I), ApoA-II, and ApoC-III) mediate the binding of 
HDL to SR-BI [2]. Recently, it was shown that lipid-free ApoE also binds to 
SR-BI and enhances CE uptake from lipoproteins [3]. In addition to HDL, 
SR-BI was found to bind a broad spectrum of ligands, including maleylated 
BSA, anionic phospholipids (PLs), modified lipoproteins (acetylated LDL, 
oxidized LDL, and hypochlorite-modified LDL), and native lipoproteins 
(HDL, LDL, and VLDL) [4–7]. In contrast, SR-BI does not bind polyanions 
(e.g., fucoidin and polyinosinic acid), which are well-known ligands for 
scavenger class A receptors. In addition to CE, SR-BI selectively takes up a 
variety of other molecules, such as lipoprotein-associated PL [8,9], HDL-
associated CE hydroxides [10], and triglycerides (TGs) [9,11].  
The importance of SR-BI in HDL cholesterol metabolism is readily observed 
in genetically altered mice. SR-BI-deficient mice are characterized by an 
increase in serum cholesterol levels, reflected in enlarged, cholesterol-rich 
HDL particles and impaired HDL cholesterol clearance [12]. Conversely, 
adenoviral hepatic SR-BI overexpression results in decreased serum HDL 
cholesterol content as well as increased liver uptake and subsequent 
delivery of HDL cholesterol to the bile [13]. In contrast with HDL cholesterol 
metabolism and despite several studies in both SR-BI transgenic mice [14-
17] and in mice with adenovirus-mediated overexpression of SR-BI [18–20], 
the role of SR-BI in the metabolism of apoB-containing lipoproteins is still 
under discussion.  
Chylomicrons (CMs) are TG-rich lipoproteins that transport dietary lipids 
from the intestine to the liver [21]. In the intestines, CMs are formed by the 
addition of lipids to ApoB-48, the structural protein of CM, which is mediated 
by microsomal triglyceride transfer protein (MTP). Upon entering the 
circulation, CMs are converted to remnants by the TG-hydrolyzing action of 
LPL and the acquisition of apolipoproteins such as apoE. CM remnants are 
subsequently taken up by the liver by an ApoE-mediated process (reviewed 
in Refs. 22–24). The essential role of ApoE in remnant clearance was 
indicated by the accumulation of remnants in ApoE-deficient mice [25]. 
Several ApoE-dependent recognition sites have been suggested to 
contribute to the removal of remnants, including the (ApoB and ApoE) LDL 
receptor receptor [25–30] and the LDL receptor-related protein/2-
macroglobulin receptor 1 (LRP1) [29,31,32]. However, it is generally 
accepted that for the initial liver recognition of remnants, the so-called 
"capture step," additional systems are needed. The initial sequestration step 
was suggested to involve heparan sulfate proteoglycans [26,33], the 
lipolysis-stimulated receptor [34–36], a TG-rich lipoprotein receptor [37,38], 
the asialoglycoprotein receptor [39], LPL [40] and/or HL [41], and a specific 
remnant receptor [42–44]. We recently observed a reduced recognition of 
160 nm TG-rich CM-like emulsion particles to freshly isolated hepatocytes 
from SR-BI deficient mice [45]. Furthermore, the postprandial TG response 
to an intragastric fat load is 2-fold higher in SR-BI deficient mice compared 
with wild-type littermates. These data suggest that SR-BI facilitates CM-
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remnant metabolism possibly by mediating the initial binding/capture of 
remnants by the liver [45]. However, it remains to be established to what 
extent this facilitating role is critically dependent on SR-BI protein levels.  
The aim of the present study was to further substantiate the role of SR-BI in 
CM metabolism by assessing the effect of adenovirus-mediated hepatic 
overexpression of SR-BI. It appears that adenovirus-mediated hepatic 
overexpression of SR-BI in C57BL/6J mice results in a decrease in plasma 
TG, a decrease in VLDL/CM-associated TG, and a modified postprandial 
TG response. In addition, a tendency to an increase in MTP expression was 
observed, suggesting increased VLDL production. These data support our 
earlier suggestion and indicate that besides its role in HDL metabolism, SR-
BI levels modulate the kinetics of CM (remnant) metabolism. 
 
 
3.2 Experimental Procedures 
 
 
3.2.1 Animals 
 
In all experiments, 10–12 week old male C57BL/6J mice (Broekman 
Institute BV, Someren, The Netherlands), weighing ~25 g were used. Mice 
were fed a regular chow diet containing 4.7% fat and no cholesterol (SDS, 
Whitham, UK). Animal experiments were performed at the Gorlaeus 
Laboratories of the Leiden/Amsterdam Center for Drug Research in 
accordance with the national laws. All experimental protocols were 
approved by the Ethics Committee for Animal Experiments of Leiden 
University. 
 
 
3.2.2 Treatment with recombinant adenovirus 
 
Construction of a recombinant replication-deficient adenoviral vector 
expressing mouse SR-BI (Ad.SR-BI) has been described previously [46]. A 
total of 5 x 108 plaque-forming units (pfu) of Ad.SR-BI or Ad.LacZ (control) 
was injected into the tail vein of the mice (n=4–5 per group) at 3 h after 
injection of Ad.LacZ (5 x 108 pfu) to saturate the uptake of viral particles by 
Kupffer cells [47]. Before injection and 5 days after injection, mice were 
fasted overnight and a blood sample for lipid determination was collected by 
tail bleeding. Subsequently, mice were anesthetized [subcutaneous 
injection of ketamine (60 mg/kg; Eurovet Animal Health), fentanyl citrate, 
and fluanisone (1.26 and 2 mg/kg, respectively; Janssen Animal Health)] 
and exsanguinated by eye bleeding. A whole body perfusion was performed 
using phosphate-buffered saline containing 1 mM EDTA (4°C, 100 mm Hg) 
for 15 min. After perfusion, liver lobules were excised and either kept in 
3.7% formalin overnight, embedded in OCT compound (Tissue-Tec), and 
frozen in liquid nitrogen for histological analysis or snap frozen in liquid 
nitrogen and stored at –80°C until RNA isolation, Western blotting, or 
hepatic lipid composition analysis. 
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3.2.3 Analysis of gene expression by real-time quantitative PCR 
 
mRNA analysis was performed as described previously [48,49]. Total RNA 
was extracted from the liver by the acid guanidinium thiocyanate-phenol 
chloroform extraction method according to Chomczynski and Sacchi [50]. 
cDNA was synthesized from 2 µg of total RNA using RevertAid M-MuLV 
reverse transcriptase according to the protocols supplied by the 
manufacturer. Quantitative gene expression analysis was performed on an 
ABI PRISM 7700 machine (Applied Biosystems, Foster City, CA) using 
SYBR-green technology (Eurogentec) with the primers listed in Table 1. 
Hypoxanthine guanine phosphoribosyl transferase (HPRT), β-actin, and 
acidic ribosomal phosphoprotein PO (36B4) were used as the standard 
housekeeping genes. Relative gene expression was calculated by 
subtracting the threshold cycle number of the target gene from the average 
threshold cycle number of HPRT, β-actin, and 36B4 and raising 2 to the 
power of this difference. The average threshold cycle number of three 
housekeeping genes was used to exclude the possibility that changes in the 
relative expression were caused by variations in the separate housekeeping 
gene expressions. 
 
Table 1 
Primers for quantitative real-time PCR analysis 
Gene GenBank Accesion Forward primer Reverse primer 
Amlicon 
size 
SR-BI U76205 GTTGGTCACCATGGGCCA CGTAGCCCCACAGGATCTCA 65 
LDLR Z19521 CTGTGGGCTCCATAGGCTATCT GCGGTCCAGGGTCATCTTC 68 
LRP1 NM008512 TGGGTCTCCCGAAATCTGTT ACCACCGCATTCTTGAAGGA 95 
MTP L47970 AGCTTTGTCACCGCTGTGC TCCTGCTATGGTTTGTTGGAAGT 50 
ABCA1 NM013454 GGTTTGGAGATGGTTATACAATAGTTGT TTCCCGGAAACGCAAGTC 96 
HMGCR M62766 TCTGGCAGTCAGTGGGAACTATT CCTCGTCCTTCGATCCAATTT 69 
ABCG1 NM053502 AGGTCTCAGCCTTCTAAAGTTCCTC TCTCTCGAAGTGAATGAAATTTATCG 85 
ABCG5 NM053754 CGCAGGAACCGCATTGTAA TGTCGAAGTGGTGGAAGAGCT 67 
ABCG8 NM130414 GATGCTGGCTATCATAGGGAGC TCTCTGCCTGTGATAACGTCGA 69 
CYP7A1 NM012942 CTGTCATACCACAAAGTCTTATGTCA ATGCTTCTGTGTCCAAATGCC 75 
CYP27 M38566 GTGTCCCGGGATCCCAGTGT CTTCCTCAGCCATCGGTGA 66 
BSEP NM021022 TGGAAAGGAATGGTGATGGG CAGAAGGCCAGTGCATAACAGA 76 
HL NM008280 CAGCCTGGGAGCGCAC CAATCTTGTTCTTCCCGTCCA 62 
LPL NM008509 CCAGCAACATTATCCAGTGCTAG CAGTTGATGAATCTGGCCACA 72 
HPRT X62085 TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG 91 
36B4 X1526775 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 85 
β-actin X03672 AACCGTGAAAAGATGACCCAGAT CACAGCCTGGATGGCTACGTA 75 
 
 
3.2.4 Western blotting 
 
Immunoblotting on protein from total liver was performed as described 
previously [49].In short, after running equal amounts of total liver protein (25 
µg) on a 7.5% SDS-PAGE gel, SR-BI was detected using rabbit polyclonal 
anti-SR-BI peptide (496–509) IgG (Abcam, Cambridge, UK) as a primary 
antibody and goat-anti-rabbit IgG (Jackson ImmunoResearch) as a 
secondary antibody. LDL receptor and LRP1 were detected using goat anti-
LDL receptor (C-20) IgG and goat anti-LRP (N-20) IgG (Santa Cruz 
Biotechnology, Inc.) as primary antibodies, respectively. As a secondary 
antibody, mouse anti-goat IgG was used (Jackson ImmunoResearch). 
Finally, immunolabeling was detected by enhanced chemiluminescence 
(Biosciences). For quantitation, ImageQuant 5.2 software was used. 
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3.2.5 Lipid analysis 
 
Serum concentrations of total cholesterol, free cholesterol, PL, and TG 
were determined using enzymatic colorimetric assays (Roche Diagnostics, 
Mannheim, Germany). Precipath L was used as an internal standard. The 
distribution of total cholesterol, PL, and TG over the different lipoproteins in 
serum was analyzed by fractionation of 30 µl of pooled serum using a 
Superose 6 column (3.2 x 30 mm, Smart-system; Pharmacia, Uppsula, 
Sweden) and determination of total cholesterol, PL, and TG as described 
above.  
 
 
3.2.6 ApoB-100 ELISA 
 
Determination of plasma ApoB-100 levels was carried out using an 
enzyme-linked immunosorbent assay with a monoclonal antibody against 
murine apoB-100 (LF3) essentially as described by Zlot et al. [51], who 
kindly provided LF3 and rabbit antisera against mouse ApoB (rabbit865).  
 
 
3.2.7 Hepatic lipid composition/liver histology 
 
Hepatic lipids were extracted according to Bligh and Dyer [52]. After 
dissolving the lipids in 2% Triton X-100, contents of cholesterol, CE, PL, 
and TG in liver tissue were determined as described above and expressed 
as micrograms per milligram of protein. Five micrometer cryosections were 
prepared on a Leica CM3050-S cryostat. Cryostat sections were routinely 
stained with hematoxylin (Sigma Diagnostics, St. Louis, MO) and Oil Red O 
(Sigma Diagnostics) for lipid visualization.  
 
 
3.2.8 Intragastric fat load-induced postprandial TG response 
 
Groups of five mice were fasted overnight. For basal TG and cholesterol 
levels, 50 µl blood samples were drawn just before 9:00 AM by tail bleeding 
into heparinized capillary tubes (time 0). At 9:00 AM, animals received an 
intragastric load of 400 µl of olive oil. After gavage, blood collection was 
performed every hour for 4 h. Plasma TG levels were measured at the 
various time points using enzymatic kits as described above. The 
distribution of TG over the different lipoproteins in plasma was analyzed by 
fractionation of 30 µl of pooled plasma using a Superose 6 column (3.2 x 30 
mm, Smart-system; Amersham Biosciences) and determination of the TG 
content of the eluted fractions as described above. 
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Fig.1. Hepatic SR-BI expression in Ad.SR-
BI-treated mice and control mice. A: Analysis 
of SR-BI expression at 5 days after adenoviral 
administration by real-time quantitative PCR in 
C57BL/6J mice treated with Ad.LacZ [5 x 108 
plaque-forming units (pfu)] or Ad.SR-BI (5 x 108 
pfu) (n=5 per group). B: Quantitation of 
Western blot analysis of SR-BI expression in 
C57BL/6J mice treated with Ad.LacZ (5 x 108 
pfu) or Ad.SR-BI (5 x 108 pfu). Below the 
quantitation histogram, a representative 
immunoblot of four samples per group is 
shown. A.U., arbitrary units. Values shown are 
means±SEM. *P<0.001 
 
 
Table 2 
Effect of SR-BI overexpression on plasma lipid levels 
Day Treatment n Total cholesterol Free cholesterol Phospholipid Triglyceride 
   mg/dl 
-3 Ad.LacZ 5 62 ± 3.7 14 ± 0.6 27 ± 0.8 113 ± 9 
5   68 ± 6.0 11 ± 1.4 24 ± 1.2 95 ± 6 
-3 Ad.SR-BI 5 62 ± 2.3 14 ± 1.1 27 ± 1.0 123 ± 14 
5   <5.0a <1.0a 1.8 ± 0.3a 63 ± 12b 
PL, phospholipid; TG, triglyceride. C57BL/6J mice (n=5 per group) were injected with Ad.LacZ 
(5 x 108 plaque-forming units) or Ad.SR-BI (5 x 108 plaque-forming units). Three days before 
injection and at 5 days after injection, overnight-fasted plasma was collected from individual 
mice and assayed for total cholesterol, free cholesterol, PL, and TG. Values are means ± SEM. 
aP<0.001, bP<0.01 compared to Ad.LacZ. 
 
 
3.3 Results 
 
 
3.3.1 Adenovirus-mediated SR-BI overexpression in C57BL/6J mice 
results in decreased plasma VLDL/CM-associated TG levels and 
plasma ApoB-100 levels 
 
SR-BI is a class B scavenger receptor that binds a broad variety of 
lipoprotein ligands. Recently, we showed that SR-BI is able to facilitate CM 
metabolism [45]. To further assess the role of SR-BI in CM metabolism, the 
receptor was overexpressed in livers of C57BL/6J mice by infusion with a 
dose of Ad.SR-BI (5 x 108 pfu), which resulted in 14-fold and 7-fold 
increases in hepatic SR-BI mRNA (Fig.1A) and protein expression (Fig.1B), 
respectively, at 5 days after infusion. Five days after Ad.SR-BI infusion, 
mice showed highly significant decreases in plasma total cholesterol and 
free cholesterol (>90%) and plasma PL (>90%) compared with mice treated 
with control adenovirus (Table 2). In addition, plasma TG levels were 
decreased significantly (2-fold) in Ad.SR-BI-treated mice compared with 
mice treated with control adenovirus (Table 2). Analysis of lipoprotein 
profiles revealed a depletion of both HDL and LDL-cholesterol (Fig.2A) and 
HDL and LDL-PL (Fig.2B) in Ad.SR-BI-treated mice compared with control 
virus-treated mice. Interestingly, Ad.SR-BI-treated mice also showed a 
significant decrease in VLDL/CM-associated TG compared with control 
virus-treated mice (Fig.2C). 
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Subsequently, ApoB-100 levels in serum of Ad.SR-BI- and Ad.LacZ-treated 
mice were determined using an enzyme-linked immunosorbent assay with a 
monoclonal antibody against murine ApoB-100 (LF3). ApoB-100 levels in 
serum of Ad.SR-BI-treated animals were significantly reduced compared 
with Ad.LacZ-treated mice (41.4% reduction; P<0.001) (Fig.3). 
 
 
Fig.2. Lipoprotein profiles in Ad.SR-BI-
treated mice and control mice. C57BL/6J 
mice (n=5 per group) were injected with 
Ad.LacZ (5 x 108 pfu) or Ad.SR-BI (5 x 108 
pfu). After 5 days, overnight-fasted plasma 
was collected and total cholesterol (A), 
phospholipid (B), and triglyceride (C) levels in 
the lipoprotein profiles of pooled plasma of 
Ad.SR-BI mice (closed squares) and control 
mice (open squares) were determined. CM, 
chylomicron 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3. Plasma apolipoprotein B-100 (ApoB-100) 
levels. C57BL/6J mice (n=5 per group) were injected 
with Ad.LacZ (5 x 108 pfu) or Ad.SR-BI (5 x 108 pfu). After 
5 days, ApoB-100 levels in serum of Ad.SR-BI- and 
Ad.LacZ-treated mice were determined using an 
enzyme-linked immunosorbent assay with a monoclonal 
antibody against murine ApoB-100 (LF3). Values shown 
are means±SEM for five mice per group. *P<0.001 
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3.3.2 Influence of Ad.SR-BI on hepatic lipid metabolism, hepatic lipid 
composition, and liver morphology 
 
Because adenovirus-mediated hepatic overexpression of SR-BI results in a 
substantial decrease of plasma cholesterol, PL, and TG, we next analyzed 
the effect of SR-BI overexpression at 5 days after infusion on hepatic genes 
involved in the uptake, metabolism, and efflux of cholesterol and TG. In 
addition to SR-BI, the uptake of cholesterol in the liver can be mediated by 
receptors such as the LDL receptor and LRP1. The decrease in LDL-
cholesterol and VLDL/CM-TG observed in Ad.SR-BI-treated mice was not 
attributable to an increase in expression of the LDL receptor or LRP1. 
Compared with control mice, the mRNA level of the LDL receptor was 
similar and that of LRP1 was decreased significantly (Fig.4A/B). In 
agreement with the mRNA levels, LDL receptor and LRP1 protein levels 
were similar and significantly decreased, respectively, in Ad.SR-BI-treated 
mice compared with control mice (Fig.4C/D). 
 
 
Fig.4. Effect of SR-BI overexpression 
on hepatic LDL receptor (LDLr) and 
LDL receptor-related protein 1 (LRP1) 
expression. At 5 days after adenoviral 
administration, LDL receptor (A) and 
LRP1 (B) expression was analyzed by 
real-time quantitative PCR in C57BL/6J 
mice treated with Ad.LacZ (5 x 108 pfu) or 
Ad.SR-BI (5 x 108 pfu) (n=5 per group). 
Also shown is the quantitation of Western 
blot analysis of LDL receptor (C) and 
LRP1 (D) expression in C57BL/6J mice 
treated with Ad.LacZ (5 x 108 pfu) or 
Ad.SR-BI (5 x 108 pfu). Values shown are 
means±SEM. *P<0.05 compared to 
Ad.LacZ. 
 
 
 
The liver has three well-known routes of cholesterol disposal. Cholesterol 
can be used for the synthesis of VLDL and HDL. The key process in VLDL 
synthesis is the intracellular association of ApoB-48/ApoB-100 with lipids in 
which the MTP is crucially involved. MTP mRNA levels have the tendency 
to be increased in Ad.SR-BI-treated mice (P=0.07) (Fig.5). Recently, it was 
shown that ABCA1 plays an essential role in the formation of HDL [53]. 
ABCA1 mRNA levels are not affected by hepatic overexpression of SR-BI 
(Fig.5). Hepatic cholesterol levels are the consequence of lipoprotein 
uptake and de novo synthesis of cholesterol by the enzyme HMG-CoA 
reductase. HMG-CoA reductase mRNA expression was not changed 
(Fig.5). As a heterodimer, ABCG5 and ABCG8 mediate biliary cholesterol 
efflux from the liver to the bile duct [54]. Recently, ABCG1 also has been 
proposed to have a role in the intracellular trafficking and efflux of 
cholesterol in the liver [48]. Neither ABCG5 and ABCG8 nor ABCG1 mRNA 
expression was changed in Ad.SR-BI-treated animals (Fig.5). Finally, 
CYP7A1 and CYP27 are responsible for the conversion of cholesterol into 
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bile acids, which can be secreted from the liver into the bile via the bile salt 
export pump (BSEP). Whereas the level of CYP27 mRNA expression was 
significantly lower in mice overexpressing SR-BI, CYP7A1 and BSEP 
expression was not different (Fig.5). LPL and HL regulate plasma TG levels 
by their TG-hydrolyzing action. The decrease in VLDL/CM-TG observed in 
Ad.SR-BI-treated mice was not attributable to an increase in the expression 
of these two enzymes, because HL was significantly lower in Ad.SR-BI-
treated mice and LPL was unchanged (Fig.5). 
Hepatic lipid content in Ad.SR-BI-treated mice was not changed, as the 
hepatic levels of PL, TG (Fig.6A), free cholesterol, or CE (Fig.6B) are all 
similar. In accordance with the above hepatic lipid composition data, Oil 
Red O staining revealed no differences in lipid depots in Ad.SR-BI-treated 
and control mice (Fig.6C). 
 
 
Fig.5. Effect of SR-BI 
overexpression on genes 
involved in hepatic 
cholesterol metabolism. 
C57BL/6J mice (n=5 per 
group) were injected with 
Ad.LacZ (5 x 108 pfu) or 
Ad.SR-BI (5 x 108 pfu). 
After 5 days, hepatic 
mRNA levels of the 
indicated genes were 
determined by real-time 
quantitative PCR. Values 
shown are means±SEM. 
*P<0.05 compared to 
Ad.LacZ. 
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Fig.6. Hepatic lipid content in Ad.SR-BI-treated mice and control mice. C57BL/6J mice 
(n=5 per group) were injected with Ad.LacZ (5 x 108 pfu) or Ad.SR-BI (5 x 108 pfu). After 5 
days, hepatic PL and TG (A), and free cholesterol (FC) and cholesteryl ester (CE; B) levels 
were analyzed. Five micrometer cryosections of livers of Ad.LacZ- and Ad.SR-BI-treated mice 
were stained with Oil Red O for lipid visualization and counterstained with hematoxylin. Values 
shown are means±SEM. 
 
 
3.3.3 Effect of SR-BI overexpression on CM metabolism in vivo 
 
We next investigated the effect of SR-BI overexpression on the postprandial 
TG response upon an intragastric fat load, which is an established 
procedure to study the kinetics of CM metabolism. After an intragastric load 
of olive oil, plasma TG levels were determined over a period of 4 h in 
Ad.SR-BI-treated and control virus-treated mice. Before gavage, Ad.SR-BI-
treated mice had significantly lower basal levels of plasma TG (Table 2). At 
2 h after olive oil administration, control virus-treated animals showed a 
postprandial increase in plasma TG (3.1-fold) (Fig.7A), which decreased 
again at 4 h after administration. In contrast, Ad.SR-BI-treated mice showed 
a 2-fold decreased TG response compared with control virus-treated mice 
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(area under the curve = 31.4 ± 2.4 vs. 17.7 ± 3.2; P<0.05). Specifically, the 
increase in plasma TG was significantly lower at 1, 2, and 3 h after gavage 
(Fig.7A). Analysis of lipoprotein profiles at 3 h after gavage (Fig.7B) showed 
that plasma TG in the VLDL/CM fraction was lower in Ad.SR-BI-treated 
mice compared with control virus-treated mice, and the reduction was 
mainly attributable to a decrease in CM-associated TG. 
 
 
Fig.7. Effect of SR-BI overexpression on the 
postprandial TG response upon an 
intragastric fat load. C57BL/6J mice (n=5 per 
group) were injected with Ad.LacZ (5 x 108 pfu; 
open squares) or Ad.SR-BI (5 x 108 pfu; closed 
squares). After 5 days, overnight-fasted mice 
received an intragastric load of 400 µl of olive oil 
at time 0. A: Subsequently, plasma TG levels 
were determined at the indicated times, and the 
data are expressed as increases in TG levels 
relative to time 0. B: At 3 h after olive oil 
administration, TG levels in the lipoprotein 
profiles of pooled plasma were determined. 
Values shown are means±SEM. *P<0.05 and 
**P< 0.01 compared to Ad.LacZ. 
 
 
 
 
 
 
 
3.4 Discussion 
 
SR-BI is a multiligand cell surface receptor capable of binding HDL, LDL, 
VLDL, modified LDL and BSA, and liposomes containing anionic PL [4–7]. 
Although the function of SR-BI in the selective uptake of CE from HDL is 
undisputable [12], conflicting information on a potential role of SR-BI in the 
metabolism of ApoB-containing lipoproteins exists [14–20].  
Using SR-BI-deficient mice, we recently showed that SR-BI can facilitate 
CM (remnant) metabolism [45]. In the present study, we investigated to 
what extent the role of SR-BI in VLDL/CM (remnant) metabolism is critically 
dependent on SR-BI protein levels by assessing the effect of adenovirus-
mediated hepatic overexpression of SR-BI in C57BL/6J mice. Adenovirus-
mediated overexpression of SR-BI led to a significant decrease in HDL-
cholesterol and was accompanied by a decrease in the main apolipoprotein 
constituent of HDL (ApoA-I) (data not shown), as also observed in other 
studies [13,15,16,46], and a substantial increase in biliary cholesterol [13]. 
Strikingly, plasma TG levels, VLDL/CM-associated TG, and plasma ApoB-
100 levels were all significantly reduced: findings that correlate with a 
potential role for SR-BI in VLDL/CM metabolism. In the present work, we 
analyzed the effect of SR-BI protein level on endogenous CM metabolism 
by giving an intragastric fat load to Ad.SR-BI-treated mice and control mice. 
After administration of olive oil, the maximum level of TG reached in the 
blood circulation was 2-fold lower, corresponding with a significant 
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decrease in the area under the curve (31.4 ± 2.4 vs. 17.7 ± 3.2; P<0.05) in 
the Ad.SR-BI-treated mice compared with control mice. Both the decreased 
plasma TG levels and the decreased postprandial response could have 
been attributed to other processes, such as decreased VLDL production, 
and/or indirect effects of overexpression of SR-BI on the expression of 
other hepatic genes involved in cholesterol and/or CM metabolism. For this 
reason, we assessed both the mRNA and protein levels of the LDL receptor 
and LRP1, which are believed to be responsible for the internalization of 
VLDL and CM remnants by the liver. The expression of the LDL receptor 
appeared unchanged, whereas the LRP level was actually lower by Ad.SR-
BI administration. Thus, the decreased plasma TG levels and the change in 
postprandial response cannot be caused by an increased expression of 
these two receptors. Hepatic expression of proteins involved in cholesterol 
transport and/or metabolism, such as ABCA1, ABCG1, ABCG8, CYP7A1, 
CYP27, and BSEP, were not increased by Ad.SR-BI administration, 
indicating that the observed change in serum lipoproteins is not related to 
these proteins. Actually, only MTP had the tendency to be increased 
(P=0.07), which suggests a compensatory mechanism to resecrete the SR-
BI-mediated hepatic uptake of TG in the form of VLDL. LPL and HL regulate 
plasma TG levels by their TG-hydrolyzing action. The decrease in 
VLDL/CM-TG observed in Ad.SR-BI-treated mice was not attributable to an 
increase in the expression of these two enzymes, because HL was 
significantly lower in Ad.SR-BI-treated mice and LPL was unchanged.  
Combined with our earlier data in SR-BI-deficient mice, the present 
experiments using transient adenovirus-mediated overexpression of SR-BI 
in C57BL/6J indicate that SR-BI levels are important for the kinetics of 
postprandial lipemia. Previous studies have suggested that postprandial 
remnant particles may predict the onset of atherosclerosis. Consistent with 
our present findings, it was suggested by Arai et al. [55] that in 
heterozygous LDL receptor deficient mice, the transgene expression of SR-
BI leads to decreased atherosclerosis, which correlated with decreased 
VLDL- and LDL-cholesterol levels [55]. Also, Wang et al. [15] and Ueda et 
al. [16,17] observed in SR-BI transgenic mice decreased levels of VLDL-
ApoB and LDL-ApoB. Kozarsky et al. [56] have shown that adenovirus-
mediated hepatic overexpression of SR-BI in fat-fed LDL receptor deficient 
mice leads to a marked decrease in HDL cholesterol and a modest 
decrease in intermediate density lipoprotein/LDL cholesterol. The modest 
reduction in non-HDL-cholesterol in these studies can be explained by the 
absent activity of the LDL receptor needed for the internalization of the 
remnants [30,57]. Furthermore, Fu, Kozarsky, and Borensztajn [20] recently 
observed that fibrate-induced hypercholesterolemia in ApoE deficient mice 
can be normalized by the overexpression of SR-BI. It was suggested that 
SR-BI can function as a remnant receptor responsible for the clearance of 
remnant particles from the circulation of ApoE-deficient mice. Together with 
our recent observation in SR-BI-deficient mice, our present experiments 
suggest that SR-BI can indeed function as an initial recognition site for 
VLDL/CM not only in ApoE-deficient mice but also under normal metabolic 
conditions. 
The mechanism responsible for the initial liver capture of CM remnants has 
been a point of continuous dispute [22–24]. In mice without ApoE-
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recognizing internalizing receptor (LRP1/LDL receptor double deficient 
mice), the initial association of lipoprotein remnants [30] and large emulsion 
particles (P.C.N. Rensen, J.K. Kruijt, and T.J.C. Van Berkel, unpublished 
results) with the liver is not affected, indicating that another molecular 
structure is responsible for the initial liver recognition. SR-BI fulfills the 
requirements as an initial recognition site in that it is a multi-ligand cell 
surface receptor with a limited substrate specificity, which includes not only 
apolipoproteins but also lipids such as phosphatidylserine, a remnant 
surface component. The present experiments are consistent with SR-BI 
serving as an initial remnant recognition site. The locally available ApoE 
[58] may subsequently be acquired and trigger internalization. Although 
ApoB-100 levels were decreased by Ad.SR-BI, our data do not necessarily 
implicate SR-BI as an internalizing receptor, because studies with 
LRP1/LDL receptor double deficient mice have clearly shown the decisive 
role of this combined system for the internalization and further catabolism of 
remnants [30,57] and large emulsion particles (P.C.N. Rensen, J.K. Kruijt, 
and T.J.C. Van Berkel, unpublished results) by the liver.  
Very interesting and consistent with our data, Pérez-Martinez et al. [59] 
recently suggested a role for SR-BI in postprandial CM metabolism in 
humans. They observed that a polymorphism in the exon 1 variant at the 
SR-BI gene locus called genotype 1/2 was associated with a lower 
postprandial response compared with that in individuals with a 1/1 genotype 
[59]. The expression levels of hepatic SR-BI in both genotypes were not 
analyzed, but this knowledge could shed additional light on the role of SR-
BI as a remnant receptor in humans.  
In summary, we have further substantiated the proposed role of SR-BI in 
CM metabolism by assessing the effect of adenovirus-mediated hepatic 
overexpression of SR-BI. Adenovirus-mediated hepatic overexpression of 
SR-BI in C57BL/6J mice resulted in a decrease in plasma TG, a decrease 
in VLDL/CM-associated TG, and a changed postprandial TG response. 
These data support our earlier suggestion that SR-BI is involved in 
facilitating CM remnant metabolism, and the present study strengthens the 
notion that besides its role in HDL metabolism, SR-BI is crucially involved in 
facilitating CM (remnant) metabolism. We conclude that overexpression of 
SR-BI accelerates CM metabolism possibly by mediating the initial capture 
of CM remnants by the liver, leading to subsequent internalization by 
receptor systems such as the LDL receptor and LRP1.  
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Type II diabetes is a disease with a heterogeneous phenotype, which is 
primarily characterized by an increase in serum glucose levels. However, 
patients suffering from diabetes usually also have lipid abnormalities, such 
as hypertriglyceridemia. Recent data have indicated that there appears to 
be a significant interaction between variation at the SR-BI locus and type II 
diabetes in determining the lipoprotein profile. Since SR-BI might thus play 
a role in the pathology of diabetes, in the current study the role of SR-BI in 
glucose metabolism was evaluated. SR-BI deficiency in mice resulted in a 
42% decrease in fasting serum glucose levels, which could not be attributed 
to a change in the expression of genes involved in hepatic glucose 
synthesis (PEPCK, PGC-1) and metabolism (L-PK). However, the hepatic 
expression of the rate-limiting enzyme in ketogenesis, HMG-CoA synthase, 
was decreased by 54% due to a hampered hepatic uptake of lipoprotein-
associated fatty acids via SR-BI. The subsequently lower production of 
ketone bodies leads to a reduction in fasting serum glucose levels due to a 
higher peripheral glucose uptake. 
In conclusion, in addition to its role in lipid metabolism, our data indicate 
that functional SR-BI is important for the maintenance of adequate fasting 
serum glucose levels. 
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4.1 Introduction 
 
Cardiovascular diseases are the most common cause of death in the 
Western world. Multiple risk factors for the development of cardiovascular 
disease have been identified, which include elevated serum lipid levels, 
hypertension, obesity, smoking, and type II diabetes [1]. Type II diabetes is 
a disease with a heterogenous phenotype, which is characterized by an 
increase in serum glucose levels combined with dyslipidemia i.e. elevated 
triglyceride and reduced high-density lipoprotein (HDL) cholesterol levels 
and postprandial lipemia (reviewed by Verges [2]). Several studies have 
indicated that the liver plays an important role in the development of the 
type II diabetic phenotype, contributing to dyslipidemia and the increase in 
glucose levels [3,4]. Interestingly, recent data by Osgood et al. have 
indicated that variation in the scavenger receptor class B type I (SR-BI) 
gene in humans is associated with both lipid concentrations and lipoprotein 
particle size. Moreover, there appears to be a significant interaction 
between variation at the SR-BI locus and type II diabetes in determining the 
lipoprotein profile [5]. In the liver, SR-BI is a key gene in reverse cholesterol 
transport since it is able to selectively remove cholesterol esters from HDL 
without the concomitant uptake of the HDL protein [6]. The importance of 
SR-BI in lipid metabolism was provided through studies in SR-BI deficient 
mice, which showed that absence of functional SR-BI resulted in 2-fold 
increased serum total cholesterol levels due to the accumulation of 
abnormally large (defective) HDL particles [7,8], leading to an increased 
susceptibility to atherosclerosis [9]. In addition to HDL, SR-BI is able to bind 
a wide variety of other ligands, including anionic phospholipids [10], 
apoptotic cells [11], and native and modified lipoproteins [6,12-14]. 
Moreover, SR-BI is also able to bind advanced glycation end products 
(AGE) [15], which are stable covalent adducts of glucose and 
proteins/nucleic acids that are formed without the aid of enzymes [16]. 
Importantly, under diabetic conditions prolonged exposure of proteins to 
high serum glucose levels leads to an excessive formation of AGE, which 
can covalently trap extravasated serum proteins to the extravascular matrix, 
and thus may contribute to capillary closure in the retina and glomerulus, 
and to arterial narrowing in the coronary, cerebral, and peripheral circulation 
[17]. Since hepatic SR-BI is able to bind and remove AGE from the 
circulation, SR-BI might be considered beneficial in the treatment of 
diabetes. To further investigate this potential beneficial role of SR-BI in 
diabetes, in the current study the role of SR-BI in the hepatic regulation of 
fasting serum glucose levels was studied in normal mice by determining the 
effect of absence of functional SR-BI on the expression of hepatic genes 
involved in the regulation of fasting serum glucose levels. 
Here we show that, under fasting conditions, SR-BI deficiency due to a 
hampered hepatic uptake of lipoprotein-associated fatty acids results in a 
decreased hepatic expression of the rate-limiting ketogenesis enzyme 
HMG-CoA synthase and a subsequent fall in fasting serum glucose levels, 
consistent with a decreased hepatic activation of PPARalpha [18]. In 
conclusion, we propose an important novel role for SR-BI in the control of 
fasting serum glucose levels. 
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4.2 Experimental Procedures 
 
 
4.2.1 Animals 
 
SR-BI deficient mice were kindly provided by Dr. M. Krieger [8]. 
Heterozygous SR-BI deficient mice were crossbred to generate wild-type 
and homozygous progeny. The offspring of the mice were analysed for the 
presence of targeted or wild-type SR-BI alleles by PCR, as described by 
Van Eck et al. [9]. Male homozygous SR-BI deficient mice and wild-type 
littermates as controls were maintained on a sterilized regular chow (RM3, 
Special Diet Services, Witham, UK). At 12-16 weeks of age, overnight 
fasted mice were anesthetized, and blood was collected for lipid and 
glucose analyses. Subsequently, a whole-body perfusion was performed 
using phosphate-buffered saline (4°C, 100 mm Hg) for 10 min. After 
perfusion, the liver was excised, weighed, and frozen in liquid nitrogen and 
stored at -80°C. Animal experiments were performed at the Gorlaeus 
Laboratories of the Leiden/Amsterdam Center for Drug Research in 
accordance with national laws. All experimental protocols were approved by 
the Ethics Committee for Animal Experiments of Leiden University. 
 
 
4.2.2 Lipid analyses 
 
Fasting serum concentrations of free and total cholesterol, phospholipids, 
free fatty acids, and triglycerides were determined using enzymatic 
colorimetric assays (Roche Diagnostics). The cholesterol distribution over 
the different lipoproteins in serum was analysed by fractionation of 30 µl 
serum of each mouse using a Superose 6 column (3.2 x 30 mm, Smart-
system, Pharmacia). Total cholesterol content of the effluent was 
determined using enzymatic colorimetric assays (Roche Diagnostics), 
taking the efficiency of recovery from the column into account. 
 
 
4.2.3 Glucose analysis 
 
Fasting serum glucose levels were determined essentially as described 
[19]. In short, 200 µl coloring reagent, containing 2,2'-azino-di(3-
ethylbenzthiazoline-6-sulphonate), glucose-oxidase, and peroxidase was 
added to 5 µl 25-times diluted serum of SR-BI deficient and wild-type mice. 
After a 30-minute incubation at 37°C, the absorbance was measured at 405 
nm and the glucose concentration was determined. 
 
 
4.2.4 Analysis of gene expression by real-time quantitative PCR 
 
Quantitative gene expression analysis on livers of SR-BI deficient mice and 
their wild-type littermates was performed as described [20]. In short, total 
RNA was isolated according to Chomczynski and Sacchi [21] and reverse 
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transcribed using RevertAidTM reverse transcriptase. Gene expression 
analysis was performed using real-time SYBR Green technology 
(Eurogentec) with the primers displayed in Table 1, which were validated for 
identical efficiencies (slope = -3.3 for a plot of Ct versus log ng cDNA). 
Hypoxanthine guanine phosphoribosyl transferase (HPRT), 18S ribosomal 
RNA (18SrRNA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
and acidic ribosomal phosphoprotein P0 (36B4) were used as the standard 
housekeeping genes. Relative gene expression numbers were calculated 
by subtracting the threshold cycle number (Ct) of the target gene from the 
average Ct of HPRT, 18SrRNA, GAPDH, and 36B4 (Cthousekeeping) and 
raising 2 to the power of this difference. The average Ct of four 
housekeeping genes was used to exclude that changes in the relative 
expression were caused by variations in the expression of the separate 
housekeeping genes. 
 
 
Table 1 
Primers for quantitative real-time PCR analysis 
Gene GenBank Accession Forward primer Reverse primer 
Amplicon 
size 
18SrRNA X00686 CCATTCGAACGTCTGCCC GTCACCCGTGGTCACCATG 69 
36B4 NM007475 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 85 
ACO NM015729 AATTGGCACCTACGCCCAG GTGGTTTCCAAGCCTCGAAG 63 
CPT-I NM013495 CACTACGGAGTCCTGCAACTTTG AGCTTGAACCTCTGCTCTGCC 72 
L-FABP NM017399 TCACCATCACCTATGGACCCA TCCAGTTCGCACTCCTCCC 67 
GADPH NM008084 TCCATGACAACTTTGGCATTG TCACGCCACAGCTTTCCA 103 
HMGCS2 NM008256 TTTCATTCCGAGTGTCCAAGG CTGACACACTAGACACCAGTTTCTCC 69 
HPRT J00423 TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG 91 
L-PK NM013631 AAGACAGTGTGGGTGGACTACCA CGTCAATGTAGATGCGGCC 70 
PEPCK NM011044 TTGAACTGACAGACTCGCCCT GATATGCCCATCCGAGTCATG 64 
PGC-1 NM008904 CCCGATCACCATATTCCAGG GTAGTGGCTTGATTCATAGTAGTAACAGGA 89 
 
 
4.2.5 Data analysis 
 
The significance of differences in relative gene expression numbers 
between livers of SR-BI deficient and wild-type mice, measured by real time 
quantitative PCR, was calculated using a two-tailed unpaired Student’s t-
test on the differences in Ct (Cthousekeeping – Cttarget gene). Probability values 
less than 0.05 were considered significant. 
 
 
3.3 Results 
 
 
In the current study, the potential beneficial role of SR-BI in the treatment of 
diabetes was investigated by determining whether SR-BI plays a role in the 
regulation of serum glucose levels in normolipidemic mice. In agreement 
with earlier studies, overnight (~16h) fasted SR-BI deficient mice have 
significantly increased serum (free) cholesterol and triglyceride levels as 
compared to wild-type controls, which is due to increased levels of HDL and 
VLDL, respectively (Table 2; Fig.1). However, no change in serum free fatty 
acid levels was seen upon SR-BI deficiency (Table 2). In contrast, the 
fasting serum glucose levels were 42% decreased in SR-BI deficient mice 
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as compared to wild-type littermate controls (P<0.01; Fig.2).  This suggests 
that indeed SR-BI plays a role in the regulation of fasting serum glucose 
levels. Blood glucose levels are maintained by the balance between 
glucose uptake by peripheral tissues and glucose secretion by the liver. 
During fasting, blood glucose levels decrease rapidly as a result of 
hampered glucose intake. In response, the liver starts breaking down 
glycogen to glucose-6-phosphate, which is subsequently converted to free 
glucose that can be excreted into serum (glycogenolysis pathway). 
However, after a longer fasting period (>8h) the breakdown of glycogen is 
replaced by gluconeogenesis, a process in which hepatic pyruvate is 
transformed into free glucose, to preserve glycogen stores [22]. 
 
 
Table 2 
Effect of SR-BI deficiency on fasting serum lipid levels 
 n Free cholesterol 
Total 
cholesterol Phospholipid Triglyceride FFA 
  mg/dl mM 
SR-BI +/+ 6 20.0 ± 0.8 62.2 ± 6.4 172 ± 4.4 81 ± 4.1 0.69 ± 0.05 
SR-BI -/- 6 84.8 ± 2.9 *** 181.9 ± 8.0 *** 183 ± 3.5 108 ± 13.2 * 0.66 ± 0.09 
Serum lipid levels were measured in SR-BI deficient (-/-) and wild-type (+/+) mice on a chow 
diet after an overnight fasting period (means+SEM). *P<0.05, ***P<0.001 compared to wild-
type mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. Effect of SR-BI deficiency on serum lipoprotein cholesterol and triglyceride 
distribution. Blood samples were drawn after an overnight fast from SR-BI deficient (●) and 
wild-type (○) mice. Sera from 6 individual mice were loaded onto a Superose 6 column and 
fractions were collected. Fractions 3-6 represent VLDL; fractions 8-12, LDL; and fractions 12-
20, HDL, respectively 
 
 
 
Fig.2. Effect of SR-BI deficiency on fasting serum 
glucose levels. Blood samples were drawn after an 
overnight fast from SR-BI deficient (closed bar) and wild-
type (open bar) mice (means+SEM; n=6); **P<0.01 
compared to wild-type mice. 
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Phosphoenolpyruvate carboxykinase (PEPCK) is generally considered to 
be the first rate-limiting step in gluconeogenesis in hepatic cells [23]. 
Furthermore, recent data from Yoon et al. suggested that nuclear 
coactivator PGC-1 is a key modulator of hepatic gluconeogenesis [24].  
Interestingly, SR-BI deficiency did not have an effect on the hepatic 
expression of PEPCK or PGC-1 (Fig.3), which indicates that absence of 
functional SR-BI does affect hepatic gluconeogenesis. In contrast to 
gluconeogenesis, the glycolytic pathway mediates the breakdown of 
glucose to pyruvate. To determine whether SR-BI deficiency affected 
glycolysis, the expression of a key enzyme of the glycolytic pathway in the 
liver, L-type pyruvate kinase (L-PK) [25], was determined in SR-BI deficient 
and wild-type mice. Pyruvate kinase expression is highly regulated upon a 
demanded change in the glycolysis rate [26,27]. No significant change in 
the expression of pyruvate kinase was observed in SR-BI deficient mice as 
compared to wild-type littermate controls (Fig.3), which suggests that SR-BI 
deficiency did not influence the glycolysis rate. 
 
 
Figure 3: Effect of SR-BI deficiency on hepatic 
mRNA expression of genes involved in 
gluconeogenesis and glycolysis. Gene expression 
analysis was performed by means of real-time 
quantitative PCR. Values are expressed as fold 
induction compared to wild-type mice (means+SEM; 
n=6). 
 
 
 
 
 
Importantly, particularly under fasting “low glucose” conditions, extrahepatic 
tissues (e.g. brain, muscle) are also able to use an alternative source of 
energy generated by the liver, namely ketone bodies. These ketone bodies 
are produced in the liver from fatty acids by fatty acid oxidation and 
subsequent ketogenesis [28]. Because no change was observed in the 
hepatic expression of genes involved in the generation and breakdown of 
glucose, the effect of SR-BI deficiency on hepatic fatty acid oxidation and 
ketogenesis was studied by determining the effect on the expression of 
genes involved in these processes. The expression of the rate-limiting 
enzyme in the peroxisomal beta-oxidation, acyl-CoA oxidase (ACO) [29], 
was not different between SR-BI deficient and wild-type mice (Fig.4). 
Moreover, the expression of carnitine palmitoyltransferase I (CPT-I), an 
essential enzyme in the beta-oxidation of long-chain fatty acids in the 
mitochondria [30], was also unchanged (Fig.4). Furthermore, no significant 
change (Fig.4) was observed in the expression of liver fatty acid binding 
protein (L-FABP), which specifically enhances the uptake and intracellular 
targeting of long and medium chain fatty acids to the nucleus [31]. In 
contrast, the hepatic expression of HMG-CoA synthase (HMGCS), a key 
enzyme in ketogenesis [32], was significantly reduced by 54% (P=0.004) in 
SR-BI deficient mice as compared to wild-type mice (Fig.5). 
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Fig.4. Effect of SR-BI deficiency on hepatic mRNA 
expression of genes involved in fatty acid 
transport and metabolism. Gene expression analysis 
was performed by means of real-time quantitative 
PCR. Values are expressed as fold induction 
compared to wild-type mice (means+SEM; n=6). 
 
 
 
 
 
 
 
Fig.5. Effect of SR-BI deficiency on hepatic mRNA expression 
of the rate-limiting ketogenesis enzyme HMG-CoA synthase 
(HMGCS2). Gene expression analysis was performed by means 
of real-time quantitative PCR. Values are expressed as fold 
induction compared to wild-type mice (means+SEM; n=6). 
 **P<0.01 compared to wild-type mice. 
 
 
 
 
 
 
 
4.4 Discussion 
 
Recently, it has been suggested that SR-BI might play a role in diabetes. In 
the current study, the effect of the absence of functional SR-BI on hepatic 
genes involved in the regulation of fasting glucose levels was determined. 
Strikingly, fasting serum glucose levels were 42% decreased in SR-BI 
deficient mice as compared to wild-type littermates without a change in the 
expression of key genes in gluconeogenesis (PEPCK and PGC-1) and 
glycolysis (pyruvate kinase), the major pathways involved in the regulation 
of hepatic glucose metabolism. Hepatic PEPCK and PGC-1 expression is 
stimulated by many different factors, including glucocorticoids, cAMP, and 
thyroid hormone [33-35], whilst the key regulator of serum glucose levels, 
insulin, is able to inhibit PEPCK and PGC-1 expression [24,33]. In contrast 
to inhibition of PEPCK expression, insulin is able to stimulate the 
expression of pyruvate kinase [36,37]. However, the unchanged hepatic 
expression of PEPCK, PGC-1, and pyruvate kinase in SR-BI deficient mice 
suggests that changes in insulin signalling and the associated 
gluconeogenesis and glycolysis pathways were not responsible for the 
decreased serum glucose levels observed in these mice. 
It became clear from human patients carrying mutations in the HMGCS 
gene, which suffer from severe hypoglycaemia [38] and hypoglycemic 
hypoketotic coma during fasting periods [39,40] that hepatic fatty acid 
oxidation and subsequent ketogenesis are also important pathways 
involved in the regulation of fasting glucose levels, since ketone bodies can 
act as an alternative source of energy for peripheral tissues. The 
expression of key enzymes in the peroxisomal (ACO) and mitochondrial 
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fatty acid oxidation (L-FABP and CPT-I) was not changed, which suggests 
that fatty acid oxidation was not affected by SR-BI deficiency. In contrast, in 
fasted SR-BI deficient mice a 54% decreased hepatic HMGCS mRNA 
expression was observed. HMGCS catalyzes the rate-limiting step in liver 
ketone body formation and its activity correlates with the supply of ketone 
bodies which serve as an alternative extra-hepatic substrate by which extra-
hepatic glucose utilization can be spared. The lack of adequate hepatic 
ketone body formation will lead to increased peripheral glucose utilization 
with consequently a net decrease in the fasting serum glucose level. 
The promoter of HMGCS contains (putative) recognition sequences for 
several transcription factors [41], such as the forkhead transcription factor 
FKHRL1 [42], hepatocyte nuclear factor 4 (HNF4) [43], and peroxisome 
proliferator-activated receptor (PPAR) [44,45]. However, data provided by 
Rodriquez et al. and Hegardt have indicated that PPARalpha mediates 
regulation of HMGCS under fasting conditions [43,46]. This suggests that 
the hepatic activity of PPARalpha is decreased in SR-BI deficient mice as 
compared to their wild-type littermates. In agreement, 24-hours fasted 
PPARalpha deficient mice also have a decreased hepatic HMGCS 
expression and a 60% lowered serum glucose level as compared to their 
wild-type littermates, with an unchanged hepatic CPT-I expression [47]. In 
addition, the hepatic expression of a novel PPARalpha target gene, 
microsomal triglyceride transfer protein (MTP) [48], trended to a decrease 
(P=0.09) in SR-BI deficient mice (data not shown). Furthermore, 
PPARalpha activation has been shown to result in increased hepatic 
secretion of ApoB-containing lipoproteins [49] since MTP is the rate-limiting 
enzyme in VLDL ApoB secretion [50]. In accordance, the VLDL secretion 
rate also shows a trend to a decrease in SR-BI deficient mice as compared 
to wild-type mice (unpublished data, M. Van Eck, R. Out, M. Hoekstra, 
I.S.T. Bos, J.K. Kruijt, and Th.J.C. van Berkel). Moreover, Mardones et al. 
have shown that the hepatic expression of cholesterol 7α-hydroxylase 
(CYP7A1), another murine PPAR target gene [51], was decreased in SR-BI 
deficient mice [52]. 
Out et al. have recently shown that SR-BI deficient mice have a hampered 
hepatic uptake of triglyceride-rich lipoproteins [53], which are a source for 
intra-hepatic fatty acids, since their triglycerides upon entry in the liver are 
rapidly lipolysed to fatty acids by lysosomal acid lipase [54]. In addition, 
multiple studies have shown that the selective uptake of HDL cholesterol 
esters, which are also a source for intra-hepatic fatty acids via breakdown 
by lysosomal acid lipase, is greatly reduced in SR-BI deficient mice [8,9], 
since SR-BI is solely responsible for the selective uptake of cholesterol 
esters from HDL by the liver [55,56]. The hampered hepatic 
association/uptake of triglycerides and cholesterol due to absence of 
functional SR-BI can thus explain the increase in serum VLDL-triglyceride 
and HDL-cholesterol levels compared to controls observed in the current 
study. Moreover, the decreased uptake of lipoprotein-associated fatty acids 
might have caused the lower PPARalpha activity (fatty acids are potent 
naturally occurring activators of PPARalpha [57,58]) and decrease in 
hepatic HMGCS expression which will lead to lower serum glucose levels. 
In conclusion, we have shown that, under fasting conditions, SR-BI 
deficiency due to a hampered hepatic uptake of lipoprotein-associated fatty 
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acids results in a decreased hepatic expression of the rate-limiting 
ketogenesis enzyme HMG-CoA synthase and a subsequent fall in fasting 
serum glucose levels. In this light, we propose an important novel role for 
SR-BI in the control of fasting serum glucose levels.  
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Since high dietary lipid levels are a common risk factor for atherosclerosis, 
many studies have been conducted to gain more insight into the 
mechanism behind atherogenesis.  Wild-type mice do develop 
atherosclerotic lesion development on an atherogenic diet containing a 
combination of increased cholesterol and fat levels and cholic acid. 
However, no atherosclerotic lesion development is observed in wild-type 
mice after 20 weeks of feeding a diet containing 0.25% cholesterol and 15% 
fat without cholic acid. The liver is an essential organ in the modulation of 
total body cholesterol homeostasis, and thus atherosclerotic lesion 
formation, since it is able to take up lipid from the circulation for biliary efflux 
and subsequent excretion via the feces. To determine whether the liver 
plays a role in the inhibition of diet induced lesion formation, in the current 
study the effect of a diet containing 0.25% cholesterol, 15% fat (without 
cholic acid) on lipid metabolism was studied in C57BL/6 mice. Feeding 
C57BL/6 mice the high cholesterol/high fat diet induces an increased 
hepatic activation of the nuclear receptors LXR and PPARalpha resulting in 
significant changes in the hepatic expression of genes involved in the 
maintenance of hepatic and total body lipid homeostasis, such as ABCA1 
(HDL production), BSEP, CYP3A11, CYP7A1, SHP (bile acid synthesis and 
metabolism), HMG-CoA reductase and SREBP-1 (lipid synthesis), CD36, 
PPARgamma (adipogenesis), and SCD1 (VLDL production). The net result 
of these adaptive changes leads to a non-atherogenic serum lipoprotein 
profile, thus preventing the development of atherosclerotic lesions in the 
vessel wall. 
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5.1 Introduction 
 
Atherosclerosis is a common cause of death in the Western world. In the 
past, several risk factors for the development of atherosclerotic lesions 
have been identified. These include smoking, diabetes, obesity, and 
changed serum lipid levels. Increased plasma very low-density lipoprotein 
(VLDL) and low-density lipoprotein (LDL) cholesterol levels are a well-
established risk factor for the development of atherosclerotic lesions [1,2], 
while increased levels of high-density lipoprotein (HDL) have been shown to 
inhibit atherogenesis [3,4]. To elucidate the pathways by which the different 
lipoproteins mediate their pro- or anti-atherogenic effect, several murine 
models of dyslipidemia have been generated. Mice that lack ApoE (ApoE 
deficient mice) spontaneously develop atherosclerotic lesions on a regular 
chow diet due to an accumulation of long circulating VLDL remnants [5]. In 
addition, LDL receptor deficient mice develop lesions on a diet containing 
increased levels of cholesterol and fat, due to an accumulation of VLDL 
remnants and LDL [6-8]. Moreover, scavenger receptor class B type I (SR-
BI) deficient mice fed a high cholesterol/high fat diet are susceptible to 
atherosclerotic lesion development [9]. Wild-type mice also do develop 
atherosclerotic lesion development on an atherogenic diet containing a 
combination of increased cholesterol and fat levels and cholic acid (Paigen 
diet) [10]. However, no atherosclerotic lesion development is observed in 
wild-type mice after 20 weeks of feeding a diet containing 0.25% cholesterol 
and 15% fat without cholic acid (Western type diet) [9], which suggests that 
wild-type mice are resistant to the induction of atherosclerotic lesion 
formation by this diet. 
The liver is an essential organ in the modulation of total body cholesterol 
homeostasis, and thus atherosclerotic lesion formation, since it is able to 
take up lipid from the circulation for biliary efflux and subsequent excretion 
via the feces [11,12]. Furthermore, the liver is the key organ involved in the 
production of HDL, which is an essential component of the reverse 
cholesterol transport pathway. To determine whether the liver plays a role in 
the inhibition of diet induced lesion formation, in the current study the effect 
of an atherogenic high cholesterol/high fat Western type diet containing 
0.25% cholesterol, 15% fat (without cholic acid) on lipid metabolism was 
studied in C57BL/6 mice. 
Here we report that, as compared to a regular chow diet, feeding a high 
cholesterol/high fat diet leads to increased serum levels of the pro-
atherogenic lipoprotein VLDL (4.2-fold) and the anti-atherogenic lipoprotein 
HDL (1.7-fold) in C57BL/6 mice, with a minor increase in hepatic lipid 
levels. The changes in the serum lipoprotein profile are due to increased 
hepatic activation of the nuclear regulators LXR and PPARalpha resulting in 
significant changes in the hepatic expression of genes involved in the 
maintenance of hepatic and total body lipid homeostasis, such as ABCA1 
(HDL production), BSEP, CYP3A11, CYP7A1, SHP (bile acid synthesis and 
metabolism), HMG-CoA reductase and SREBP-1 (lipid synthesis), CD36, 
PPARgamma (adipogenesis), and SCD1 (VLDL production). The net result 
of these adaptive changes is a non-atherosclerotic serum lipoprotein profile, 
thus preventing the development of atherosclerotic lesions in the vascular 
wall. 
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5.2 Experimental Procedures 
 
 
5.2.1 Animals 
 
Male C57BL/6 mice (10-12 weeks old) were obtained from Charles River 
Laboratories (Maastricht, The Netherlands). Mice were maintained on 
sterilized regular chow containing 4.3% (w/w) fat with no added cholesterol 
(RM3; Special Diet Services, Witham, U.K.) or were fed a semi-synthetic 
diet containing 15% (w/w) fat and 0.25% (w/w) cholesterol (Diet W; Hope 
Farms, Woerden, The Netherlands) for two weeks. Subsequently, after an 
overnight (~16 h) fasting period, serum was drawn for lipid analyses, which 
was followed by a whole-body perfusion using phosphate-buffered saline 
(4°C, 100 mm Hg) for 10 min. After perfusion, the liver was excised, 
weighed, and frozen in liquid nitrogen and stored at -80°C. Animal 
experiments were performed at the Gorlaeus Laboratories of the 
Leiden/Amsterdam Center for Drug Research in accordance with national 
laws. All experimental protocols were approved by the Ethics Committee for 
Animal Experiments of Leiden University. 
 
 
5.2.2 Lipid analyses 
 
Fasting serum concentrations of free and total cholesterol, phospholipids, 
and triglycerides were determined using enzymatic colorimetric assays 
(Roche Diagnostics). The cholesterol distribution over the different 
lipoproteins in serum was analysed by fractionation of 30 µl serum of each 
mouse using a Superose 6 column (3.2 x 30 mm, Smart-system, 
Pharmacia). Total cholesterol content of the effluent was determined using 
enzymatic colorimetric assays (Roche Diagnostics), taking the efficiency of 
recovery from the column into account. Hepatic lipids were extracted 
according to Bligh and Dyer [13]. After dissolving the lipids in 2% Triton X-
100, contents of total cholesterol and triglycerides in liver tissue were 
determined as described above and expressed as µg lipid/mg of protein. 
 
 
5.2.3 VLDL triglyceride production 
 
Mice fed a regular chow or high cholesterol/high fat diet were injected 
intravenously after an overnight fast with 500 mg of Triton WR 1339 
(Sigma) per kg body weight as a 15 g/dl solution in 0.9% NaCl. Previous 
studies have shown that plasma VLDL clearance is virtually completely 
inhibited under these conditions [14]. Blood samples (50 µl) were taken at 
0, 1, 2, 3, and 4 hours after Triton WR-1339 injection. Serum triglycerides 
were determined enzymatically as described above. The hepatic VLDL 
production rate was calculated from the slope of the curve and expressed 
as mg/dl/h. 
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5.2.4 Analysis of gene expression by real-time quantitative PCR 
 
Quantitative gene expression analysis on isolated liver was performed as 
described [15]. In short, total RNA was isolated according to Chomczynski 
and Sacchi [16] and reverse transcribed using RevertAidTM reverse 
transcriptase. Gene expression analysis was performed using real-time 
SYBR Green technology (Eurogentec) with the primers displayed in Table 
1. The primers used were validated for identical efficiencies (slope = -3.3 for 
a plot of threshold cycle number (Ct) versus log ng cDNA). Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), 18S ribosomal RNA (18SrRNA), β-
actin, and acidic ribosomal phosphoprotein P0 (36B4) were used as the 
standard housekeeping genes. Relative gene expression numbers were 
calculated by subtracting the threshold cycle number (Ct) of the target gene 
from the average Ct of GAPDH, 18SrRNA, β-actin, and 36B4 (Ct 
housekeeping) and raising 2 to the power of this difference. The average Ct 
of four housekeeping genes was used to exclude that changes in the 
relative expression were caused by variations in the separate housekeeping 
gene expressions. 
 
Table 1 
Primers for quantitative real-time PCR analysis 
Gene GenBank Accesion Forward primer Reverse primer 
Amplicon 
size 
18SrRNA X00686 CCATTCGAACGTCTGCCC GTCACCCGTGGTCACCATG 69 
36B4 NM007475 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 85 
ABCA1 NM013454 GGTTTGGAGATGGTTATACAATAGTTGT TTCCCGGAAACGCAAGTC 96 
β-actin X03672 AACCGTGAAAAGATGACCCAGAT CACAGCCTGGATGGCTACGTA 75 
BSEP NM021022 TGGAAAGGAATGGTGATGGG CAGAAGGCCAGTGCATAACAGA 62 
CD36 NM007643 GTTCTTCCAGCCAATGCCTTT ATGTCTAGCACACCATAAGATGTACAGTT 110 
CYP3A11 NM007818 GGATGAGATCGATGAGGCTCTG CCAGGTATTCCATCTCCATCACA 74 
CYP7A1 NM007824 CTGTCATACCACAAAGTCTTATGTCA ATGCTTCTGTGTCCAAATGCC 95 
GADPH NM008084 TCCATGACAACTTTGGCATTG TCACGCCACAGCTTTCCA 103 
HMGCR M62766 TCTGGCAGTCAGTGGGAACTATT CCTCGTCCTTCGATCCAATTT 69 
LDLR Z19521 CTGTGGGCTCCATAGGCTATCT GCGGTCCAGGGTCATCTTC 68 
LRP1 NM008512 TGGGTCTCCCGAAATCTGTT ACCACCGCATTCTTGAAGGA 95 
PPAR(g) NM011146 CATGCTTGTGAAGGATGCAAG TTCTGAAACCGACAGTACTGACAT 131 
SCD1 NM009127 TACTACAAGCCCGGCCTCC CAGCAGTACCAGGGCACCA 65 
SHP L76567 CTATTCTGTATGCACTTCTGAGCCC GGCAGTGGCTGTGAGATGC 72 
SR-BI NM016741 GGCTGCTGTTTGCTGCG GCTGCTTGATGAGGGAGGG 63 
SREBP-1 AB017337 GACCTGGTGGTGGGCACTGA AAGCGGATGTAGTCGATGGC 74 
 
 
5.2.5 Data analysis 
 
The significance of differences in relative gene expression numbers 
between livers isolated from mice fed a regular chow or a high 
cholesterol/high fat diet, measured by real time quantitative PCR, was 
calculated using a two-tailed Student’s t-test on the differences in Ct 
(Cthousekeeping – Cttarget gene). The difference in Ct values was tested for 
normality using Graphpad Instat 3 software (Graphpad Software, Inc.). 
Probability values less than 0.05 were considered significant. 
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5.3 Results 
 
Serum lipid levels in C57BL/6 mice are greatly affected upon feeding a high 
cholesterol/high fat diet containing 0.25% cholesterol and 15% fat for two 
weeks. Free cholesterol and cholesterol ester levels are increased 81% 
(P=0.0012) and 92% (P<0.001), respectively, with a 78% (P=0.002) 
increase in the serum phospholipid level as compared to the chow diet 
(Table 2). In addition, the serum triglyceride level trends to an increase 
(30%; P=0.14) as compared to the chow diet. On the chow diet, cholesterol 
in the serum of C57BL/6 mice is mainly present in HDL (72.6%), and to a 
minor extent in LDL (26.0%) and VLDL (1.4%) (Fig.1). However, the high 
cholesterol/high fat diet induced a marked 4.2-fold (P=0.032) increase in the 
level of VLDL-associated cholesterol, without changing the VLDL lipid 
composition (Fig.1). 
The liver plays an essential role in the regulation of serum VLDL 
(cholesterol) levels, since it is able 1) to decrease serum levels through 
receptor-mediated uptake of VLDL, and 2) to increase circulating VLDL 
levels by stimulating the synthesis and subsequent secretion of VLDL. 
Importantly, the hepatic mRNA expression of the LDL receptor and the LDL 
receptor-related protein (LRP1), the two receptors that are predominantly 
involved in the serum clearance of VLDL (remnant) particles by the liver 
[17,18], were unchanged by the high cholesterol/high fat diet (Fig.2). This 
suggests that the uptake of VLDL was not changed by high cholesterol/high 
fat diet feeding. In contrast, the VLDL secretion rate was significantly 
increased by 20% (P=0.014) upon feeding the high cholesterol/high fat diet 
(Fig.3). These combined data thus suggest that the rise in the serum VLDL 
cholesterol level by the high cholesterol/high fat diet was the result of an 
increased VLDL secretion rate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. Effect of a high cholesterol/high fat diet on the serum cholesterol distribution and 
lipoprotein lipid composition. Blood samples were drawn after an overnight fast while 
feeding a regular chow (○) or a high cholesterol/high fat diet (●) for two weeks. A) Sera from 5 
individual C57BL/6 mice were loaded onto a Superose 6 column and fractions were collected. 
Fractions 3-7 represent VLDL; fractions 8 to 15, LDL; and fractions 15 to 19, HDL, respectively 
(means+SEM; n=5). B) VLDL and HDL were isolated by ultracentrifugation from pooled serum 
of 5 overnight fasted C57BL/6 mice on a high cholesterol/high fat or chow diet for two weeks 
and the lipid composition was determined (in w/w% of total lipids). 
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Fig.2. Effect of a high cholesterol/high fat diet on 
mRNA expression of genes involved in VLDL and LDL 
uptake in livers of C57BL/6 mice fed a regular chow 
(white bars) or a high cholesterol/high fat diet (black 
bars) for two weeks. Gene expression analysis was 
performed by means of real-time quantitative PCR. 
Values are expressed as fold induction compared to the 
chow diet (means+SEM; n=4/5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3. Effect of a high cholesterol/high fat diet on the VLDL production rate. C57BL/6 
mice were fed a regular chow (○) or a high cholesterol/high fat diet (●) for two weeks and 
fasted overnight before Trion WR1339 injection. Subsequently, triglyceride accumulation was 
measured over time and the VLDL production rate was determined (means+SEM; n=5). 
*P<0.05 as compared to chow diet. 
 
 
Strikingly, next to a 4.2-fold increase in the pro-atherogenic lipoprotein 
VLDL, the high cholesterol/high fat diet also significantly stimulated the 
serum level, but not lipid composition, of the anti-atherogenic lipoprotein 
HDL by 69% (P<0.001; Fig.1). As for VLDL, serum HDL levels are highly 
controlled by the liver. Hepatic expression of the ATP-binding cassette 
transporter A1 (ABCA1) is important for generation of nascent HDL [19,20], 
whilst functional expression of scavenger receptor class B type I (SR-BI) is 
necessary for the selective uptake of cholesterol esters from mature HDL 
into the liver [21,22]. The mRNA expression of SR-BI was not significantly 
changed by the high cholesterol/high fat diet (Fig.4). In contrast, the 
expression of ABCA1 was increased by 43% upon feeding the high 
cholesterol/high fat diet. However, the increase failed to reach statistical 
significance (p=0.16) due to a large variation in the expression of ABCA1 in 
the chow-fed mice (Fig.4). ABCA1 mRNA expression can be stimulated by 
the nuclear receptor liver X receptor (LXR), which upon its activation by 
oxysterols and subsequent heterodimerization with the retinoic X receptor 
(RXR) is able to bind a LXR/RXR response element in the promoter of 
ABCA1 [23]. 
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Fig.4. Effect of a high cholesterol/high fat diet on 
mRNA expression of genes involved in HDL 
synthesis/metabolism in livers of mice fed a regular 
chow (white bars) or a high cholesterol/high fat diet 
(black bars) for two weeks. Gene expression analysis 
was performed by means of real-time quantitative PCR. 
Values are expressed as fold induction compared to the 
chow diet (means+SEM; n=4/5). 
 
 
 
 
Fig.5. Effect of a high cholesterol/high fat diet on 
mRNA expression of LXR target genes in livers of 
mice fed a regular chow (white bars) or a high 
cholesterol/high fat diet (black bars) for two weeks. 
Gene expression analysis was performed by means of 
real-time quantitative PCR. Values are expressed as 
fold induction compared to the chow diet 
(means+SEM; n=4/5). *P<0.05, ***P<0.001 compared 
to chow diet. 
 
 
 
 
To determine the effect of the high cholesterol/high fat diet on hepatic LXR 
activation, the effect on additional established LXR target genes was 
investigated. The expression of sterol regulatory element-binding protein 1 
(SREBP-1), cholesterol 7α-hydroxylase (CYP7A1) and stearoyl-CoA 
desaturase-1 (SCD1) was significantly induced 2.3-, 1.7-, and 7.0-fold, 
respectively, by the high cholesterol/high fat diet (Fig.5), which suggests 
that indeed LXR activation was stimulated on the diet. 
Increased expression of CYP7A1 has been shown to result in an increased 
formation of bile acids [24]. To determine whether the high cholesterol/high 
fat diet did increase the formation of bile acids, the effect of the diet on the 
hepatic expression of bile acid-regulated genes was investigated. In 
agreement with an increased bile acid formation, a significant increase in 
the expression of the bile acid receptor farnesoid X receptor (FXR) target 
genes small heterodimer partner (SHP; 1.4-fold) and bile salt efflux pump 
(BSEP; 1.5-fold) was observed (Fig.6). In contrast, the expression of 6α-
testosterone hydroxylase (CYP3A11) was 6.8-fold (P<0.001) decreased by 
the high cholesterol/high fat diet (Fig.6). 
 
 
Fig.6. Effect of a high cholesterol/high fat diet 
on the mRNA expression of genes involved in 
bile acid metabolism in livers of mice fed a 
regular chow (white bars) or a high 
cholesterol/high fat diet (black bars) for two 
weeks. Gene expression analysis was performed 
by means of real-time quantitative PCR. Values are 
expressed as fold induction compared to the chow 
diet (means+SEM; n=4/5). *P<0.05, ***P<0.001 
compared to chow diet. 
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Interestingly, recent data provided by Seo et al. [25] suggest that LXR also 
plays a role in the execution of adipocyte differentiation through an 
induction of the expression of peroxisome proliferators-activated receptor 
(PPAR) gamma, a central regulator of adipocyte gene expression and 
differentiation [26]. In accordance, the expression of PPARgamma as well 
as the expression of fatty acid translocase CD36/FAT, which is strongly 
induced during the adipocyte differentiation [27] and regulated by 
PPARgamma [28], was increased by the high cholesterol/high fat diet 
(Fig.7). Since increased hepatic adipogenesis is associated with an 
increased storage of fat in the liver, the effect of the high cholesterol/high fat 
diet on hepatic lipid levels was determined. The diet did affect hepatic lipid 
content, but to a relatively small extent. The hepatic total cholesterol level 
was increased 38% (P=0.005), while the hepatic concentration of 
triglycerides, the main lipid constituent in liver, remained at the control level 
upon feeding the high cholesterol/high fat diet (Fig.7). Multiple studies have 
indicated that an increase in hepatic lipid levels results in a repressed 
expression of HMG-CoA reductase, the essential enzyme in de novo 
cholesterol synthesis [29-31]. Accordingly, the hepatic HMG-CoA reductase 
expression was reduced by the high cholesterol/high fat diet to 63% 
(P=0.022) of that on the chow diet (Fig.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.7. Effect of a high cholesterol/high fat diet on the mRNA expression of genes 
involved in A) adipogenesis and B) de novo cholesterol synthesis in livers of mice fed a 
regular chow (white bars) or a high cholesterol/high fat diet (black bars) for two weeks. 
C) Effect of a high cholesterol/high fat diet on hepatic lipid levels of mice fed a regular 
chow (white bars) or a high cholesterol/high fat diet (black bars) for two weeks. Gene 
expression analysis was performed by means of real-time quantitative PCR. Values are 
expressed as fold induction compared to the chow diet (means+SEM; n=4/5). *P<0.05, 
**P<0.01 compared to chow diet. 
 
 
5.4 Discussion 
 
Clinical data provided by Castelli have indicated that in humans a 2-fold rise 
in LDL levels results in a ~2-fold increased risk for cardiovascular diseases 
(CVD), whilst a 2-fold rise in HDL levels results in a ~4-fold decreased risk 
for CVD [32]. The observed rise in the anti-atherogenic HDL level of 
C57BL/6 mice on the high cholesterol/high fat diet in the current study might 
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therefore abrogate the increased atherogenic risk caused by the rise in pro-
atherogenic VLDL levels, resulting in the absence of atherosclerotic lesion 
formation in wild-type mice on this diet as observed by Van Eck et al. [9]. 
The increase in the serum VLDL level correlates with an increased VLDL 
secretion rate, while the expression of receptors involved in the hepatic 
uptake of VLDL, the LDL receptor and LRP1 [17,18], is unchanged. The 
rise in serum HDL levels can be explained the increased hepatic expression 
of ABCA1. The essential role for ABCA1 in the production/lipidation of HDL 
is apparent from mice with a targeted disruption of ABCA1, which leads to a 
virtual absence of HDL cholesterol [33]. The increase in ABCA1 expression 
can be the consequence of an increased hepatic LXR activation as judged 
from the concomitant increases in the expression of several other LXR 
target genes such as SREBP-1 [34], CYP7A1 [35], and SCD1 [36] on the 
high cholesterol/high fat diet. The high cholesterol/high fat diet does also 
stimulate the expression of SHP and BSEP, which are target genes of FXR. 
Makishima et al. [37] have shown that bile acids are physiological ligands 
for nuclear receptor FXR and the increased expression of SHP/BSEP 
therefore suggests that the high cholesterol/high fat diet induced the 
formation of bile acids. This is in agreement with in vitro and in vivo data 
provided by Pandak et al. [38] and Miyake et al. [24], respectively, that an 
increase in the expression of CYP7A1, as observed on the high 
cholesterol/high fat diet, results in a marked activation of the classic 
pathway of bile acid biosynthesis. Since FXR activation through stimulation 
of SHP leads to an inhibition of CYP7A1 expression, the increased 
expression of CYP7A1 observed on the diet suggests that the stimulatory 
effect of LXR overrides the inhibitory effect of FXR, as already proposed by 
Gupta et al. [39]. Strikingly, the expression of another gene product 
stimulated by the bile acid lithocholic acid through activation of the nuclear 
receptor pregnane X receptor (PXR), CYP3A11 [40], was decreased upon 
feeding the high cholesterol/high fat diet. A recent study has indicated an 
important role for PPARalpha in the downregulation of hepatic CYP3A11 
expression by peroxisome proliferators [41]. Combined with the fact that the 
high cholesterol/high fat diet contains a high level of fatty acids, potent 
activators of PPARalpha [42], these findings suggest that feeding the mice 
the high cholesterol/high fat diet resulted in a significant induction of the 
hepatic PPARalpha activity. In agreement, the expression of an established 
PPARalpha target gene, carnitine palmitoyltransferase-I (CPT-I) [43], was 
stimulated by the high cholesterol/high fat diet (data not shown). 
Furthermore, the promoter of SCD1 contains a cis-linked PPAR response 
element [44], which suggests that the striking 7-fold increase in SCD1 
expression might, next to the increase in LXR activation, also be caused by 
an increased activation of PPARalpha. In earlier studies, the hepatic SCD1 
activity has been shown to correlate with plasma triglyceride concentrations 
[45,46]. In parallel, the serum triglyceride concentration did indeed increase 
on the high cholesterol/high fat diet, but the increase failed to statistical 
significance. The absence of a striking increase might be due to the 
enhanced PPARalpha activation, since Staels et al. have suggested that 
activation of PPARalpha by fibrates results in a decreased VLDL production 
[47]. However, the VLDL secretion rate was increased. This corresponds to 
the observations of Grefhorst et al. that increased hepatic LXR activation 
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coincides with an increased VLDL-triglyceride secretion rate [48]. Although 
an increased PPARalpha activity was observed on the high cholesterol/high 
fat diet, no change in the mRNA expression of PPARalpha or PPARdelta 
was seen (data not shown), which indicates that increased PPARalpha 
activity was not caused by an increased transcription of the PPARalpha 
gene, but was likely due to an enhanced activation of the PPARalpha/RXR 
complex. In contrast, the expression of PPARgamma and its target gene 
CD36/FAT was increased on the diet, due to the increased LXR activation. 
Yu et al. have indicated that overexpression of PPARgamma in the liver 
leads to an induction of adipogenic transformation of hepatocytes with 
adipose tissue-specific gene expression and lipid accumulation, resulting in 
a novel type of adipogenic hepatic steatosis [49]. These findings 
correspond to our observation that the high cholesterol/high fat diet induced 
an increase in the hepatic lipid content. However, the rise (38%) in the intra-
hepatic cholesterol level was relatively small. This might be the combined 
result of 1) an increased VLDL secretion, 2) an increased lipidation of HDL 
via ABCA1, 3) an increased metabolism of cholesterol to bile acids by 
CYP7A1 for subsequent excretion into bile via BSEP, and 4) a decreased 
cholesterol synthesis due to inhibition of HMG-CoA reductase expression. 
In conclusion, we propose that the liver by maintaining its intra-hepatic lipid 
balance, through increased activation of both LXR and PPARalpha, plays 
an essential role in the resistance of wild-type mice to high cholesterol/high 
fat diet induced atherosclerotic lesion development. The net result of these 
adaptive changes is a non-atherosclerotic serum lipoprotein profile, thus 
preventing the development of atherosclerotic lesions in the vascular wall 
(Fig.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.8. Overview of the effects of the high cholesterol/high fat diet on hepatic genes 
involved in lipid metabolism and serum lipoprotein levels. Depicted are the pathways 
involved in the regulation of gene expression. Dietary fatty acids activate the nuclear receptor 
PPARalpha, whilst dietary cholesterol-derived oxysterols activate the nuclear receptor LXR 
leading to marked alterations in the hepatic expression of genes involved in bile acid formation, 
adipogenesis, and VLDL and HDL synthesis. However, the net result of these adaptive 
changes is a non-atherosclerotic serum lipoprotein profile. 
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Progressive familial intrahepatic cholestasis represent a group of inherited, 
autosomal recessive disorders, which are characterized by progressive liver 
disease with impairment of bile flow, resulting in complete liver failure and 
early death. Recently, several studies have suggested that ligands for the 
nuclear receptor farnesoid X receptor (FXR) may have therapeutic use in 
treating cholestatic liver disease. However, until now no conclusive 
evidence for a role of bile acids or FXR in atherosclerotic lesion formation 
has been described. In the current study the effect of FXR activation by bile 
acids on atherogenesis was studied in ApoE deficient mice, a well-
established atherosclerotic mouse model. Taurocholic acid, a naturally 
occurring bile acid that is able to activate FXR, does indeed inhibit hepatic 
bile acid synthesis and cholesterol synthesis. However, due to a 50% 
downregulation of the LDL receptor in the liver, serum VLDL cholesterol 
levels are increased upon FXR activation, resulting in a marked 3.9-fold 
increase in atherosclerotic lesion formation. 
We conclude that the administration of statins, which lead to upregulation of 
LDL receptors, can be beneficial in order to maintain the attractivity of FXR 
as a promising therapeutic target for treating or preventing gallstone 
disease. 
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6.1 Introduction 
 
Progressive familial intrahepatic cholestasis (PFIC) represents a group of 
inherited, autosomal recessive disorders with various causes, including 
defects of hepatocanalicular transport of bile salts or phospholipids and 
defects of bile acid synthesis. Cholestasis may occur due to impairment of a 
specific molecular process, or as a secondary consequence of structural 
damage of the hepatocyte or bile duct. Clinically, PFIC is characterized by 
progressive liver disease with impairment of bile flow, leading to elevated 
plasma concentrations of biliary constituents, resulting in jaundice and liver 
toxicity [1-3]. Recently, Alvarez et al. have shown that the hepatic 
expression of the nuclear receptor farnesoid X receptor (FXR; NR1H4) was 
dramatically reduced in patients with cholestatic liver disease [4]. In 
addition, Liu et al. have recently shown that administration of a synthetic 
agonist for FXR is able to inhibit liver toxicity in a rat model for ANIT 
induced intrahepatic cholestasis [5]. Furthermore, Moschetta et al. have 
shown that treatment with a synthetic FXR agonist prevented sequelae of 
cholesterol gallstone disease in a mouse model for human cholesterol 
gallstone disease [6]. These combined findings suggest that FXR agonists 
may have therapeutic use in treating cholestatic liver disease. 
Importantly, FXR is activated by naturally occuring bile acids, such as 
chenodeoxycholic acid, deoxycholic acid, and cholic acid. Furthermore, 
high expression of FXR has been detected in intestine, liver, adrenal, and 
kidney, where the receptor functions in the regulation of the bile acid 
metabolism through several mechanisms: 1) it decreases the bile acid 
synthesis via inhibition of cholesterol 7α-hydroxylase (CYP7A1) expression 
[7], 2) it increases the bile acid excretion rate via stimulation of the bile salt 
efflux pump (BSEP; ABCB11) expression [8], and 3) it stimulates bile acid 
glucuronidation through increasing UDP-glucuronosyltransferase 2B4 
(UGT2B4) expression, leading to increased urinary excretion [9]. 
Interestingly, in addition to their function in regulating bile acid homeostasis 
via FXR, multiple animal studies have indicated a role for bile acids in the 
initiation and progression of atherosclerosis, an important cause of death in 
the Western world. Lichtman et al. have shown that adding cholic acid to a 
high fat diet leads to a more pronounced atherosclerotic lesion formation in 
LDL receptor deficient mice [10]. Cholic acid feeding of C57Bl/6 mice 
induces a reduction of plasma HDL levels [11], which has been associated 
with an increased risk for cardiovascular disease [12]. In contrast, fatty acid 
bile acid conjugates inhibit atherosclerosis formation in C57BL/6 mice [13], 
whilst hyodeoxycholic acid also efficiently suppresses atherosclerosis 
formation and plasma cholesterol levels in chow- and cholesterol-fed LDL 
receptor deficient mice [14]. In summary, the role of bile acids in 
atherogenesis remains unclear. Furthermore, the role of the bile acid-
activated receptor FXR in atherosclerosis has not been clarified. Therefore, 
in the present study the effect of FXR activation by bile acids on 
atherogenesis was studied in mice that lack ApoE (ApoE deficient mice). 
These mice spontaneously develop atherosclerosis on a regular chow diet 
[15], which makes them a good model to study atherosclerotic plaque 
formation. 
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Here we show that taurocholic acid, a naturally occurring bile acid that is 
able to activate FXR, inhibits hepatic bile acid synthesis and cholesterol 
synthesis. Furthermore it appears to downregulate the LDL receptor, 
leading to a rise in serum VLDL, resulting in a marked increase in 
atherosclerotic lesion formation. We conclude that the administration of 
statins, which leads to upregulation of LDL receptors, can be beneficial in 
order to maintain the attractivity of FXR as a promising therapeutic target 
for treating or preventing gallstone disease. 
 
 
6.2 Experimental Procedures 
 
 
6.2.1 Animals 
 
Ten-week-old male ApoE deficient (ApoE-/-) mice were obtained from 
Jackson Labs (Bar Harbor, Mass). The mice were kept on a regular 
dark/light cycle, and received water and a regular chow diet (chow) or a 
regular chow diet with 0.5% taurocholic acid (TCA) added for 2 or 8 weeks, 
respectively. After an overnight fasting period (~16h), mice were 
anesthetized and blood was collected for analysis of serum lipids. 
Subsequently, a whole-body perfusion was performed using phosphate-
buffered saline (4°C, 100 mm Hg) for 10 min. After perfusion, the liver and 
heart plus aortic root were excised. The liver was frozen in liquid N2 and 
stored at –80°C. The heart plus aortic root were stored in 3.7% formalin. 
Animal experiments were performed at the Gorlaeus Laboratories of the 
Leiden/Amsterdam Center for Drug Research in accordance with national 
laws. All experimental protocols were approved by the Ethics Committee for 
Animal Experiments of Leiden University. 
 
 
6.2.2 Lipid analyses 
 
Fasting serum concentrations of free cholesterol, cholesterol esters, and 
triglycerides were determined using enzymatic colorimetric assays (Roche 
Diagnostics). The total cholesterol distribution over the different lipoproteins 
in serum was analysed by fractionation of 30 µl serum of each mouse using 
a Superose 6 column (3.2 x 30 mm, Smart-system, Pharmacia). Total 
cholesterol content of the effluent was determined using enzymatic 
colorimetric assays (Roche Diagnostics), taking the efficiency of recovery 
from the column into account. Hepatic lipids were extracted according to 
Bligh and Dyer [16]. After dissolving the lipids in 1% Triton X-100, contents 
of free cholesterol, cholesterol esters, and triglycerides in liver tissue were 
determined as described above and expressed as µg/mg of protein. 
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6.2.3 VLDL triglyceride production 
 
ApoE-/- mice fed a regular chow or a regular chow with 0.5% taurocholic 
acid added for 2 weeks were injected intravenously after an overnight fast 
with 500 mg of Triton WR1339 (Sigma) per kg body weight as a 15 g/dl 
solution in 0.9% NaCl. Previous studies have shown that plasma VLDL 
clearance is virtually completely inhibited under these conditions [17]. Blood 
samples were taken at 0, 1, 2, 3, and 4 hours after Triton WR1339 injection. 
Serum triglycerides were analysed enzymatically as described above. The 
hepatic VLDL production rate was calculated from the slope of the curve 
and expressed as mg/ml/h. At 4 hours after Triton WR1339 injection, the 
mice were anesthetized and an additional large blood sample was taken via 
the orbital plexus. From the large blood sample 1.25 ml pooled serum of 5 
mice was brought to 1.063 g/ml with potassium bromide in a volume of 4 
ml, transferred to SW41 centrifuge tubes, and layered with 1.063 g/ml, 
1.019 g/ml, and 1.006 g/ml salt solutions. After 22 hours at 40.000 rpm and 
4°C, the VLDL fraction was carefully removed by pipetting off 1.2 ml. In this 
VLDL, triglycerides, phospholipids, and cholesterol were measured 
enzymatically. This composition of the VLDL is a mixture of VLDL that 
circulated before administration of Triton WR1339 and nascent VLDL 
produced during the 4-h period after Triton WR1339 administration. To 
obtain the composition of nascent VLDL, the contribution of circulating 
VLDL was determined and corrected for, as described previously [18]. 
 
 
6.2.4 Assessment of Lesion Formation in the Aortic Root 
 
Serial sections of the aortic root were cut using a Leica CM3050S cryostat. 
The atherosclerotic lesion area was quantified in oil red O-stained cryostat 
sections using the Leica image analysis system, consisting of a Leica 
DMRE microscope coupled to a video camera and Leica Qwin Imaging 
software (Leica Ltd., Cambridge, England). Mean lesion area (in µm2) was 
calculated from 10 consecutive oil red O-stained sections, starting at the 
appearance of the tricuspid valves. 
 
 
6.2.5 Analysis of gene expression by real-time quantitative PCR 
 
Quantitative gene expression analysis on livers of chow- or TCA-fed ApoE 
deficient mice was performed as described [19]. In short, total RNA was 
isolated according to Chomczynski and Sacchi [20] and reverse transcribed 
using RevertAidTM reverse transcriptase. Gene expression analysis was 
performed using real-time SYBR Green technology (Eurogentec). Primers 
(Eurogentec; Table 1) were designed using Primer Express Software and 
validated for identical efficiencies (slope = -3.3 for a plot of Ct versus log ng 
cDNA). Hypoxanthine guanine phosphoribosyl transferase (HPRT), 18S 
ribosomal RNA (18SrRNA), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), β-actin, and acidic ribosomal phosphoprotein P0 (36B4) were 
used as the standard housekeeping genes. Relative gene expression 
numbers were calculated by subtracting the threshold cycle number (Ct) of 
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the target gene from the average Ct of HPRT, 18SrRNA, GAPDH, β-actin, 
and 36B4 (Cthousekeeping) and raising 2 to the power of this difference. The 
average Ct of five housekeeping genes was used to exclude that changes 
in the relative expression were caused by variations in the expression of the 
separate housekeeping genes. 
 
 
6.2.6 Data analysis 
 
The significance of differences in atherosclerotic lesion size or relative gene 
expression numbers in the liver of chow- or TCA-fed mice was calculated 
using a two-tailed unpaired Student’s t-test. Probability values less than 
0.05 were considered significant 
  
 
Table 1 
Primers for quantitative real-time PCR 
Gene Forward primer Reverse primer 
18SrRNA CCATTCGAACGTCTGCCC GTCACCCGTGGTCACCATG 
36B4 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 
ABCA1 GGTTTGGAGATGGTTATACAATAGTTGT TTCCCGGAAACGCAAGTC 
ABCG5 TGGCCCTGCTCAGCATCT ATTTTTAAAGGAATGGGCATCTCTT 
ABCG8 CCGTCGTCAGATTTCCAATGA GGCTTCCGACCCATGAATG 
ACAT-1 TGTTTCTCTGGGCCATCCA CTTCAGGGCATGAGCCATATG 
ACAT-2 CAGAGGGCCAAGGTGGC CAACCTGCCGTCAAGACATG 
β-actin AACCGTGAAAAGATGACCCAGAT CACAGCCTGGATGGCTACGTA 
BSEP TGGAAAGGAATGGTGATGGG CAGAAGGCCAGTGCATAACAG 
CYP7A1 CTGTCATACCACAAAGTCTTATGTCA ATGCTTCTGTGTCCAAATGCC 
GADPH TCCATGACAACTTTGGCATTG TCACGCCACAGCTTTCCA 
HMGCR TCTGGCAGTCAGTGGGAACTATT CCTCGTCCTTCGATCCAATTT 
HPRT TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG 
LDLR CTGTGGGCTCCATAGGCTATCT GCGGTCCAGGGTCATCTTC 
LRP1 TGGGTCTCCCGAAATCTGTT ACCACCGCATTCTTGAAGGA 
SHP CTATTCTGTATGCACTTCTGAGCCC GGCAGTGGCTGTGAGATGC 
SR-BI GGCTGCTGTTTGCTGCG GCTGCTTGATGAGGGAGGG 
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6.3 Results 
 
Earlier studies by Srivastava et al. have indicated that in C57BL mice 
feeding cholic acid decreases serum HDL levels, whilst inducing serum 
VLDL/LDL levels [11,21]. In the current study we determined whether FXR 
activation by taurocholic acid (TCA), the taurine conjugate of cholic acid, 
also resulted in changed serum lipid levels in the ApoE-/- mice, a well-
established atherosclerosis mouse model. ApoE-/- mice were fed a regular 
chow diet or a regular chow diet with 0.5% TCA for 8 weeks and 
subsequently serum free cholesterol (FC) and cholesterol ester (CE) levels 
were measured. After 8 weeks on a regular chow diet, free cholesterol and 
cholesterol ester levels were significantly increased by 78% (P<0.001) and 
84% (P<0.001), respectively, as compared to 0 weeks of diet feeding (Table 
2). Strikingly, compared to the animals fed the regular chow diet alone for 8 
weeks, the TCA-fed animals showed a remarkable 1.9-fold (P<0.001) and 
3.5-fold (P<0.001) further increase in free cholesterol and cholesterol esters 
(Table 2). 
 
 
Table 2 
Primers for quantitative real-time PCR 
Diet Time (weeks) Free cholesterol (mg/dl) Cholesterol ester (mg/dl) 
Chow Baseline 147 ± 8.3 490 ± 46 
 8 264 ± 27 900 ± 61 
TCA Baseline 156 ± 7 531 ± 34 
 8 528 ± 50 *** 3406 ± 395 *** 
Serum free cholesterol (FC) and cholesterol ester (CE) levels were measured in ApoE-/- mice 
before and after 8 weeks of 0.5% TCA (TCA) or regular chow (Chow) diet feeding. Data 
represent means±SEM of 8-10 mice. *** P<0.001 compared to chow diet at 8 weeks. 
 
 
Multiple studies have indicated that a persistently high level of serum 
cholesterol ultimately leads to a series of responses that promote 
atherosclerosis (22,23). Since the level of cholesterol was increased more 
rapidly in TCA-fed ApoE deficient mice, the effect of TCA on plaque 
formation was studied in these mice. In agreement with an important role 
for a rise in serum lipids in atherogenesis, TCA feeding of ApoE deficient 
mice induced a significant 3.9-fold increase in atherosclerotic plaque 
development as compared to chow-fed mice (P<0.001; Fig.1). This 
suggests an important role for bile acid activation of FXR in the 
development of atherosclerosis in ApoE-/- mice. 
The increase in plaque formation (3.9-fold) seems to be the direct result of 
the increase in serum total cholesterol level (3.4-fold). Importantly, the liver 
is an essential organ in the removal of excess cholesterol from the body by 
mediating metabolism to bile acids and excretion to the bile. To determine 
whether the liver plays a role in the TCA-mediated increase in VLDL, in a 
separate experiment ApoE-/- mice were fed TCA or chow for only 2 weeks 
to increase the serum cholesterol level, but to minimize the possibility of a 
secondary response to the increase in serum cholesterol. 
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Fig.1. Taurocholic acid treatment induces atherosclerotic lesion development. Formation 
of atherosclerotic lesions was determined at the aortic root in ApoE-/- mice after 8 weeks of 
feeding a regular chow diet (chow) or a regular chow diet with 0.5% taurocholic acid (TCA) 
added. Left, quantification of the mean lesion area (means±SEM; n=8-10). Right, 
representative photomicrographs of oil red O-stained cross-sections of the aortic root at the 
level of the tricuspid valves. ***P<0.001 compared to the chow diet. 
 
 
Table 3 
Effect of 2-week TCA feeding on serum and hepatic lipid levels in ApoE-/- mice 
  Free cholesterol Cholesterol ester Triglyceride 
Chow 164 ± 7.1 630 ± 43 160 ± 21 Serum (mg/dl) 
TCA 242 ± 9.7 *** 1239 ± 27 *** 101 ± 8.7 * 
Chow 7.0 ± 1.0 15.4 ± 2.8 33.5 ± 3.3 Liver (µg/mg protein) 
TCA 9.7 ± 0.9 12.0 ± 0.8 26.5 ± 1.2 
Serum and hepatic lipid levels were measured in ApoE-/- mice after 2 weeks of 0.5% TCA 
(TCA) or regular chow (Chow) diet feeding. Data represent means±SEM of 5 mice. *P<0.05, 
***P<0.001 compared to chow diet. 
 
 
As anticipated, feeding mice a 0.5% TCA for 2 weeks significantly induced 
serum free cholesterol and cholesterol ester levels by 48% (P<0.001) and 
97% (P<0.001), respectively, as compared to mice on a regular chow diet 
(Table 3). Analysis of the lipoprotein fractions separated by FPLC revealed 
that ApoE-/- mice on the chow diet primarily transport their serum 
cholesterol in VLDL particles (Fig.2a). The increase in the serum total 
cholesterol level induced by 2-week TCA feeding could be attributed to an 
increase in the VLDL cholesterol level (Fig.2a). However, TCA feeding 
significantly reduced the serum triglyceride level by 37% (P=0.032; Table 
3). As a result, the circulating VLDL of TCA-fed mice contained a 23% 
higher cholesterol concentration and a 56% lower triglyceride concentration 
as compared to circulating VLDL from mice fed the regular chow diet 
(Fig.2b). In contrast, the secretion rate of nascent VLDL was 0.80±0.11 
mg/ml/h for TCA-fed and 1.02±0.09 mg/ml/h for chow-fed animals indicating 
that the VLDL secretion rate was not significantly affected by TCA 
treatment. Moreover, no change in the secreted VLDL composition was 
seen after TCA treatment (Fig.2b), indicating that the changes in circulating 
VLDL composition were not the result of differences in the VLDL 
production. 
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Fig.2. Taurocholic acid treatment induces serum VLDL levels and changes the 
circulating VLDL composition. (a) Blood samples of ApoE-/- mice were drawn after an 
overnight fast while feeding a regular chow diet (○) or a regular chow diet with 0.5% taurocholic 
acid (●) added for 2 weeks. Sera from 5 individual mice were loaded onto a Superose 6 
column and fractions were collected. Fractions 3-7 represent VLDL; fractions 8-15, LDL; and 
fractions 15-19 HDL, respectively.  (b) VLDL was isolated by ultracentrifugation from pooled 
plasma of 5 ApoE-/- mice on a regular chow diet (chow) or a regular chow diet with 0.5% 
taurocholic acid added for 2 weeks after an overnight fast (circulating VLDL) or 4 h after Triton 
WR1339 administration (nascent VLDL), and lipid composition was determined (in w/w% of 
total lipids). 
 
 
In addition to a change in the serum lipid levels, TCA feeding also affected 
the lipid levels in the livers of ApoE-/- mice. The hepatic free cholesterol 
level had a tendency to increase 38% (P=0.083), whilst the cholesterol 
ester and triglyceride levels were respectively 22% and 21% lowered by 
TCA as compared to regular chow controls (Table 3). 
To evaluate the cause of the change in serum and hepatic lipid levels, gene 
expression analysis using real-time PCR was performed on genes involved 
in cholesterol and bile acid metabolism. The biological function of FXR in 
the liver is to regulate bile acid metabolism through repression of bile acid 
and induction of bile acid excretion (24,25). In accordance, the hepatic 
mRNA expression of the rate-limiting enzyme in bile acid synthesis, 
cholesterol 7α-hydroxylase (CYP7A1), was decreased by TCA to only 
5.2±0.5% of the control value (P<0.001; Fig.3). In agreement with data 
provided by Goodwin et al. (26) that ligands for FXR repress CYP7A1 
expression through a direct increase in the nuclear receptor small 
heterodimer partner (SHP), TCA treatment significantly stimulated SHP 
expression (P=0.007; Fig.3). As observed for SHP, TCA feeding also 
increased the expression of the bile salt efflux pump (BSEP; Fig.3), which is 
another established gene product regulated by bile acids and synthetic FXR 
ligands. However, the increase failed to reach statistical significance due to 
a large variation in the expression of BSEP in the TCA-fed mice. 
The expression of HMG-CoA reductase (HMGCR), the rate-limiting enzyme 
in de novo cholesterol synthesis was decreased for 24% (P=0.013) by TCA 
(Fig.3). In addition, TCA similarly decreased the expression of the 
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cholesterol ester synthesis enzyme acyl coenzyme A:cholesterol 
acyltransferase (ACAT) type 1 by 33% (P=0.005; Fig.3). In contrast, hepatic 
ACAT-2 expression, which under standard feeding conditions is ~3-fold 
lower than the ACAT-1 expression (relative expression 0.14±0.015 vs 
0.43±0.028), was not changed by TCA (Fig.3), suggesting an ACAT type-
specific inhibition by TCA. 
Interestingly, data provided by Rudling have indicated that the mRNA levels 
for the LDL receptor and HMGCR are regulated in parallel in the liver in vivo 
during various metabolic perturbations as well as at normal physiologic 
conditions [27]. We therefore also investigated the effect of TCA on the LDL 
receptor and other receptors involved in hepatic cholesterol uptake. 
Strikingly, the LDL receptor expression was 50% decreased (P=0.002) 
upon TCA feeding, with minor changes in the SR-BI, and LRP1 expression 
(Fig.3). 
In contrast to the strong decrease in the CYP7A1 and LDL receptor 
expression, no change in the expression of the ABC transporters ABCA1, 
ABCG5, or ABCG8 was observed as a result of TCA feeding (Fig.3). This 
suggests that TCA feeding 1) decreased the synthesis of bile acids from 
cholesterol by CYP7A1, 2) decreased the uptake of cholesterol via the LDL 
receptor, but that it 3) had no effect on the efflux of cholesterol to the serum 
or the bile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3. Taurocholic acid treatment affects the hepatic expression of genes involved bile 
acid metabolism, cholesterol(ester) synthesis, and cholesterol uptake, but not efflux. 
Gene expression analysis was performed by means of real-time quantitative PCR on the livers 
of ApoE-/- mice fed a regular chow diet (white bars) or a regular chow diet with 0.5% 
taurocholic acid added (black bars) for 2 weeks. Values are expressed as fold induction 
compared to the chow diet (means±SEM; n=5). *P<0.05, **P<0.01, ***P<0.001 compared to 
the chow diet. 
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6.4 Discussion 
 
Recent studies have indicated that FXR agonists may have therapeutic use 
in treating cholestatic liver disease [5,28-30]. Importantly, bile acids are the 
natural occurring ligands for FXR and some contradictory data have been 
published on the role of bile acids, and thus FXR, in atherosclerosis, a 
major cause of death in the Western world. Therefore, in the present study 
the effect of FXR activation by bile acids on atherogenesis was studied in 
ApoE deficient mice. These mice spontaneously develop atherosclerotic 
plaques on a regular chow diet, and they are therefore considered to be an 
established animal model to study atherogenesis. 
Strikingly, feeding ApoE-/- mice TCA, a natural FXR ligand, for 8 weeks 
resulted in a marked increase in atherosclerotic lesion development. 
Hakamata et al. have shown that VLDL/LDL from ApoE-/- mice is able to 
transform macrophages to foam cells [31]. The effect of TCA on lesion 
development in ApoE-/- mice, therefore, seems to be a direct result of the 
increased circulating VLDL cholesterol level observed after TCA treatment. 
The secretion rate and composition of nascent VLDL was not changed by 
two weeks TCA feeding, which indicates that the circulating VLDL level was 
induced through another mechanism. Importantly, without changing the 
VLDL secretion rate, TCA feeding did decrease the serum triglyceride 
concentration in ApoE-/- mice resulting in a changed circulating VLDL 
composition (relatively more cholesterol and less triglycerides). This is in 
agreement with data provided by Kast et al. [32], which showed that FXR 
activation induced hepatic expression of ApoC-II, an activator of lipoprotein 
lipase (LPL) [33], and data from Claudel et al. [34], which showed that FXR 
agonists suppress the hepatic expression of ApoC-III, an inhibitor of LPL 
[35], leading to a subsequent decrease in serum triglycerides in vivo. 
Importantly, in the current study also a significant increase in hepatic ApoC-
II expression was observed (data not shown). These combined findings 
indicate that in ApoE-/- mice, TCA treatment stimulated LPL activity, 
resulting in cholesterol-rich/triglyceride poor circulating VLDL particles. 
However, albeit an unchanged VLDL secretion rate and an increase in LPL 
activity, TCA treatment still led to an increase in the serum VLDL level. 
Since the uptake VLDL is also an important factor in the control of the 
serum VLDL level, the effect of TCA on hepatic VLDL catabolism was 
studied. It is generally accepted that cholesterol ester enriched VLDL 
clearance by the liver is mediated by the LDL receptor, but also by an LDL 
receptor-independent recognition site on parenchymal cells, possibly LRP1 
[36,37]. However, since LRP1 binds ApoE, which is absent in ApoE-/- mice, 
an essential role for LRP1 in VLDL clearance is unlikely. Murayama et al. 
showed that overexpression of the LDL receptor in ApoE-/- mice resulted in 
a marked lowering of plasma ApoB-containing lipoproteins and a drastic 
suppression of early atherogenesis pointing to the LDL receptor as an 
important mediator of liver uptake of cholesterol ester-rich VLDL [38]. 
Strikingly, TCA feeding resulted in a 50% decrease in LDL receptor 
expression in ApoE-/- mice, which might explain the increase in VLDL 
cholesterol levels and the subsequent increase in atherogenesis in these 
mice. The co-ordinate decreases in the expression of the LDL receptor and 
HMGCR by TCA are in agreement with the observations of Rudling that the 
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mRNA levels for the LDL receptor and HMGCR are regulated in parallel in 
the liver in vivo [27]. Since activators of the nuclear receptor LXR have 
been shown to induce the hepatic expression of ABCG5/G8 [39] and 
ABCA1 [40], the absence of an effect of TCA on ABCG5/G8 and ABCA1 
indicates that TCA treatment did not affect the activation status of LXR. In 
contrast, the nuclear receptor FXR was activated by TCA, as expected, as 
can be concluded from the observed rise in SHP and BSEP expression and 
the drastic decrease in CYP7A1 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4. Proposed mechanism of the pro-atherogenic effect of taurocholic acid (TCA). 
TCA, by activating FXR, stimulates hepatic BSEP expression and inhibits CYPA1 expression, 
resulting in a subsequent decrease in LDL receptor (LDLR) expression. The combination of 
hepatic LDL receptor inhibition and increased serum LPL activity, due to increased ApoC-II 
levels, leads to an accumulation of cholesterol ester-rich VLDL in the circulation, which 
consequently results in a 3.9-fold increase in atherosclerotic lesion formation. 
 
 
In conclusion, we have provided data that taurocholic acid, a naturally 
occurring bile acid that is able to activate FXR, inhibits hepatic bile acid 
synthesis and cholesterol synthesis and downregulates the LDL receptor. 
This latter phenomenon leads to a rise in serum VLDL, resulting in a 
marked increase in atherosclerotic lesion formation (Fig.4). In the light that 
FXR agonists are promising therapeutic agents for treating or preventing 
gallstone disease, the observed increase in atherosclerotic lesion formation 
can be considered as contraindication. However, the observed 
downregulation of LDL receptors might be reversed by statin treatment, a 
Atherosclerotic 
lesion development
CBA
Acetyl-CoA
CE-rich 
VLDL
CE
TG-rich 
VLDL
BILE
TCA
LIVER
ABCG5
ABCG8
CYP7A1
BSEP
ACAT
LDLR
HMGCR
CBA
Acetyl-CoA
CE-rich 
VLDL
CE
TG-rich 
VLDL
BILE
LIVER
ABCG5
ABCG8
CYP7A1
BSEP
ACAT
LDLR
HMGCR
(+)
(-)
(-) (+)
(3.9x)
(+)
(+)
Atherosclerotic 
lesion development
LPL
ApoC-II
LPL
ApoC-II
Chapter 6 
 
 
108 
frequently used drug to treat or prevent cardiovascular disease in humans. 
Statins inhibit HMG-CoA reductase, leading to cholesterol depletion in the 
liver and subsequent upregulation of LDL receptors. Upregulation of LDL 
receptors in the liver induces LDL-cholesterol removal from blood and 
consequently leads to a lowering in the risk for atherosclerosis. Therefore 
we suggest that the treatment of patients at risk for cholesterol gallstone 
disease and acute pancreatitis with FXR agonists have to be combined with 
statin treatment in order to prevent FXR’s pro-atherogenic action. 
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Hepatic cholesterol(ester) uptake from serum coupled to intracellular 
processing and biliary excretion are important features in the removal of 
excess cholesterol from the body. ATP-binding cassette (ABC) transporters 
play an important role in hepatic cholesterol transport. The liver consists of 
different cell types and ABC transporters may exert different physiological 
functions dependent on the individual cell type. Therefore, in the current 
study, we compared using real-time PCR the mRNA expression of ABC 
transporters and genes involved in the regulation of cholesterol metabolism 
in liver parenchymal, endothelial, and Kupffer cells. 
It appears that liver parenchymal cells contain high expression levels 
compared to endothelial and Kupffer cells of SR-BI (~3 fold), PPARα and 
PPARγ (8-20 fold), CYP7A1 (>100 fold) and ABCG5/G8 (~5 fold). Liver 
endothelial cells show a high expression of CYP27, LXRβ, PPARδ and 
ABCG1, suggesting a novel specific role for these genes in endothelial 
cells. In Kupffer cells, the expression level of LXRα, ABCA1 and in 
particular ABCG1 is high leading to an ABCG1 mRNA expression level 
which is 70 fold higher than for parenchymal cells. It can be calculated that 
51% of the total liver ABCG1 expression resides in Kupffer cells and 24% in 
endothelial cells, suggesting an intrahepatic specific role for ABCG1 in 
Kupffer and endothelial cells. Due to a specific stimulation of ABCG1 in 
parenchymal cells by a high cholesterol diet, the contribution of 
praenchymal cells to the total liver increased from 25 to 60%. 
Our data indicate that for studies on the role of ABC transporters and their 
regulation in liver, their cellular localization should be taken into account, 
allowing proper interpretation of metabolic changes, which are directly 
related to their (intra)cellular expression level. 
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7.1 Introduction 
 
Transport of cholesterol through the body is an important process in the 
maintenance of total body cholesterol homeostasis. One specific 
component is the transport of excessive cholesterol from the periphery to 
the liver by the high-density lipoprotein (HDL). This process is called 
reverse cholesterol transport (RCT) and consists of three different stages: 
the efflux of peripheral cellular cholesterol to HDL, the transport of 
cholesterol esters through the blood to the liver, and the uptake of 
cholesterol esters by the liver [1]. Cholesterol esters are taken up into the 
liver through selective uptake by the HDL receptor, scavenger receptor 
class BI (SR-BI) [2], where they are primarily (~50%) catabolised to bile 
acids, through conversion by cholesterol 7α-hydroxylase (CYP7A1) and 
sterol 27-hydroxylase (CYP27) [3] for biliary excretion via the bile salt 
export protein (BSEP) [4]. A second major catabolic route (~40%) is the 
direct efflux of cholesterol from the liver into the bile via the ATP-binding 
cassette half transporters ABCG5 and ABCG8, which together function as a 
biliary sterol efflux regulator [5]. Additionally, cholesterol also effluxes from 
the liver to produce very low-density lipoproteins (VLDL), which are 
converted to remnants that function as precursors for low-density 
lipoproteins. Native HDL might also be formed by the ATP-binding cassette 
transporter A1 (ABCA1)-mediated cholesterol efflux [6]. Recently, another 
member of the ABC transporter family, ABCG1, has been proposed to play 
a role in the intracellular trafficking and efflux of cholesterol [7]. However, 
the exact role of ABCG1 in the liver, especially in relation to ABCG5 and 
ABCG8, remains to be clarified. 
The identification of SR-BI and novel members of the ATP-binding cassette 
transporter family, including ABCA1, ABCG1, ABCG5, and ABCG8, has 
allowed the molecular characterization of the individual transporters 
responsible for the intracellular trafficking and excretion of cholesterol 
(derivatives). In the liver, it has been shown that SR-BI is primarily 
responsible for the selective uptake of cholesterol esters from HDL [8], 
while ABCG5/G8 and ABCG1, and ABCA1, are proposed mediators of 
efflux to the bile and to HDL, respectively [6,9]. However, the liver is a 
complex tissue and contains, in addition to the parenchymal cells, which are 
localized around the bile canaliculi, endothelial cells, and tissue 
macrophages (Kupffer cells). To assess the individual function of the ABC 
transporters and their regulation by nuclear hormone receptors it is 
therefore essential to establish their cellular localization in the liver. 
Here we report that key mediators in liver cholesterol homeostasis, in 
particular PPARα, PPARγ and ABCG1, are differentially expressed in 
specific cell types of the rat liver. Our data stress that it is necessary to 
focus on the regulation of genes involved in cholesterol homeostasis in the 
different cell types of the liver, to get molecular insight in their mechanism of 
regulation and the consequences for liver cholesterol transport. 
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7.2 Experimental Procedures 
 
 
7.2.1 Animals 
 
In the study, three male Wistar rats (200-250 g) were fed a chow diet 
containing 4.3% (w/w) fat and no cholesterol, and three rats were fed a 
high-cholesterol diet containing 2% (w/w) cholesterol, 5% olive oil (w/w), 
and 0.5% (w/w) cholic acid for two weeks. Rats were anaesthetized and the 
vena porta was cannulated. Subsequently, the liver was perfused for 10 min 
with oxygenated Hanks’ buffer pH 7.4, containing HEPES (1.6 g/l). The 
perfusion was continued for 10 minutes with Hanks’/HEPES buffer 
containing 0.05% (w/v) collagenase (type IV, Sigma) and 1 mM CaCl2. 
Parenchymal cells were isolated after mincing the liver in Hanks’ buffer 
containing 0.3% BSA, filtering through nylon gauze and centrifugation for 
three times 10 min at 50 g. The pellets consisted of pure (>99%) 
parenchymal cells (PC) as judged by light microscopy. The supernatants 
were centrifuged for 10 min at 500 g in order to harvest the non-
parenchymal cells. By means of centrifugal elutritation the endothelial cells 
(EC) and Kupffer cells (KC) were separated [10]. The purity of each cell 
fraction (>95% for both) was checked by light microscopy, after staining for 
peroxidase activity with 3,3-diaminobenzidin (Sigma). 
 
 
7.2.2 Analysis of gene expression by real-time quantitative PCR 
 
Total RNA was isolated from rat liver parenchymal, endothelial, and Kupffer 
cells using TriZol reagent (Life Technologies) according to the 
manufacturer’s instructions. Purified RNA was DNAse treated (DNAse I, 10 
U/µg total RNA) and reverse transcribed (RevertAid M-MuLV Reverse 
Transcriptase) according to the protocols supplied by the manufacturer. 
Quantitative gene expression analysis was performed on an ABI PRISM 
7700 machine (Applied Biosystems, Foster City, CA) using SYBR Green 
technology. PCR primers (Table 1) were designed using Primer Express 
1.7 software with the manufacturer’s default settings (Applied Biosystems) 
and validated for identical efficiencies (slope = -3.3 for a plot of Ct versus 
log ng cDNA). In 96-wells optical plates, 12.5 µl SYBR Green master mix 
was added to 12.5 µl cDNA (corresponding to 50 ng of total RNA input) and 
300 nM of forward and reverse primers in water. Plates were heated for 2 
min at 50°C and 10 min at 95°C. Subsequently 40 PCR cycles consisting of 
15 sec at 95°C and 60 sec at 60°C were applied. At the end of the run, 
samples were heated to 95°C with a ramp time of 20 min to construct 
dissociation curves to check that single PCR products were obtained. The 
absence of genomic DNA contamination in the RNA preparations was 
confirmed by using total RNA samples that had not been subjected to 
reverse transcription. Hypoxanthine guanine phosphoribosyl transferase 
(HPRT) was used as the standard housekeeping gene. Ratios of target 
gene and HPRT expression levels (relative gene expression numbers) were 
calculated by subtracting the threshold cycle number (Ct) of the target gene 
from Ct of HPRT and raising 2 to the power of this difference. Ct values are 
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defined as the number of PCR cycles at which the fluorescent signal during 
the PCR reaches a fixed treshold. Target gene mRNA expressions are thus 
expressed relative to HPRT expression. 
 
 
7.2.3 Data analysis 
 
The significance of differences in relative gene expression numbers 
between the different liver cell types, from three different cell isolations, 
measured by real-time quantitative PCR was calculated using a two-tailed 
Student’s t-test on the differences in Ct (CtHPRT – Cttarget gene). Probability 
values less than 0.05 were considered significant. 
 
 
 
Table 1 
Primers for quantitative real-time PCR analysis 
Gene 
 
GenBank 
accession 
Forward primer 
 
Reverse primer 
 
Amplicon 
size 
ABCA1 ** ATCTCATAGTATGGAAGAATGTGAAGCT CGTACAACTATTGTATAACCATCTCCAAA 132 
ABCG1 NM053502 AGGTCTCAGCCTTCTAAAGTTCCTC TCTCTCGAAGTGAATGAAATTTATCG 85 
ABCG5 NM053754 CGCAGGAACCGCATTGTAA TGTCGAAGTGGTGGAAGAGCT 67 
ABCG8 NM130414 GATGCTGGCTATCATAGGGAGC TCTCTGCCTGTGATAACGTCGA 69 
CYP27 M38566 GTGTCCCGGGATCCCAGTGT CTTCCTCAGCCATCGGTGA 66 
CYP7A1 NM012942 CTGTCATACCACAAAGTCTTATGTCA ATGCTTCTGTGTCCAAATGCC 75 
HPRT X62085 TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG 91 
LXRα NM031627 TCAGCATCTTCTCTGCAGACCGG TCATTAGCATCCGTGGGAACA 144 
LXRβ NM031626 AAGCTGGTGAGCCTGCGC CGGCAGCTTCTTGTCCTG 81 
PPARα NM013196 TGAACAAAGACGGGATG TCAAACTTGGGTTCCATGAT 106 
PPARγ NM013124 CATGCTTGTGAAGGATGCAAG TTCTGAAACCGACAGTACTGACAT 131 
PPARδ NM012141 GAGGGGTGCAAGGGCTTCTT CACTTGTTGCGGTTCTTCTTCTG 97 
SR-BI U76205 GTTGGTCACCATGGGCCA CGTAGCCCCACAGGATCTCA 65 
** Primer sequences based on an alignment of human (NM005502) and murine (XM109397) 
ABCA1 
Hepatic cell type specific gene expression 
 
 
117 
7.3 Results 
 
The last step in reverse cholesterol transport is the hepatic uptake and 
cellular processing of cholesterol esters from HDL by SR-BI [1]. The mRNA 
expression of SR-BI in the different cell types of the liver was investigated 
with quantitative real-time PCR to determine which cell type is mainly 
expressing SR-BI. A significantly higher SR-BI expression was observed in 
parenchymal cells compared to endothelial and Kupffer cells (Fig.1). 
In the liver, amongst others, cholesterol is used for bile acid synthesis. 
Therefore, the mRNA expression patterns of two key enzymes in bile acid 
synthesis, CYP7A1 and CYP27, in the different hepatic cell types were 
examined. A relatively high level of CYP7A1 expression was observed in 
parenchymal cells, which was over 200 fold higher than the expression 
levels found in endothelial and Kupffer cells (Fig.1). Accordingly, CYP27 
expression (Fig.1) was observed in parenchymal cells, but also in 
endothelial cells. 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. Relative SR-BI, CYP7A1, and CYP27 mRNA expression levels as determined by 
real-time quantitative PCR in rat liver parenchymal (PC), endothelial (EC), and Kupffer 
(KC) cells on a chow diet. Values are expressed relative to HPRT expression (means+SEM). 
*P<0.05, **P<0.01 and ***P<0.001 compared to PC expression (t-test, as described under 
“Experimental procedures”). 
 
 
Because a second route of cholesterol disposal from the liver is through 
direct excretion of cholesterol into the bile via the half transporters ABCG5 
and ABCG8, we investigated whether the expression of ABCG5/8 is also 
higher in parenchymal cells than in non-parenchymal cells. Figure 2 clearly 
indicates that ABCG5 and ABCG8 expression was indeed 5- to 10-fold 
higher in parenchymal cells compared to endothelial and Kupffer cells. 
In the liver, ABCA1 was recently suggested to be involved in the efflux of 
cholesterol for production of HDL [6]. Although no conclusive evidence has 
been shown, in the liver ABCG1, like ABCG5/G8 is proposed to play a role 
in biliary efflux [11]. In macrophages, ABCA1 and ABCG1 expression is 
induced in response to cholesterol loading and both proteins are potentially 
involved in cholesterol efflux to ApoA-I [12]. Since both ABCA1 and ABCG1 
are implicated in the same physiological functions, we determined whether 
both genes also have a comparable expression distribution profile over the 
different cell types of the liver. Contrarily to the assumption, ABCA1 was 
mainly expressed in parenchymal and Kupffer cells (Fig.2), while ABCG1 
was 76-fold and 27-fold higher expressed in Kupffer and endothelial cells 
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than in parenchymal cells, respectively (Fig.2). In contrast to ABCA1, 
ABCG1 is thus mainly expressed in non-parenchymal cells, which suggests 
a limited role of ABCG1 in the excretion of cholesterol directly into the bile 
under the standard feeding conditions. In addition, ABCG1 expression was 
analysed in the different hepatic cells isolated from rats on a high 
cholesterol diet. Interestingly, hepatic parenchymal cell ABCG1 expression 
increased ~4-fold in response to a high cholesterol diet, whilst no significant 
effect on endothelial and Kupffer cell ABCG1 expression was observed 
(Fig.3). Although ABCG1 levels were significantly increased in parenchymal 
cells in response to a high cholesterol diet, ABCG1 expression levels were 
still respectively 10- and 12-folds higher in endothelial and Kupffer cells as 
compared to parenchymal cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2. Relative ABCG5, ABCG8, ABCA1, and ABCG1 mRNA expression levels as 
determined by real-time quantitative PCR in rat liver parenchymal (PC), endothelial (EC), 
and Kupffer (KC) cells on a chow diet. Values are expressed relative to HPRT expression 
(means+SEM). *P<0.05, and ***P<0.001 compared to PC expression (t-test, as described 
under “Experimental Procedures”). 
 
 
Fig.3. The effect of a high cholesterol diet on 
the relative ABCG1 mRNA expression levels as 
determined by real-time quantitative PCR in rat 
liver parenchymal (PC), endothelial (EC), and 
Kupffer (KC). Values from rats on a chow (black 
bars) and on a high cholesterol diet (hached bars) 
are expressed relative to HPRT expression 
(means+SEM.). *P<0.05 compared to the ABCG1 
expression on a chow diet (t-test, as described 
under “Experimental Procedures). 
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Analysis of LXR expression in the different cell types was performed to 
investigate a potential relation with expression patterns of the ABC 
transporters. LXRα had a comparable distribution pattern as found for 
ABCA1, with a relatively high expression in parenchymal and Kupffer cells 
as compared to endothelial cells (fig.4). A significantly higher expression of 
LXRβ was found in endothelial liver cells compared to parenchymal and 
Kupffer cells, respectively (Fig.4), which suggests that LXRβ may be a more 
important mediator in endothelial cells. 
It has been shown that PPARγ activators are able to regulate LXR 
expression, and thereby indirectly influence ABCA1 mRNA levels [13], and 
that ligands for PPARδ directly regulate the expression of ABCA1 via an 
unknown mechanism [14]. Therefore, we also investigated the PPAR gene 
expression in the different cell types. Figure 4 clearly indicates that PPARα 
expression is found mostly in parenchymal cells, with an 82 and 23 fold 
higher expression in these cells than in endothelial cells and Kupffer cells, 
respectively. The PPARγ distribution pattern is comparable to that found for 
PPARα (Fig.4), suggesting a major function of these genes in parenchymal 
cells. PPARδ mRNA levels were almost equal in the different cells, although 
endothelial cell PPARδ expression was somewhat higher as compared to 
parenchymal and Kupffer cells (Fig.4). These data indicate that within the 
various liver cell types PPARδ will have a more general function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4. Relative expression levels of nuclear receptors LXR and PPAR as determined by 
real-time quantitative PCR in rat liver parenchymal (PC), endothelial (EC), and Kupffer 
(KC) cells on a chow diet. Values are expressed relative to HPRT expression (means+SEM). 
**P<0.01 compared to PC expression; #P<0.05 compared to EC expression (t-test, as 
described under “Experimental Procedures”). 
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7.4 Discussion 
 
Hepatic cholesterol uptake from serum coupled to intracellular processing 
and bile excretion are important features in the last step of reverse 
cholesterol transport. It has been shown that disruption of cholesterol 
homeostasis plays an essential role in the pathology of many diseases such 
as cholestasis [15] and atherosclerosis [16]. In the liver, SR-BI plays a 
crucial role in the selective uptake of cholesterol esters from HDL [2]. 
Additionally, studies on ATP-binding cassette transporters suggested that 
hepatic ABCA1 is involved in HDL production [6], while ABCG5/G8 and 
ABCG1 were indicated to mediate biliary efflux of cholesterol from the liver 
[7,9]. Repa et al. showed that treatment of mice with synthetic ligands of 
LXR markedly increased liver ABCG5/G8 expression [17]. In vitro 
observations by Malerod et al. also indicate that LXR is able to regulate 
hepatic SR-BI expression through a direct interaction with a newly 
discovered LXR/RXR response element in the SR-BI promoter [18]. It is 
however still unclear how hepatic ABCA1 and ABCG1 expression is 
regulated and what the precise consequence of their regulation is on 
hepatic cholesterol levels and transport. The liver consists of several 
different cell types, including parenchymal, endothelial and Kupffer cells. It 
is therefore important to study the expression levels of SR-BI and the ATP-
binding cassette transporters in the individual hepatic cell types, to get a 
more detailed view on their specific functions and regulatory mechanisms in 
the liver. Earlier studies performed by Pieters et al. showed that uptake of 
HDL cholesterol esters into liver parenchymal cells is efficiently coupled to a 
rapid synthesis of bile acids [19]. Accordingly, Fluiter et al. observed that 
the receptor responsible for the selective uptake of cholesterol esters into 
the liver, SR-BI, has a relatively high expression in parenchymal cells as 
compared to endothelial and Kupffer cells [20]. These combined 
observations stressed an important role for parenchymal cells in the last 
step of the reverse cholesterol transport process. 
In the current study, we investigated, using real-time quantitative PCR, the 
mRNA expression of genes involved in hepatic cholesterol transport and 
metabolism in liver parenchymal, endothelial and Kupffer cells. Real-time 
PCR is a highly sensitive method to quantify mRNA expression levels in 
vitro and in vivo. mRNA levels have been shown to strongly correlate with 
protein expression levels, indicating that a substantial portion of changes in 
protein levels are a consequence of altered mRNA levels, rather than post-
transcriptional modifications [21]. Importantly, Wellington et al. showed a 
high concordance of ABCA1 mRNA and protein levels in the liver [22]. 
Additionally, we observed in the present study the highest SR-BI mRNA 
expression in the parenchymal cells as compared to endothelial and Kupffer 
cells, which is in accordance with the high Western blot protein expression 
data for SR-BI as reported by Fluiter et al. [20]. We thus suggest that our 
quantitative mRNA data for the various cell types are indicative for the 
activity of the particular genes of interest and their metabolic function. For 
SR-BI, the mRNA and protein expression data in parenchymal cells are 
consistent with our data that the parenchymal cholesterol ester uptake is 
dramatically reduced in SR-BI deficient mice as compared to non-
transgenic littermates (unpublished data). Cholesterol 7α-hydroxylase 
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(CYP7A1) and sterol 27-hydroxylase (CYP27) are the key enzymes in 
classical and alternative bile acid synthesis pathways [23]. The relatively 
high expression of these two bile acid synthesis enzymes observed in 
parenchymal cells is in agreement with the data provided by Pieters et al., 
as it was shown that uptake of HDL cholesterol esters by the parenchymal 
cells is efficiently coupled to bile acid synthesis [19]. Interestingly, an 
equally high expression of CYP27 compared to parenchymal cells was 
observed in liver endothelial cells. In agreement, Reiss et al. have detected 
the same high levels of CYP27 activity in cultured vascular endothelial cells 
[24]. The observed difference between the CYP7A1 and CYP27 expression 
patterns suggests differential functions for these bile acid synthesizing 
enzymes. Interestingly, Babiker et al. suggested that CYP27 mediated 
elimination of cholesterol from macrophages and endothelial cells may be 
an alternative or complement to HDL-mediated reverse cholesterol 
transport under low-HDL conditions. They observed a high secretion of 3β-
hydroxy-cholestenoic acid, an intermediate of the CYP27 mediated 
alternative bile acid formation pathway, from endothelial cells and 
macrophages to albumin containing medium [25]. Efflux of hepatic 
cholesterol to the serum compartment by ABCA1 for the production of 
native HDL is a second important route in maintaining cholesterol 
homeostasis [6]. An equally high relative expression of ABCA1 was 
observed in parenchymal and Kupffer cells, while a ~4 fold lower 
expression of ABCA1 was seen in liver endothelial cells. In macrophages, 
ABCA1 is a critical regulator of the specific ATP-dependent cholesterol 
efflux to ApoA-I, leading to an inhibition of foam cell formation [26]. Kupffer 
cells are liver macrophages, which play an important role in the uptake of 
(modified) lipoproteins [19,27]. The high uptake and an accordingly high 
efflux of cholesterol from Kupffer cells might be the metabolic mechanism 
for the relatively high ABCA1 expression level observed in these cells. 
Haghpassand et al. [28], and Van Eck et al. [29], have shown that 
monocyte/macrophage ABCA1 only minimally contributes to the overall 
plasma HDL levels. The observed high expression levels of ABCA1 in 
parenchymal cells, combined with the observation that ABCA1 functions on 
the basolateral surface of hepatocytes [30], suggest that the liver does 
contribute to HDL production by the efflux of cholesterol from parenchymal 
cells via ABCA1. A third catabolic route for hepatic cholesterol is the direct 
excretion into the bile, which accounts for ~40% of the total liver catabolism. 
Recently, two members of the ATP-binding cassette transporters, ABCG5 
and ABCG8, have been shown to coordinately participate in the hepatic 
sterol secretion into bile [31]. Mutations in either ABCG5 or ABCG8 are 
sufficient to cause sitosterolemia, a disorder that is characterized by 
elevated plasma levels of sterols [32]. Because parenchymal cells are 
responsible for bile acid formation, a relatively high expression of the biliary 
transporters such as ABCG5/G8 in these cells compared to endothelial and 
Kupffer cells is consistent with their suggested function. The expression 
pattern of ABCG5 resembled ABCG8, which is in agreement with the 
statements that these transporters operate as heterodimers to regulate 
biliary cholesterol efflux [9,33]. 
Interestingly, a novel member of the ABC transporter family, ABCG1, has 
also been proposed to have a function in the intracellular trafficking and 
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biliary efflux of cholesterol in the liver [11]. Contrarily to the expectations, 
ABCG1 expression was mainly observed in non-parenchymal cells of the 
rat liver. A 76 fold and 27 fold higher ABCG1 expression was observed in 
Kupffer and endothelial cells than in parenchymal cell under standard 
feeding conditions. Although Kupffer and endothelial cells only contribute 
for 2.5% and 3.3% to the total liver protein, they do contain 51% and 24% of 
total liver ABCG1 expression, respectively. Such a high specific ABCG1 
expression in Kupffer cells was not expected, although ABCG1 has also 
been proposed to play a role in the cholesterol efflux from peripheral 
macrophages [7]. Importantly, after putting rats for two weeks on a high 
cholesterol diet, ABCG1 expression increased 4 fold in parenchymal cells, 
while no significant change in ABCG1 expression in endothelial and Kupffer 
cells was observed. The absence of a similar induction of ABCG1 in 
endothelial and Kupffer cells in response to diet feeding may well be 
caused by an already maximal activity of ABCG1 in these cells even on a 
chow diet. Also, the differences in expression and intracellular localization 
of direct activators (e.g. LXRα) and repressors (e.g. ZNF202) of ABCG1 
might contribute to the difference in its transcriptional regulation between 
different cell types as earlier mentioned by Schmitz et al. [11]. Although 
endothelial and Kupffer cell ABCG1 expressions were still 10 and 12 fold 
higher than that in parenchymal cells, the relative contribution of ABCG1 in 
the parenchymal cells to total liver increased from 25 to 60%. This suggests 
that under high cholesterol conditions ABCG1 might indeed contribute to 
the transport of cholesterol in the parenchymal cells. 
Recent pharmacological interest is focussed upon the regulation of SR-BI 
and the ABC transporters by newly discovered nuclear hormone receptors, 
the liver X receptors (LXRs), and peroxisome proliferator-activated 
receptors (PPARs), respectively [34,35]. Therefore, we also studied their 
cellular localization in the different cell types of the liver. Two different types 
of the liver X receptor have been discovered so far, LXRα and LXRβ, 
respectively. A relatively high expression of LXRα was observed in 
parenchymal cells. In the liver, LXRα plays an essential role in the 
regulation of CYP7A1 and thus the formation of bile acids [36]. CYP7A1 
was found almost exclusively in the parenchymal cells, which coincides with 
the high expression of LXRα in these cells. Contrarily, equally high LXRα 
expression levels were observed in Kupffer cells, where CYP7A1 
expression was almost absent. In macrophages however, LXRα plays a 
crucial role in the regulation of lipid efflux via ABCA1 [37]. Kupffer cells also 
contain high expression levels of ABCA1, which is consistent with a role for 
LXRα in the regulation of ABCA1 in these cells. Between the different cell 
types of the liver, LXRβ was ubiquitously expressed, with a somewhat 
higher expression in endothelial cells versus parenchymal and Kupffer cells. 
The expression distribution of LXRβ thus does not resemble the one found 
for LXRα, which suggests that, in the liver, LXRβ may have a different 
function than LXRα. 
In the liver, PPARα is suggested to play a role in the formation of bile acids, 
because it is able to bind a PPAR response element (PPRE) in the sterol 
12α-hydroxylase promoter, leading to increased levels of cholic acid [38]. 
This might explain the extremely high expression of PPARα found in 
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parenchymal cells as compared to endothelial and Kupffer cells. The high 
expression of PPARγ observed in parenchymal cells suggests that PPARγ, 
like PPARα, also has a major function in these cells. Contrarily, PPARδ is 
ubiquitously expressed between the different cell types of the liver, 
suggesting a more general function for PPARδ in all cell types of the liver. 
In conclusion, we have provided data that several ABC transporters and 
nuclear hormone receptors involved in liver cholesterol homeostasis are 
differentially expressed in the specific cell types of the liver. In order to 
study their intracellular transport function inside the liver it appears to be 
essential to take into account their cellular localization, as especially evident 
for ABCG1. This appears specifically true for studies on the regulation of 
the transporters by nuclear receptors, as metabolic changes are directly 
coupled to the specific (intra)cellular expression level of the cholesterol 
transporters.  
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Background/Aims: Feeding rodents atherogenic diets enriched in 
cholesterol or cholic acid changes hepatic cholesterol metabolism. In the 
present study, the effect of an atherogenic diet enriched in cholesterol and 
cholic acid on cellular hepatic cholesterol metabolism was studied. 
Methods: Gene and protein expression analysis was performed on 
parenchymal, endothelial, and Kupffer cells isolated from rats fed a chow or 
atherogenic diet using quantitative real-time PCR and immunoblotting, 
respectively. 
Results: The atherogenic diet raised the serum cholesterol concentration 
11-fold, mostly in the VLDL fraction, and led to heavy lipid loading of rat 
liver parenchymal and Kupffer cells. Only moderate changes in the 
expression of genes involved in cholesterol metabolism were observed in 
parenchymal cells on the diet, while PPARδ expression was 6.8-fold 
decreased. Kupffer cells, however, showed a highly adaptive response with 
a 2- to 9-fold induction of SR-BI, ABCA1, and ABCG5/G8, and an 82-fold 
induction in CYP7A1 mRNA expression, respectively. 
Conclusion: Heavy lipid loading of parenchymal cells leads to moderate 
gene expression changes, while Kupffer cells respond highly adaptive by 
stimulating the expression of genes involved in cholesterol metabolism and 
transport. 
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8.1 Introduction 
 
The liver is an essential organ in the removal of excess cholesterol from the 
blood circulation for excretion into the bile [1,2]. The liver regulates its intra-
hepatic cholesterol homeostasis, by maintaining an appropriate balance 
between the regulatory free cholesterol and the more inert cholesterol ester 
pool. The liver consists of different cell types: parenchymal, endothelial, and 
Kupffer cells that may exert different functions in the hepatic flux of 
cholesterol. Parenchymal liver cells are located between bile canaliculi and 
blood sinuses, and mediate chylomicron- and very low-density lipoprotein 
(VLDL)-remnant and high-density lipoprotein (HDL) cholesterol ester 
removal from the blood circulation [3,4]. Additionally, parenchymal liver cells 
perform the biliary efflux of cholesterol and its conversion products, bile 
acids [5]. Hepatic endothelial cells line the blood sinuses, where they 
function in the removal of modified lipoproteins from the blood circulation 
and mediate their natural barrier function. Kupffer cells are tissue 
macrophages located within the blood sinuses of the liver. They mainly 
function in the removal of bacteria and in the clearance of modified 
lipoproteins from the circulation [6,7]. 
Recently, we have shown that the relative expression of genes involved in 
hepatic cholesterol metabolism is markedly different for rat parenchymal, 
endothelial and Kupffer cells under standard feeding conditions [8]. In the 
current study, the effect of diet-induced lipid loading on the expression of 
genes involved in cholesterol uptake, metabolism, and efflux were studied 
in rat liver parenchymal, endothelial, and Kupffer cells to gain insight in the 
cell specific regulation of cholesterol metabolism. 
Feeding an atherogenic diet enriched in cholesterol and cholic acid disrupts 
liver cholesterol homeostasis leading to heavy lipid loading of rat liver 
parenchymal, Kupffer, and to a lesser extent of endothelial cells. The 
regulatory response of genes responsible for the uptake of LDL (LDL-
receptor) and HDL cholesterol esters (scavenger receptor B type 1; SR-BI) 
and ATP-binding cassette transporter (ABC) genes involved in cholesterol 
trafficking (ABCA1, ABCG5, and ABCG8) were analysed on mRNA level. In 
addition, the genes important for the conversion of cholesterol to bile acids 
(cholesterol 7α-hydroxylase; CYP7A1) and the biliary secretion of bile acids 
(bile salt export pump; BSEP) were studied. In order to correlate the 
observed changes with regulation by nuclear hormone receptors, we also 
determined the effect of the atherogenic diet enriched in cholesterol and 
cholic acid on the gene expression of the nuclear receptors liver X receptor 
(LXR), farnesoid X receptor (FXR), and peroxisome proliferator-activated 
receptors (PPAR) α, γ, and δ. 
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8.2 Experimental Procedures 
 
 
8.2.1 Animals 
 
Male Wistar rats were obtained from Charles River Laboratories. Rats were 
fed a regular chow diet, containing 4.3% (w/w) fat and no cholesterol 
(Special Diet Services, Witham, UK), or a cholesterol/cholic acid enriched 
diet, containing 2% (w/w) cholesterol, 5% (w/w) olive oil, and 0.5% (w/w) 
cholic acid (Hope Farms, Woerden, The Netherlands) for two weeks. 
Subsequently, hepatic parenchymal (PC), endothelial (EC), and Kupffer  
cells (KC) were isolated essentially according to the method of Nagelkerke 
et al. [9]. The purity and identification of the cells was analysed after 3,3’-
diaminobenzediene peroxidase staining and phase contrast microscopy. 
KC’s are peroxidase postitive and stain brown under these conditions. Diet 
feeding had no significant effect on the viability or purity of the different cell 
fractions. The parenchymal fractions consisted for >99% of parenchymal 
cells, the endothelial fractions contained ~95% endothelial cells and ~5% 
Kupffer cells, whilst the Kupffer cell fractions contained ~90% Kupffer cells 
and 10% endothelial cells under both standard and high cholesterol/cholic 
acid feeding conditions. Animal experiments were performed at the 
Gorlaeus laboratories of the Leiden/Amsterdam Center for Drug Research 
in accordance with the National Laws. All experiments were approved by 
the Ethics Committee for Animal Experiments of Leiden University. 
 
 
8.2.2 Serum lipid analyses 
 
Serum concentrations of total and free cholesterol, and triglycerides were 
determined using enzymatic colorimetric assays (Roche Diagnostics). The 
cholesterol distribution over the different lipoproteins in serum was analysed 
by fractionation of 30 µl serum of each rat using a Superose 6 column 
(3.2x30 mm, Smart-system, Pharmacia). Total cholesterol content of the 
effluent was determined using enzymatic colorimetric assays (Roche 
Diagnostics). 
 
 
8.2.3 Assessment of lipid accumulation in liver parenchymal, 
endothelial, and Kupffer cells 
 
Isolated liver parenchymal, endothelial, and Kupffer cells were cyto-spinned 
on gelatin-coated slides. Lipid accumulation was visualised using oil red O 
(Sigma). A Leica DMRE microscope coupled to a video camera and Leica 
Qwin Imaging software (Leica Ltd.) was used to take photographs of the 
stained cells (1000x magnification). 
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8.2.4 Immunoblotting 
 
Immunoblotting on protein from isolated liver parenchymal, endothelial, and 
Kupffer cells was performed as described previously [10]. In short, after 
running equal amounts of total cell protein on a 7.5% SDS-PAGE gel, 
ABCA1 was detected using murine monoclonal ABCA1 primary antibody 
(AC-10; Dr. M. Hayden, Vancouver, Canada) [11] and a goat-anti-mouse 
IgG (Jackson ImmunoResearch) secondary antibody. 
 
 
8.2.5 Analysis of gene expression by real-time quantitative PCR 
 
Quantitative gene expression analysis on isolated liver parenchymal, 
endothelial, and Kupffer cells was performed as described [8]. In short, total 
RNA was isolated according to Chomczynski and Sacchi [12] and reverse 
transcribed using RevertAidTM reverse transcriptase. Gene expression 
analysis was performed using real-time SYBR Green technology 
(Eurogentec) with the primers displayed in Table 1. Hypoxanthine guanine 
phosphoribosyl transferase (HPRT) and acidic ribosomal phosphoprotein 
P0 (36B4) were used as the standard housekeeping genes. Relative gene 
expression (R.E.) numbers were calculated by subtracting the threshold 
cycle number (Ct) of the target gene from the average Ct of HPRT and 
36B4 (Ct housekeeping) and raising 2 to the power of this difference. The 
average Ct of two housekeeping genes was used to exclude that changes 
in the relative expression were caused by variations in the separate 
housekeeping gene expressions. The Ct values for 36B4 (means±SEM; 
n=6) were 24.6±1.0 and 24.8±1.6 for parenchymal cells, 24.8±1.1 and 
25.5±0.6 for endothelial cells, and 24.0±0.8 and 24.5±1.1 for Kupffer cells 
on the chow or the cholesterol/cholic acid enriched diet, respectively. The 
Ct values for HPRT (means±SEM; n=6) were 26.3±1.1 and 26.0±1.6 for 
parenchymal cells, 26.8±0.7 and 25.5±0.6 for endothelial cells, and 
25.3±1.4 and 25.0±1.4 for Kupffer cells on the chow or the 
cholesterol/cholic acid enriched diet, respectively. 
 
 
8.2.6 Data analysis 
 
The significance of differences in relative gene expression numbers 
between hepatic cells isolated from rats fed a chow or a cholesterol/cholic 
acid enriched diet, measured by real time quantitative PCR, was calculated 
using a two-tailed Student’s t-test on the differences in Ct (Cthousekeeping – 
Cttarget gene). The difference in Ct values was tested for normality using 
Graphpad Instat 3 software (Graphpad Software, Inc.). Probability values 
less than 0.05 were considered significant. 
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Table 1 
Primers for quantitative real-time PCR analysis 
Gene GenBank accession Forward primer Reverse primer 
Amplicon 
size 
36B4 X15267 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 85 
ABCA1 ** ATCTCATAGTATGGAAGAATGTGAAGCT CGTACAACTATTGTATAACCATCTCCAAA 132 
ABCG5 NM053754 CGCAGGAACCGCATTGTAA TGTCGAAGTGGTGGAAGAGCT 67 
ABCG8 NM130414 GATGCTGGCTATCATAGGGAGC TCTCTGCCTGTGATAACGTCGA 69 
BSEP NM031760 TGGAAAGGAATGGTGATGGG CAGAAGGCCAGTGCATAACAGA 77 
CYP7A1 NM012942 CTGTCATACCACAAAGTCTTATGTCA ATGCTTCTGTGTCCAAATGCC 95 
HPRT X62085 TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG 91 
LDL 
receptor NM175762 AGCCGATGCATTCCTGACTC AGTTCATCCGAGCCATTTTCAC 68 
LXRα NM031627 TCAGCATCTTCTCTGCAGACCGG TCATTAGCATCCGTGGGAACA 144 
LXRβ NM031626 AAGCTGGTGAGCCTGCGC CGGCAGCTTCTTGTCCTG 81 
PPARα NM013196 TGAACAAAGACGGGATG TCAAACTTGGGTTCCATGAT 106 
PPARγ NM013124 CATGCTTGTGAAGGATGCAAG TTCTGAAACCGACAGTACTGACAT 131 
PPARδ NM012141 GAGGGGTGCAAGGGCTTCTT CACTTGTTGCGGTTCTTCTTCTG 97 
SHP L76567 CTATTCTGTATGCACTTCTGAGCCC GGCAGTGGCTGTGAGATGC 72 
SR-BI U76205 GTTGGTCACCATGGGCCA CGTAGCCCCACAGGATCTCA 65 
** Primer sequences based on an alignment of human (NM005502) and murine (XM109397) 
ABCA1 
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8.3 Results 
 
 
8.3.1 The effect of an atherogenic diet on serum and hepatic cellular 
lipid levels 
 
Male Wistar rats (six per group) were fed either regular chow (4.3% (w/w) 
fat and no cholesterol) or a diet enriched in cholesterol and cholic acid (2% 
(w/w) cholesterol, 5% (w/w) olive oil, and 0.5% (w/w) cholic acid) for two 
weeks and fasted overnight before sacrifice. Feeding the diet enriched in 
cholesterol and cholic acid resulted in 4-fold increased serum free 
cholesterol, and 11-fold increased serum cholesterol ester levels, with 
unchanged serum triglyceride levels as compared to rats on chow diet 
(Table 2). The observed changes in serum cholesterol levels were caused 
by a major increase in cholesterol ester rich beta-migrating VLDL (Fig.1; 
[13]). The liver of rats fed the cholesterol/cholic acid enriched diet showed 
visible whitening as compared to control liver, indicative for heavy lipid 
loading (Fig.2A). Oil red O staining of isolated parenchymal, endothelial, 
and Kupffer cells indicated heavy lipid loading of parenchymal, Kupffer 
cells, and to a lesser extent of endothelial cells after two weeks of feeding 
the cholesterol/cholic acid enriched diet (Fig.2B). Earlier data provided by 
Fluiter et al. showed that the total cellular cholesterol concentration 
increased 12- and 23-fold in parenchymal and Kupffer cells, respectively, 
upon feeding this cholesterol/cholic acid enriched diet [14].  
 
 
 
Table 2 
Effect of a cholesterol/cholic acid enriched diet on serum lipid levels 
Diet n 
Total cholesterol 
(mg/ml) 
Free cholesterol 
(mg/ml) 
Triglycerides 
(mg/ml) 
Chow 6 0.39 ± 0.04 0.15 ± 0.02 0.69 ± 0.053 
Cholesterol/cholic acid enriched 5 3.40 ± 0.5*** 0.64 ± 0.14 ** 0.56 ± 0.098 
Serum lipid levels were measured in overnight fasted rats after feeding a chow or a 
cholesterol/cholic acid enriched diet for two weeks. Data represent means+SEM. **P<0.01 and 
***P<0.001 compared to chow diet values. 
 
 
 
Fig.1. Effect of a cholesterol/cholic acid 
enriched diet on the rat serum 
cholesterol distribution. Blood samples 
were drawn after an overnight fast while 
feeding a regular chow (circles) or a 
cholesterol/cholic acid enriched diet 
(triangles) for two weeks. Sera from 5-6 
individual rats were loaded onto a Superose 
6 column and fractions were collected. 
Fractions 3-7 represent VLDL; fractions 8 to 
15, LDL; and fractions 15 to 19, HDL, 
respectively. 
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Fig.2. A cholesterol/cholic acid enriched diet induces lipid loading of rat liver 
parenchymal and Kupffer and to a minor extent endothelial cells leading to whitening of 
the liver. A) Photographs were taken of the liver during perfusion to visualize the colour 
difference between livers on the cholesterol/cholic acid enriched diet (right) as compared to the 
regular chow diet (left). B) Parenchymal, endothelial, and Kupffer cells of rats fed a 
cholesterol/cholic acid enriched diet for two weeks were isolated and stained for lipid content 
with oil red O. 
 
 
8.3.2 The effect of an atherogenic diet on genes involved in the uptake 
of cholesterol 
 
The effect of the atherogenic diet on the mRNA expression level of genes 
involved in the hepatic uptake of cholesterol from the serum was 
determined in parenchymal, endothelial, and Kupffer cells using real-time 
quantitative PCR. Parenchymal LDL receptor expression was significantly 
50% decreased (R.E. 0.030 vs 0.059) by the atherogenic diet as compared 
to the chow diet (Fig.3). No significant effect of the diet on the LDL receptor 
expression was observed in endothelial and Kupffer cells (R.E. 0.0096 vs 
0.0084, and 0.014 vs 0.010, respectively). The mRNA expression of the 
receptor involved in the selective uptake of HDL cholesterol esters, SR-BI, 
was not significantly changed by the diet in parenchymal and endothelial 
cells (R.E. 0.48 vs 0.66, and 0.17 vs 0.21, respectively). In contrast, SR-BI 
mRNA levels were 3-fold (Fig.3) increased in Kupffer cells, from 0.12 to 
0.35 (R.E.), respectively. 
 
 
8.3.3 The effect of an atherogenic diet on genes involved in 
cholesterol metabolism and efflux 
 
In addition to SR-BI, several other gene products are involved in the efflux 
of cholesterol from the different hepatic cell types. The direct biliary efflux of 
cholesterol from parenchymal cells is mediated by the ABC half 
transporters ABCG5 and ABCG8 [15]. Recently, it has been shown that 
hepatic ABCA1 plays an essential role in the formation of HDL [16].  
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Fig.3. Effect of a cholesterol/cholic acid enriched diet on LDL receptor (LDLR) and SR-BI 
mRNA expression in parenchymal, endothelial, and Kupffer cells of rats fed a regular 
chow (white bars) or a cholesterol/cholic acid enriched diet (black bars) for two weeks. 
Gene expression analysis was performed by means of real-time quantitative PCR. Values are 
expressed as fold induction compared to the chow diet (means+SEM; n=5-6). *P<0.05 
compared to the chow diet (t-test, as described under “Experimental Procedures”). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4. Effect of a cholesterol/cholic acid enriched diet on ABC transporter mRNA 
expression in parenchymal, endothelial, and Kupffer cells of rats fed a regular chow 
(white bars) or a cholesterol/cholic acid enriched diet (black bars) for two weeks. Gene 
expression analysis was performed by means of real-time quantitative PCR. Values are 
expressed as fold induction compared to the chow diet (means+SEM; n=5-6). *P<0.05 and 
**P<0.01 compared to the chow diet (t-test, as described under “Experimental Procedures”). 
 
 
Fig.5. Effect of a cholesterol/cholic acid 
enriched diet on ABCA1 protein expression in 
parenchymal (PC), endothelial (EC), and 
Kupffer cells (KC) of rats fed a regular chow 
(C) or cholesterol/cholic acid enriched diet 
(CH/CA) for two weeks.  
 
 
Accordingly, ABCA1 deficient mice have virtually no HDL cholesterol levels 
[17]. On the cholesterol/cholic acid enriched diet, ABCG5 and ABCG8 
expression in parenchymal and endothelial cells is not significantly 
influenced. Interestingly, in Kupffer cells ABCG5 and ABCG8 expression is 
stimulated 9-fold (R.E. 0.049 vs 0.005) and 2.4-fold (R.E. 0.015 vs 0.006), 
respectively, by the cholesterol/cholic acid enriched diet (Fig.4). 
Furthermore, ABCA1 expression is stimulated 3.5- and 3-fold in endothelial 
(R.E. 0.17 vs 0.05) and Kupffer cells (R.E. 0.41 vs 0.14), but not in 
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parenchymal cells (R.E. 0.11 vs 0.13; Fig.4). The observed induction of 
ABCA1 mRNA levels in endothelial and Kupffer cells on a high cholesterol 
diet was also established on the protein level by western blotting using an 
ABCA1-specific antibody (Fig.5). 
Another important route for cholesterol removal from the liver is the 
metabolism of cholesterol to bile acids by CYP7A1 and subsequent 
excretion into the bile via the BSEP. No significant change in CYP7A1 
expression was detected in parenchymal and endothelial cells upon 
cholesterol/cholic acid diet feeding. Strikingly, the cholesterol/cholic acid 
enriched diet induced a highly significant 82-fold increase (R.E. 0.29 vs 
0.0035) in Kupffer cell CYP7A1 expression (Fig.6). In addition, a ~17-fold 
increase (R.E. 0.85 vs 0.05) in Kupffer cell BSEP expression was observed, 
which failed to reach statistical significance due to a wide variation of 
expression in these cells (p=0.07). In contrast, BSEP expression was 
unchanged in parenchymal (R.E. 1.43 vs 1.57) and endothelial cells (R.E. 
0.048 vs 0.035) in response to the cholesterol/cholic acid enriched diet 
(Fig.6). Surprisingly, the expression of an important repressor of CYP7A1 
mRNA expression, SHP [18], was also increased 3.2-fold in Kupffer cells 
(R.E. 0.0094 vs 0.0028) and to a lesser extent (66%; R.E. 0.012 vs 0.007) 
in parenchymal cells (Fig.6). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.6. Effect of a cholesterol/cholic acid enriched diet on cholesterol 7α-hydroxylase 
(CYP7A1), bile salt export pump (BSEP), and small heterodimer partner (SHP) mRNA 
expression in parenchymal (PC), endothelial (EC), and Kupffer cells (KC) of rats fed a 
regular chow (white bars) or a cholesterol/cholic acid enriched diet (black bars) for two 
weeks. Gene expression analysis was performed by means of real-time quantitative PCR. 
Values are expressed as fold induction compared to the chow diet (means+SEM; n=5-6). 
*P<0.05, ***P<0.001 compared to the chow diet (t-test, as described under “Experimental 
Procedures”). 
 
 
8.3.4 The effect of an atherogenic diet on the expression of nuclear 
hormone receptors 
 
Recently it was shown that several members of the nuclear hormone 
receptor family are involved in the transcriptional control of genes involved 
in cholesterol metabolism. No significant effect on the expression of LXRα/β 
was detected in any cell type of the liver upon high cholesterol/cholic acid 
feeding, whilst also FXRα/β expression was unchanged (data not shown). 
Cheema et al. have shown that CYP7A1 expression can also be positively 
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regulated by fatty acids via binding of the nuclear hormone receptor PPARα 
to an additional PPARα/RXRα binding site [19]. Therefore, the regulation of 
PPARα expression by the cholesterol/cholic acid enriched diet was also 
studied in parenchymal, endothelial, and Kupffer cells. PPARα expression 
was significantly stimulated 7.5-fold in Kupffer cells (R.E. 0.104 vs 0.014) by 
the cholesterol/cholic acid enriched diet (Fig.7). In addition, the expression 
of PPARγ, a key regulator of intracellular fatty acid metabolism gene 
expression [20], was significantly increased 3.6-fold (R.E. 0.012 vs 0.032) in 
Kupffer cells. Finally, the expression of PPARδ, whose function in hepatic 
lipid metabolism remains to be clarified, was decreased 6.8-fold in 
parenchymal cells (R.E. 0.014 vs 0.092) on the cholesterol/cholic acid 
enriched diet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.7. Effect of a cholesterol/cholic acid enriched diet on the different PPAR mRNA 
expression in parenchymal, endothelial, and Kupffer cells of rats fed a regular chow 
(white bars) or a cholesterol/cholic acid enriched diet (black bars) for two weeks. Gene 
expression analysis was performed by means of real-time quantitative PCR. Values are 
expressed as fold induction compared to the chow diet (means+SEM; n=5-6). *P<0.05 and 
**P<0.01 compared to the chow diet (t-test, as described under “Experimental Procedures”). 
 
 
8.4 Discussion 
 
We have recently shown that the expression of genes involved in 
cholesterol uptake, metabolism, and efflux is markedly different between 
parenchymal, endothelial, and Kupffer cells in the rat liver [8]. It remains to 
be established whether differences in cellular localization also lead to a 
difference in regulation of genes involved in hepatic cholesterol metabolism. 
In the current study, the effect of a high cholesterol/cholic acid diet-induced 
lipid loading on the expression of genes involved in cholesterol uptake, 
metabolism, and efflux were studied in rat liver parenchymal, endothelial, 
and Kupffer cells to gain insight in the cell specific regulation of cholesterol 
metabolism. A diet, enriched in cholesterol (2%) and cholic acid (0.5%) was 
used, because combination of these two components in a diet is commonly 
used to induce aortic atherosclerotic lesion formation in rats and mice [21-
23]. In addition, Chiang et al. [24] have shown that addition of cholic acid to 
a diet containing cholesterol induces higher rises in plasma and hepatic 
total cholesterol levels than the cholesterol enriched diet alone. In the 
current study, the cholesterol/cholic acid enriched diet drastically increased 
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serum levels of VLDL cholesterol (β-VLDL), leading to heavy lipid loading of 
parenchymal and Kupffer cells, and to a lesser extent of endothelial cells. 
The expression of SR-BI, a crucial determinant in the selective uptake of 
HDL cholesterol esters into the liver, was not significantly affected by the 
diet in parenchymal and endothelial cells. Interestingly, SR-BI mRNA 
expression was increased in Kupffer cells in response to lipid loading by the 
cholesterol/cholic acid enriched diet. This observation is in agreement with 
data provided by Fluiter et al. [14], who showed that SR-BI protein 
expression in Kupffer cells is 4-fold stimulated by a high cholesterol diet. 
Recent studies have proposed a novel role for SR-BI in the efflux from 
macrophages of free cholesterol to HDL [25,26]. Since SR-BI expression is 
induced upon lipid loading of Kupffer cells, it is suggested that Kupffer cells, 
upon lipid loading, induce SR-BI mediated cholesterol efflux in order to 
eliminate excess cholesterol. 
Recent data have indicated that ABCA1 is also a major determinant in the 
efflux of cholesterol from macrophages. Bortnick et al. have directly 
correlated ABCA1 mRNA expression with cholesterol efflux to apoAI in 
various cell lines [27], whilst Van Eck et al. have shown that leukocyte 
selective deficiency of ABCA1 results in increased susceptibility to 
atherosclerosis [28]. The cholesterol/cholic acid enriched diet had no effect 
on parenchymal ABCA1 expression, but it did significantly stimulate ABCA1 
expression in endothelial and Kupffer cells. The unchanged ABCA1 
expression observed in parenchymal cells is in agreement with data 
provided by Denis et al. [29] who indicated that ABCA1 expression is 
constitutive in hepatic cells, whilst sterols are able to stimulate ABCA1 
expression in macrophages. Venkateswaran et al. have suggested that the 
increase in macrophage ABCA1 expression in response to cellular 
cholesterol loading is the consequence of increased activation of the 
nuclear hormone receptor LXRα [30]. Recently, LXRα was also shown to 
be a positive regulator of the hepatic expression of ABCG5 and ABCG8 
[31], two half transporters, which together function as a full transporter 
involved in the hepatic biliary cholesterol efflux [32]. Interestingly, the 
expression of ABCG5 and ABCG8 was significantly increased in lipid laden 
Kupffer cells. The relative expression level of Kupffer cell ABCG5/G8 is 
rather low as compared to the expression in parenchymal cells under 
standard feeding conditions [8], which indicates that ABCG5/G8 normally 
does not play a crucial role in Kupffer cells. Since Kupffer cells do not 
directly efflux cholesterol into bile, the observed increase in ABCG5/G8 
expression suggests a novel role for these transporters in the efflux of 
cholesterol from lipid laden Kupffer cells. Strikingly, no significant effect of 
the cholesterol/cholic acid enriched diet was observed on parenchymal and 
endothelial ABCG5/G8 expression. Berge et al. have shown that cholesterol 
feeding up-regulates the hepatic expression of ABCG5/G8 [15]. The 
absence of an induction of ABCG5/G8 in parenchymal cells might be the 
result of diet induced stimulation of SHP (66%) in these cells, since it has 
been shown that the nuclear receptor SHP is able to interact with LXR to 
modulate its transcriptional activity [33].  
In the liver, CYP7A1 is a key enzyme in the conversion of cholesterol to bile 
acids for excretion into the bile [38]. Importantly, both LXRα and FXR 
control the expression of CYP7A1. In rodents, LXRα induces the 
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expression of CYP7A1 via binding as a heterodimer with the RXRα to 
AGGTCA-like response elements in its promoter [35]. In contrast, FXR 
inhibits CYP7A1 expression via induction of SHP. In agreement with our 
data, Gupta et al. [36] have shown that feeding a diet enriched in 
cholesterol and cholic acid stimulates hepatic SHP expression. She also 
suggested that under conditions of both SHP and LXR alpha activation, the 
stimulatory effect of LXR alpha overrides the inhibitory effect of FXR and 
results in an induction of rat CYP7A1 mRNA levels [36]. This is in 
agreement with our data that CYP7A1 was slightly increased in 
parenchymal and endothelial cells by the cholesterol/cholic acid enriched 
diet. The major induction (~80 fold) in Kupffer cell CYP7A1 expression by 
the diet also suggests a major role for LXRα compared to FXR in the 
regulation in these cell types. Interestingly, a role for CYP7A1 in the 
metabolism and efflux of cholesterol in macrophages has already been 
proposed by Moore and Davis [37] and our data provide the first evidence 
that in vivo loading of macrophages markedly induces the CYP7A1 efflux 
pathway. 
Feeding the cholesterol/cholic acid enriched diet increased serum β-VLDL 
levels and led to an 8-fold increase in PPARα expression in Kupffer cells. 
Although the expression level of PPARα was still very low as compared to 
the expression in parenchymal cells, these data do suggest that PPARα 
possibly was involved in the huge stimulation of CYP7A1 expression 
observed in Kupffer cells. In addition, the observed increase in Kupffer cell 
SR-BI expression might be caused by the induction of PPARα expression 
as well, since Chinetti et al. [38] have suggested that PPARα is a direct 
regulator of SR-BI expression in macrophages. 
Multiple studies have suggested a major role for PPARγ in the regulation of 
macrophage ABCA1 expression and cholesterol efflux to apoAI [39,40]. A 
small but significant induction in PPAR expression was observed solely in 
Kupffer cells, which suggests that, in addition to LXRα, PPARγ might also 
contribute to the observed induction in ABCA1 expression. In contrast, a 
strong decrease in PPARδ expression was found in parenchymal cells, but 
not Kupffer and endothelial cells. Although several studies have suggested 
that PPARδ is involved in muscle and intestinal fatty acid homeostasis 
[41,42], the exact function of PPARδ in hepatic cholesterol homeostasis 
remains to be clarified. Oliver et al. have shown that PPARδ activation does 
decrease serum VLDL levels and lead to an increase in serum HDL levels, 
thereby stimulating reverse cholesterol transport [43]. It will be interesting to 
study the effect of low parenchymal PPARδ expression on the VLDL 
secretion by these cells. 
In conclusion, we have shown that heavy lipid loading of parenchymal cells 
leads to moderate gene expression changes, while Kupffer cells respond 
highly adaptive by stimulating the expression of genes involved in 
cholesterol metabolism and transport. The highly adaptive response of 
endothelial and in particular Kupffer cells will enable efficient transport of 
cholesterol to extracellular acceptors (ApoA-I and HDL), thereby preventing 
malfunctioning of the cells under atherogenic conditions.  
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The liver is an essential organ in the clearance of excess cholesterol from 
the blood and subsequent excretion into the bile. The liver contains several 
different cell types, which all have their specific localization and function. 
However, the majority of the liver cells consist of parenchymal cells, which 
are the major player in cholesterol and glucose metabolism. To gain insight 
in the pathways involved in the response of liver parenchymal cells to 
increased dietary lipid levels, in current study the time-dependent changes 
in gene expression in this specific cell type upon feeding a Western type 
diet were determined using microarray analysis. Western type diet feeding 
resulted in a drastic increase in both free (5.8-fold) and total (5.2-fold) 
serum cholesterol levels in the first two weeks, with only small additional 
increases after 4 and 6 weeks. During the first two weeks of Western type 
diet feeding 244 genes displayed a change in gene expression of at least 2-
fold; 158 genes were upregulated, and 86 were downregulated. The largest 
number of genes (total 41; upregulated 30, downregulated 11) was 
associated with biological processes involving lipid, fatty acid and steroid 
metabolism. Dietary (time-dependent) upregulation of genes involved in 
glycolysis and fatty acid synthesis could be confirmed using quantitative 
real-time PCR. The data indicate that liver parenchymal cells stimulate 
glycolysis and lipogenesis to maintain (intracellular) homeostasis in 
response to an increased dietary lipid level.  Furthermore, our studies 
indicate a very important role for the transcription factors SREBP and LXR 
in the (initial) response of the parenchymal liver cells to the increased levels 
of dietary lipid. 
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9.1 Introduction 
 
Cholesterol is an important constituent of membranes in all different organs 
and cells in the body. In steroidogenic tissues (e.g. testis, ovaries) and the 
liver cholesterol serves also as a precursor in the formation of steroid 
hormones and bile acids, respectively. However, due to the increased 
consumption of diets containing relatively high levels of cholesterol and/or 
fat in the Western world, it is expected that an excess of circulating plasma 
cholesterol in the general population will rise dramatically. Increased levels 
of circulating cholesterol are considered to be a major risk factor for 
atherosclerosis and subsequent cardiovascular diseases (e.g. myocardial 
infarction, stroke) [1], which are the leading cause of death in the Western 
world. In addition to the dietary risk for high plasma cholesterol levels, 
several mutations in the LDL receptor gene are associated with familial 
hypercholesterolemia. Familial hypercholesterolemia is a dominantly 
inherited error of metabolism characterised by raised plasma low-density 
lipoprotein (LDL) levels, xanthomas of skin and tendons, and premature 
heart disease due to atherosclerosis of the coronary arteries [2]. 
The liver is an essential organ in the clearance of excess cholesterol from 
the blood and subsequent excretion into the bile [3,4]. Due to the important 
role of the liver in metabolism, several studies have recently been 
conducted using microarray technology to determine the molecular 
mechanisms underlying long-term high fat diet-induced alterations in total 
mouse liver [5-8]. The liver however contains several different cell types, 
which all have their specific localization and function. Kupffer cells are 
tissue macrophages strategically located within the liver sinusoids, and their 
function is the removal of bacteria and the clearance of modified 
lipoproteins. In addition, hepatic endothelial cells line the sinusoids, where 
they function in the removal of modified lipoproteins and mediate their 
natural barrier function. However, the majority of the liver cells consist of 
parenchymal cells (~60%), which occupy >90% of the total liver protein 
mass. Parenchymal liver cells are located between bile canaliculi and 
sinusoids, where they mediate the uptake and metabolism of cholesterol for 
biliary excretion. Since the parenchymal liver cell is the major player in 
cholesterol and glucose metabolism, we have quantified in the current study 
the time-dependent changes in gene expression in this specific cell type 
upon feeding a Western type diet containing 0.25% cholesterol and 15% fat 
to gain insight in the pathways involved in the response of liver 
parenchymal cells to increased dietary lipid levels. For this purpose we 
have subjected RNA from isolated parenchymal cells of atherosclerosis 
prone mice (LDL receptor deficient mice) to microarray analysis. 
Western type diet feeding resulted in a drastic increase in both free (5.8-
fold) and total (5.2-fold) cholesterol levels in the first two weeks, with only 
small additional increases after 4 and 6 weeks. Since the serum lipid levels 
already stabilized at a higher level after 2 weeks of Western type diet 
feeding, we specifically focused on the early changes in gene expression in 
parenchymal liver cells. During the first two weeks of Western type diet 
feeding 244 genes displayed a change in gene expression of at least 2-fold; 
158 genes were upregulated, and 86 were downregulated. The largest 
number of genes (total 41; upregulated 30, downregulated 11) were 
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associated with biological processes involving lipid, fatty acid and steroid 
metabolism. Dietary (time-dependent) upregulation of genes involved in 
glycolysis and fatty acid synthesis could be confirmed using quantitative 
real-time PCR. The data indicate that liver parenchymal cells stimulate 
glycolysis and lipogenesis to maintain (intracellular) homeostasis in 
response to an increased dietary lipid level.  In addition, our studies indicate 
a very important role for the transcription factors SREBP and LXR in the 
(initial) response of the parenchymal liver cells to the increased levels of 
dietary lipid. 
 
 
9.2 Experimental Procedures 
 
 
9.2.1 Animals 
 
Homozygous LDL receptor deficient mice [9,10] were obtained from The 
Jackson Laboratory as mating pairs and bred at the Gorlaeus Laboratories, 
Leiden, The Netherlands. Female mice were maintained on sterilized 
regular chow containing 5.7% (wt/wt) fat and no cholesterol (Hope Farms, 
Woerden, The Netherlands), or were fed a semi-synthetic Western type diet 
containing 15% (wt/wt) cacao butter and 0.25% (wt/wt) cholesterol for 2, 4, 
or 6 weeks. Subsequently, parenchymal liver cells were isolated essentially 
according to the method of Nagelkerke et al. [11]. The purity and viability of 
the cells was analysed using trypan blue staining and phase contrast 
microscopy. Western type diet feeding had no effect on the viability or purity 
of the isolated cells; the liver parenchymal cell fractions consisted for >99% 
of parenchymal cells with a viability >95% under both standard and Western 
type diet feeding conditions. 
 
 
9.2.2 Serum lipid analyses 
 
Serum concentrations of free and total cholesterol were determined using 
enzymatic colorimetric assays (Roche Diagnostics). The cholesterol 
distribution over the different lipoproteins in serum was analysed by 
fractionation of 30 µl serum of each mouse using a Superose 6 column 
(3.2×30 mm, Smart-system, Pharmacia). Total cholesterol content of the 
effluent was determined using enzymatic colorimetric assays (Roche 
Diagnostics). 
 
 
9.2.3 Microarray analysis 
 
The Mouse Genome Survey Arrays used in the study contained 32.996 
different spots, which included transcripts from the public domain as well as 
from the Celera library. 
Total RNA from liver parenchymal cells was isolated according to 
Chomczynski and Sacchi [12]. Double stranded cDNA was prepared from 2 
µg of total RNA. An in vitro transcription (IVT) reaction was used to 
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synthesize 50-100 µg of UTP-digoxigenin-labeled cRNA. Equal amounts of 
cRNA (10 µg) from 2 pooled RNA samples of 2 mice (total of 4 mice) per 
time point was hybridized to Mouse Genome Survey Arrays for 16 hours at 
55°C. Subsequently, an alkalic phosphatase-linked digoxigenin antibody 
was incubated with the array and the phosphatase activity was initiated to 
start the chemiluminescent signal. The chemiluminescent (cRNA) and 
fluorescent (spot backgound) signals of the cRNA and standard controls 
spots were scanned for 5 and 25 seconds using an AB1700 
Chemiluminescence Analyzer (Applied Biosystems). Using the software 
supplied with the AB1700 apparatus, the spot chemiluminescent signal was 
normalized over the fluorescent signal of the same spot (using the standard 
control signals) to obtain the normalized signal value that was used for 
further analysis. In addition, a signal to noise ratio for every spot was 
obtained, which needed to be at least 1 at each time point in order to use 
the spot for further analysis. In the analysis, the median value of the 
normalized signal of two independent arrays containing pooled RNA from 2 
mice for each time point was calculated as an indication for the relative 
gene expression number at that time point. Genes whose mRNA levels 
were changed 2-fold or more were designated as differentially expressed 
genes. Differentially expressed genes were classified into functional 
categories based on the Panther (Protein ANalysis THrough Evolutionary 
Relationships) Classification System (Celera). 
 
 
9.2.4 Analysis of gene expression by real-time quantitative PCR 
 
Quantitative gene expression analysis on isolated liver parenchymal cells 
was performed as described [13]. In short, total RNA was isolated 
according to Chomczynski and Sacchi [12] and reverse transcribed using 
RevertAid™ reverse transcriptase. Gene expression analysis was 
performed using real-time SYBR Green technology (Eurogentec) with the 
primers displayed in Table 1. Hypoxanthine guanine phosphoribosyl 
transferase (HPRT), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), and acidic ribosomal phosphoprotein P0 (36B4) were used as 
the standard housekeeping genes. Relative gene expression numbers were 
calculated by subtracting the threshold cycle number (Ct) of the target gene 
from the average Ct of HPRT, GAPDH, and 36B4 (Cthousekeeping) and 
raising 2 to the power of this difference. The average Ct of three 
housekeeping genes was used to exclude that changes in the relative 
expression were caused by variations in the separate housekeeping gene 
expressions. 
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Table 1 
Primers for quantitative real-time PCR 
 GenBank 
Accession 
Forward primer Reverse primer Amplicon 
size 
36B4 NM007475 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 85 
ACAS2 NM019811 GCTGTCGCAGAGGCAGCT AAAGCAGTAGAGGCATTCGCC 66 
ACC XM109883 AGAATCTCCTGGTGACAATGCTTATT GCTCTGTGAGGATATTTAGCAGCTC 87 
ACLY NM134037 AGGTACCCTGGGTCCACATTC CTACGATCATCTTGACTCCTGGAGT 73 
FABP5 BC002008 GGAAGGAGAGCACGATAACAAGA GGTGGCATTGTTCATGACACA 73 
GADPH NM008084 TCCATGACAACTTTGGCATTG TCACGCCACAGCTTTCCA 103 
HPRT J00423 TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG 91 
L-PK NM013631 AAGACAGTGTGGGTGGACTACCA CGTCAATGTAGATGCGGCC 70 
ME NM008615 TTAAGGATCCACTGTACATCGGG GGCGTCATACTCAGGGCCT 62 
SCD1 NM009127 TACTACAAGCCCGGCCTCC CAGCAGTACCAGGGCACCA 65 
SREBP-1 AB017337 GACCTGGTGGTGGGCACTGA AAGCGGATGTAGTCGATGGC 74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. A) The effect of a Western type diet on serum free (○) and total (●) cholesterol 
levels in LDL receptor deficient mice. B) The effect of a Western type diet on the serum 
cholesterol distribution in LDL receptor deficient mice. Blood samples were drawn on a 
chow diet (○) and two weeks on a Western type diet (●). Sera from individual mice were loaded 
onto a Superose 6 column and fractions were collected. Fractions 3-7 represent VLDL; 
fractions 8-15, LDL; and fractions 15-19, HDL, respectively. 
 
 
 
9.3 Results 
 
 
9.3.1 Western type diet feeding induces an atherogenic serum 
lipoprotein profile 
 
Feeding LDL receptor deficient mice a Western type diet containing 0.25% 
cholesterol and 15% fat resulted in a significant rise in free and total serum 
cholesterol levels (Fig.1A). In addition, the Western type diet induced an 
atherogenic lipoprotein profile as compared to the chow diet, with significant 
increases in serum LDL and VLDL cholesterol levels (Fig.1B). 
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9.3.2 Western type diet feeding induces changes in liver parenchymal 
gene expression 
 
Liver parenchymal cells were isolated from LDL receptor deficient mice on a 
regular chow or Western type diet according to the method of Nagelkerke et 
al. [11]. Western type diet feeding had no effect on the viability or purity of 
the different cell fractions, since the parenchymal fractions consisted for 
>99% of parenchymal cells under both standard chow and Western type 
diet feeding conditions with a viability >95%. After isolation, parenchymal 
liver cell RNA was subjected to reverse transcription and second strand 
cDNA synthesis. Subsequently, using an IVT (amplification) reaction 
digoxigenin-labeled cRNA (chemiluminescent) was prepared, of which 10 
µg was hybridized to Mouse Genome Survey Arrays containing 32.996 
different spots consisting of 60-mer oligo’s. Subsequently, the 
chemiluminescent (cRNA) and fluorescent (spot backgound) signals were 
determined and the spot chemiluminescent signal was normalized over the 
fluorescent signal of the same spot to obtain the normalized signal value 
that was used for further analysis. In addition, a signal to noise ratio for 
every spot was obtained, which needed to be at least 1 at each time point in 
order to use the spot for further analysis. 
The gene expression levels of parenchymal cells isolated from mice fed the 
Western type diet were compared to that on chow diet. Only the genes 
whose mRNA levels were changed 2-fold or more were designated as 
differentially expressed genes. By these criteria, 244 genes were found to 
have significant changes in expression after two weeks of diet feeding; 158 
genes were upregulated whilst 86 were downregulated in parenchymal cells 
of mice fed the Western type diet as compared to mice on a chow diet. By 
analyzing the biological processes in which these genes play a role, it 
appeared that most of the regulated genes were associated with lipid, fatty 
acid, and steroid metabolism (Table 2). In total 41 genes were involved in 
lipid, fatty acid, and steroid metabolism; 11 genes were 2-fold or more 
downregulated (Table 3) after two weeks on the Western type diet, whilst 
30 genes were 2-fold or more upregulated (Table 4) as compared to the 
chow diet. The downregulated genes included members of the cytochrome 
P450 family, such as CYP4A14 (2-fold) and CYP7A1 (2-fold), enzymes 
involved in hepatic lipid metabolism i.e. fatty acid omega-oxidation [14] and 
the conversion of cholesterol to bile acids [15]. In addition, the expression of 
carnitine O-octanoyltransferase (Crot) and cytosolic acyl-CoA thioesterase 
1 (Cte1), enzymes involved in hepatic fatty acid [16] and acyl-CoA 
metabolism [17], respectively, was also decreased 2.3- and 2.6-fold, 
respectively. Furthermore, retinol binding protein 1 expression was 2.8-fold 
decreased by the Western type diet. The single known function of this 
protein in rodents is to transport retinol, a derivative from vitamin A, from 
hepatic stores to target tissues, where it plays an essential role in many 
biological functions [18]. 
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Table 2 
Number of genes differentially expressed in liver parenchymal cells on the Western type 
dieta 
Molecular function Number of genes 
Biological process unclassified 65 
Lipid, fatty acid and steroid metabolism 41 
Immunity and defense 30 
Signal transduction 30 
Nucleoside, nucleotide and nucleic acid metabolism 20 
Transport 19 
Developmental processes 19 
Carbohydrate metabolism 18 
Protein metabolism and modification 16 
Electron transport 12 
Other metabolism 10 
Cell structure and motility 10 
Sensory perception 9 
Cell cycle 8 
Sulfur metabolism 8 
Amino acid metabolism 6 
Oncogenesis 6 
Cell proliferation and differentiation 5 
Coenzyme and prosthetic group metabolism 3 
Apoptosis 3 
Intracellular protein traffic 3 
Cell adhesion 2 
Homeostasis 2 
Neuronal activities 2 
Phosphate metabolism 1 
a Genes designated as differentially expressed by the Western type diet were those for which 
the normalized signal was increased or decreased at least 2.0-fold after two weeks on the 
Western type diet. Classification of the differentially regulated genes by molecular function was 
based upon the Panther classification. 
 
 
Table 3 
Genes involved in lipid, fatty acid, and steroid metabolism that are downregulated in 
liver parenchymal cells on the Western type diet 
Celera Gene ID Gene name Fold 
mCG123382 unassigned; cytochrome P450 4A 0.28 
mCG6017 cytochrome P450, family 4, subfamily a, polypeptide 14;Cyp4a14 0.32 
mCG9784 retinol binding protein 1, cellular;Rbp1 0.35 
mCG141486 unassigned; cytochrome P450 4A 0.37 
mCG4926 cytosolic acyl-CoA thioesterase 1;Cte1 0.38 
mCG17029 unassigned; retinol dehydrogenase-related 0.40 
mCG5270 phospholipase A2, group XII;Pla2g12 0.44 
mCG1181 carnitine O-octanoyltransferase;Crot 0.44 
mCG131266 unassigned; L-carnitine dehydratase 0.46 
mCG4371 cytochrome P450, family 7, subfamily a, polypeptide 1;Cyp7a1 0.49 
mCG2997 unassigned; enoyl-CoA hydratase-related 0.50 
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Table 4 
Genes involved in lipid, fatty acid, and steroid metabolism that are upregulated in liver 
parenchymal cells on the Western type diet 
Celera Gene ID Gene name Fold 
mCG141926 glycerol phosphate dehydrogenase 2, mitochondrial;Gpd2 2.0 
mCG14176 mevalonate (diphospho) decarboxylase;Mvd 2.0 
mCG5402 lipin 2;Lpin2 2.2 
mCG145523 RIKEN cDNA 6330406P08 gene;6330406P08Rik; arylsulfatase 2.2 
mCG142632 unassigned; glycerol-3-phosphate acyltransferase 2.2 
mCG8819 unassigned; sterol regulatory element binding protein 1 (SREBP-1) 2.2 
mCG19918 hydroxysteroid dehydrogenase-6, delta<5>-3-beta;Hsd3b6 2.3 
mCG21999 cytochrome P450, family 17, subfamily a, polypeptide 1;Cyp17a1 2.3 
mCG17020 retinol dehydrogenase 6;Rdh6 2.3 
mCG21052 fatty acid binding protein 2, intestinal;Fabp2 2.4 
mCG17550 RIKEN cDNA 1110011E12 gene;1110011E12Rik; phosphomevalonate kinase 2.4 
mCG129300 unassigned; sialyltransferase 2.4 
mCG14909 phospholipase C, beta 3;Plcb3 2.5 
mCG14387 ELOVL family member 5, elongation of long chain fatty acids (yeast);Elovl5 2.7 
mCG10969 apolipoprotein A-IV;Apoa4 2.7 
mCG10998 ELOVL family member 2, elongation of long chain fatty acids (yeast);Elovl2 2.9 
mCG17532 phospholipid transfer protein;Pltp 4.0 
mCG141659 acetoacetyl-CoA synthetase;Aacs 5.3 
mCG141310 unassigned; acetyl-CoA carboxylase 5.5 
mCG21064 acetyl-Coenzyme A synthetase 2 (ADP forming);Acas2 5.9 
mCG18119 unassigned; glycerol-3-phosphate acyltransferase 6.7 
mCG131749 stearoyl-CoA desaturase 1;Scd1 7.4 
mCG3541 unassigned; acetyl-CoA carboxylase 8.6 
mCG125511 ELOVL family member 6, elongation of long chain fatty acids (yeast);Elovl6 8.6 
mCG9729 unassigned; fatty acid binding protein 14.3 
mCG7050 thyroid hormone responsive SPOT14 homolog (Rattus); Thrsp 16.5 
mCG22653 unassigned; fatty acid binding protein 16.5 
mCG5289 unassigned; fatty acid binding protein 16.6 
mCG22278 unassigned; fatty acid binding protein 19.3 
mCG1638 fatty acid binding protein 5, epidermal;Fabp5 22.3 
 
 
The genes associated with lipid, fatty acid, and steroid metabolism that 
were upregulated after two weeks of Western type diet included 
predominantly genes involved in lipid and fatty acid biosynthesis, 
metabolism, and transport. Strikingly, the most highly regulated genes (>10-
fold) included 4 members of the fatty acid binding protein family, such as 
epidermal fatty acid binding protein (E-FABP or FABP5). In addition, the 
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expression of Spot14 (S14), a protein involved in hepatic lipogenesis [19], 
was 16-fold higher in the parenchymal cells of mice on a Western type diet, 
while the acetyl-CoA carboxylase (ACC) and stearoyl-CoA desaturase 1 
(SCD1) genes were stimulated 5-fold by Western type diet feeding. ACC 
and SCD1 both play an important role in hepatic fatty lipogenesis, since 
they are key enzymes in the de novo production of malonyl-CoA (for fatty 
acid synthesis) [20], and oleate and palmitoleate [21], which are the major 
fatty acids found in triglycerides, cholesteryl esters, and phospholipids. The 
expression of a short-chain dehydrogenase that is expressed most 
intensely in liver and kidney, retinol dehydrogenase 6 (RDH6/CRAD1) [22], 
was 2.3-fold induced by the Western type diet as compared to chow diet. 
Interestingly, also the expression of two genes involved in HDL synthesis 
and metabolism were regulated upon Western type diet feeding. The 
expression of phospholipid transfer protein (PLTP) was upregulated 4.0-
fold, whilst apolipoprotein A-IV (ApoA-IV) expression was stimulated 2.7-
fold after two weeks of diet feeding as compared to control. PLTP is an 
important factor in the modulation of HDL lipid composition and size [23] 
and ApoA-IV levels influence the metabolism and anti-atherogenic 
properties of HDL [24]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2. Time dependent effect of a Western type diet on parenchymal liver cell expression 
of fatty acid binding protein 5, stearoyl-CoA dismutase 1, acetyl-CoA synthetase 2, and 
acetyl-CoA carboxylase as determined by microarray (○) and validated by real-time 
quantitative PCR (●). Values (n=2-4) are expressed as fold induction on the Western type diet 
as compared to the chow diet (0 weeks). 
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Fig.3. Time dependent effect of a Western type diet on parenchymal liver cell expression 
of key genes involved in glycolysis and fatty acid synthesis as determined by 
microarray (○) and validated by real-time quantitative PCR (●). Values (n=2-4) are 
expressed as fold induction on the Western type diet as compared to the chow diet (0 weeks). 
 
 
9.3.3 Quantitative evaluation of the effect of the Western type diet on 
lipogenic pathways 
 
Since the microarray indicated several genes associated with lipogenesis 
as most upregulated by the Western type diet, the effect of the Western 
type diet on pathways involved in lipogenesis was further examined. 
Changes in gene expression observed by DNA microarray analysis were 
confirmed with a selection of genes by real-time quantitative PCR (SYBR 
Green) technology, using the same (non-amplified) parenchymal cell RNA 
samples as used in the microarray hybridization (Fig.2). When gene 
expression profiles obtained by microarray analysis and real-time PCR 
were compared, their (time-dependent) patterns were very similar with 
regard to the direction (up- or downregulation) and degree of differences in 
expression. Strikingly, the expression of several enzymes needed for the 
biosynthesis of fatty acids (i.e. acetyl-CoA carboxylase, acetyl-CoA 
synthetase, stearoyl-CoA dismutase 1) was induced 4-fold or more in the 
first two weeks of feeding the Western type diet and subsequently stabilized 
at a relatively high level as compared to the control diet for 6 weeks. These 
data suggest that the lipogenesis rate was increased on the Western type 
diet. Accordingly, the expression of other key genes involved in the 
synthesis of fatty acids from glucose (i.e. pyruvate kinase, malic enzyme) 
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was upregulated by the Western type diet (Fig.3). Importantly, also the 
expression of a nuclear receptor that is a crucial factor in lipogenesis, sterol 
regulatory element binding protein 1 (SREBP-1), was increased after two 
weeks of Western type diet feeding and remained elevated in time (Fig.3). 
These combined data suggest that liver parenchymal cells stimulate the 
expression of genes involved in glycolysis and fatty acid synthesis to 
maintain their intracellular homeostasis in response to an increased dietary 
lipid level (Fig.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4. Schematic overview of the genes involved in glycolysis and fatty acid synthesis 
that are regulated by the Western type diet in parenchymal liver cells. Genes regulated by 
the Western type diet are boxed and the fold change in their expression on the Western type 
diet as compared to the chow diet is indicated. 
 
 
9.4 Discussion 
 
The purpose of the current study was to determine the effect of a Western 
type diet containing increased levels of cholesterol and fat on gene 
expression of liver parenchymal cells, which are the major player in hepatic 
metabolism, in an atherosclerotic mouse model. More specifically, the early 
(time-dependent) response of the parenchymal cells to the diet was studied 
using microarray technology. Most of the genes expressed differentially 
after two weeks of Western type diet were those involved in lipid, fatty acid, 
and steroid metabolism. 
It has been shown in an earlier study that LDL receptor deficient mice on a 
Western type diet rapidly become hyperinsulinemic, hyperglycemic, and 
obese compared with chow-fed mice [25]. Since parenchymal cells are 
important in maintaining glucose homeostasis, the huge increase in the 
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expression of genes involved in the metabolism of glucose to acetyl-CoA 
such as pyruvate kinase (>10-fold) in parenchymal cells can be seen as a 
protective action to maintain homeostasis. The observed decrease in the 
expression of enzymes involved in fatty acid oxidation in liver parenchymal 
cells, as judged by the decreased expression of CYP4A14, carnitine O-
octanoyltransferase and cytosolic acyl-CoA thioesterase, can also be seen 
as protective action of the liver to maintain homeostasis, since impaired 
hepatic fatty acid oxidation has been associated with decreased serum 
glucose levels due to reduced formation of ketone bodies, another source 
of energy for peripheral tissues [26]. Importantly, CYP4A14, carnitine O-
octanoyltransferase and cytosolic acyl-CoA thioesterase expressions are 
transcriptionally controlled by the nuclear receptor peroxisome proliferator-
activated receptor (PPAR) alpha [27-29]. The lowered expression of 
carnitine O-octanoyltransferase and cytosolic acyl-CoA thioesterase 
observed on the Western type diet therefore suggests that diet feeding 
results in an inhibition of PPARalpha activity. In agreement, the expression 
of two additional PPARalpha target genes, retinol binding protein (RBP) [30] 
and phospholipase A2 (PLA2) [31], was also decreased in the current 
study. Data from Horton et al. have indicated that PLA2-mediated release of 
arachidonic acid from membrane phospholipids contributes to cell injury 
and death [32]. The decreased PPARalpha-regulated PLA2 expression 
observed on the Western type diet might thus also be associated with an 
intracellular protective action of the parenchymal cells. Furthermore, data of 
Guerre-Millo et al. have suggested that hepatic PPARalpha plays a role in 
the development of insulin resistance in response to a Western type high-
fat diet, since PPARalpha-mediated fatty acid oxidation is efficiently coupled 
to hepatic glucose production (gluconeogenesis) and a subsequent rise in 
serum glucose levels [33]. In conclusion, our data suggest that the 
decrease in parenchymal liver cell PPARalpha activation in LDL receptor 
deficient mice on a Western type diet may be considered as a protective 
reaction against cell injury, insulin resistance, and diabetes. Data from 
several studies have implied that PPARalpha also regulates the 
transcription of fatty acid binding proteins [34,35]. However, in the current 
study we observed that PPARalpha activity was decreased, whilst the 
mRNA expression of FABP5 and 4 novel fatty acid binding protein 
transcripts was drastically (~20-fold) increased. Schachtrup et al. have 
recently shown that the PPAR response element in the promoter of FABP5 
is not functional, which suggests that the increase in the expression of 
FABP5 observed on the Western type diet was not due to a change in 
PPARalpha activation, but was likely due to the action of another upstream 
regulator [36]. 
A recent study by Ide et al. has shown that strong activation of the nuclear 
receptor liver X receptor (LXR) can interfere with PPARalpha mediated fatty 
acid degradation through competition for binding to their common 
heterodimeric partner, the retinoic X receptor (RXR) [37]. It is likely that the 
activity of LXR was stimulated in parenchymal liver cells on the Western 
type diet, since the expression of PLTP and ApoA-IV, two genes that in the 
liver are regulated by LXR [38,39], was upregulated by the diet. Strikingly, 
Schultz et al. imply that LXR, in addition to its role in cholesterol 
metabolism, plays a crucial role in lipogenesis control by the direct induction 
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of lipogenic gene expression via stimulation of SREBP-1 expression 
[40,41]. In agreement, the expression of SREBP-1 was stimulated by the 
Western type diet with a paralleled increase in the glycolytic and lipogenic 
enzymes L-type pyruvate kinase, Spot14, acetyl-CoA carboxylase, stearoyl-
CoA dismutase 1, acetyl-CoA synthetase, malic enzyme, and ATP-citrate 
lyase. Several studies have provided evidence that these genes are all 
upregulated by SREBP-1 [42,43]. Recently also a SREBP-1 binding site in 
the promoter of retinol dehydrogenase 6 (RDH6), an enzyme that 
transforms vitamin A (retinol) in its active metabolite all-trans retinoic acid, 
was identified by Chai et al. [22]. In accordance with the observed increase 
in SREBP-1 expression and activity, the expression of RDH6 was also 
increased 2.3-fold in the parenchymal cells. Interestingly, Maxwell et al. 
have identified FABP5 as a novel putative SREBP-1 target gene [5]. The 
~20-fold increase in FABP5 observed on the Western type diet may 
therefore be the result of the increased SREBP-1 expression/activity. Based 
upon these combined findings, it can thus be concluded that Western type 
diet feeding induces increased parenchymal liver cell LXR activation 
resulting in an increased glycolysis and lipogenesis via stimulation of 
SREBP-1 and a decreased fatty acid oxidation through inhibition of 
PPARalpha activity by LXR. Grefhorst et al. have also recently shown that 
stimulation of lipogenesis by pharmacological activation of LXR in C57BL/6 
mice leads to the production of large triglyceride-rich VLDL particles, which 
are efficiently cleared, resulting in unchanged serum triglyceride levels [44]. 
In contrast, in the current study Western type diet-induced LXR activation in 
LDL receptor deficient mice resulted in a significant rise in VLDL cholesterol 
levels due to an impaired clearance of VLDL via the LDL receptor uptake 
system. These combined findings indicate that LXR activation of 
lipogenesis indeed does result in increased VLDL particle production. 
Accordingly, disruption of the LDL receptor gene in transgenic SREBP-1 
mice results in the accumulation of these lipoproteins in the circulation, due 
to an increased synthesis and secretion and a blocked degradation via the 
LDL receptor [45]. 
Earlier studies by Recinos et al. [8] using microarray analysis of total liver 
RNA have indicated that feeding LDL receptor deficient or wild-type mice a 
high fat diet results in significant changes in the hepatic expression genes 
involved in cholesterol metabolism, but also in the expression of CD68 and 
CD63. These latter two proteins are not expressed in parenchymal cells, 
the main (metabolic) cell type of the liver, but in Kupffer and stellate cells 
[46,47], which makes it difficult to give a good interpretation of the exact 
effect on metabolic processes in the liver. In the current study, the effect of 
a Western type diet on the gene expression in one specific cell type of the 
liver was evaluated using microarrays, which gives a more clear-cut view on 
the specific biological process that are affected by the Western type diet. 
We therefore stress the importance of using an isolated single cell type for 
further studies using microarray analysis. 
In summary, in the present study, genes differentially expressed in liver 
parenchymal cells on a Western type diet were examined using microarray 
analysis and real-time PCR. The microarray data indicate that the Western 
type diet affects transcriptional programs involving lipid, fatty acid, and 
steroid metabolism such as glycolysis and lipogenesis. 
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In conclusion, we suggest that liver parenchymal cells in response to an 
increased dietary lipid level stimulate glycolysis and lipogenesis to maintain 
(intracellular) homeostasis. In addition, our studies suggest a very important 
role for SREBP and LXR transcription factors in the (initial) response of the 
parenchymal cells to the increased dietary lipid levels (Fig.5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5. Mechanistic overview of the Western type diet effect on pathways involved in 
glucose and lipid metabolism in isolated parenchymal liver cells. The Western type diet 
induces the activity of the nuclear receptor LXR in parenchymal liver cells. The increased LXR 
activation results in 1) an inhibition of the activity of the nuclear receptor PPARalpha leading to 
a subsequently decreased expression of genes involved in fatty acid oxidation, 2) an increased 
expression of the LXR target genes PLTP and ApoA-IV, and 3) an increased 
expression/activity of SREBP-1 resulting in stimulation of the expression of genes involved in 
glycolysis and lipogenesis. 
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Summary and Perspectives 
 
 
10.1 Summary 
 
High serum VLDL and LDL, and low serum HDL levels are important risk 
factors for the development of atherosclerosis, the main cause of 
cardiovascular diseases and thus death in the Western world [1,2]. 
Regulation of serum lipid levels is exerted by the liver since this organ is 
able to remove lipid from the blood circulation by mediating the uptake of 
lipoproteins [3,4]. In addition, the liver is responsible for the 
production/secretion of VLDL and HDL [5,6]. Inside the liver, control of intra-
hepatic cholesterol homeostasis is maintained by an appropriate balance 
between the regulatory free cholesterol and the more inert cholesterol ester 
pool and by secretion of cholesterol into bile and/or conversion into bile 
acids. In this thesis the modulation of hepatic gene expression in response 
to diet induced metabolic changes is studied. Furthermore, the specific role 
of the HDL receptor SR-BI in these responses is analysed. 
 
 
10.1.1 Multiple roles for hepatic SR-BI in metabolism 
 
The liver is able to remove HDL cholesterol via several different routes; the 
LDL receptor/LRP1 uptake system mediates whole particle uptake of ApoE-
enriched HDL [7] and more importantly SR-BI is able to mediate the 
selective uptake of HDL cholesterol esters into the liver without 
internalization and degradation of the HDL particle [8]. 
Since its discovery and cloning in 1994, SR-BI has been characterized as a 
multi-ligand receptor which plays an important role in the selective uptake of 
cholesterol esters from HDL. However, no quantitative data on the 
importance of HDL cholesterol ester uptake via SR-BI were available. In 
chapter 2 data are presented which indicate that absence of functional SR-
BI in mice results in a significant decrease in the clearance rate of HDL 
cholesterol esters from the circulation. In addition, we show that the uptake 
of cholesterol esters in the liver and adrenals is greatly affected (~90% 
decrease), with a total absence of selective uptake of cholesterol esters. 
We therefore conclude that SR-BI is the sole molecule involved in the 
selective uptake of cholesterol esters in the liver and adrenals from HDL. 
Interestingly, recent data from Out et al. [9] have suggested a role for SR-BI 
in the removal of ApoB-containing lipoproteins by mediating the initial 
association of remnants while the subsequent internalization occurs via 
other receptor systems such as the LDL receptor and LRP1. In chapter 3 it 
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is shown that hepatic overexpression of SR-BI results in decreased serum 
VLDL levels and a lower postprandial serum triglyceride response upon an 
intragastric fat load. These data establish that upregulation of SR-BI 
expression will lower the level of atherogenic chylomicron remnants. Type II 
diabetes is a disease with a heterogeneous phenotype, which is primarily 
characterized by an increase in serum glucose levels [10]. However, 
patients suffering from diabetes usually also have lipid abnormalities, such 
as hypertriglyceridemia. Interestingly, Osgood et al. have recently observed 
that there appears to be a significant interaction between variation at the 
SR-BI locus and type II diabetes in determining the lipoprotein profile [11]. 
Since SR-BI might thus play a role in the pathology of diabetes, in chapter 
4 the role of SR-BI in glucose metabolism was evaluated. Strikingly, SR-BI 
deficiency, due to a hampered hepatic uptake of lipoprotein-associated fatty 
acids, results in a decreased hepatic expression of HMG-CoA synthase, the 
rate-limiting enzyme in ketogenesis. The lower production of ketone bodies 
leads to a subsequent reduction in fasting serum glucose levels. In addition 
to its role in lipid metabolism, our data indicate that functional SR-BI is 
important for the maintenance of adequate fasting serum glucose levels. 
 
 
10.1.2 Nuclear receptors modulate hepatic lipid metabolism 
 
Diets enriched in lipid have been widely used to study the metabolic effect 
of changes in serum lipid levels on total body lipid metabolism and 
atherogenesis. Several orphan nuclear receptors have been suggested to 
play a role in the regulation of (hepatic) lipid metabolism. Recent data have 
indicated that a specific diet containing 0.25% cholesterol and 15% fat does 
induce atherogenesis in ApoE [12], SR-BI [13], and LDL receptor [12,14,15] 
deficient mice, but not in wild-type mice [13]. Since the liver plays an 
important role in lipid metabolism, in chapter 5 it was evaluated whether 
hepatic nuclear receptor-mediated regulation of gene expression plays a 
role in the absence of atherosclerotic lesion formation in wild-type mice. 
Feeding C57BL/6 mice the high cholesterol/high fat diet induces an 
increased hepatic activation of the nuclear receptors LXR and PPARalpha 
resulting in significant changes in the hepatic expression of genes involved 
in the maintenance of hepatic and total body lipid homeostasis, such as 
ABCA1 (HDL production), BSEP, CYP3A11, CYP7A1, SHP (bile acid 
synthesis and metabolism), HMG-CoA reductase and SREBP-1 (lipid 
synthesis), CD36, PPARgamma (adipogenesis), and SCD1 (VLDL 
production). The net result of these adaptive changes leads to a non-
atherogenic serum lipoprotein profile, thus preventing the development of 
atherosclerotic lesions in the vessel wall. 
In contrast, adding taurocholic acid, a naturally occurring bile acid that is 
able to activate FXR, to a regular chow diet results in a markedly increased 
atherosclerotic lesion formation in ApoE deficient mice, a well-established 
atherosclerosis mouse model (chapter 6). Recent data have suggested 
that therapeutic activation of FXR might be beneficial in treating or 
preventing cholesterol gallstone disease [16,17]. In agreement, in chapter 6 
it is shown that taurocholic acid does inhibit hepatic bile acid synthesis by 
decreasing CYP7A1 expression ~20-fold through stimulation of the 
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expression of nuclear receptor SHP. However, due to a subsequent rise in 
the intra-hepatic free cholesterol level, taurocholic acid treatment also 
resulted in a downregulation of the hepatic LDL receptor expression and a 
concomitant rise in the serum total cholesterol level of the pro-atherogenic 
lipoprotein VLDL leading to the enhanced atherosclerotic lesion 
development. In the light that FXR agonists are promising therapeutic 
agents for treating or preventing gallstone disease, the observed increase 
in atherosclerotic lesion formation can be considered as contraindication for 
pharmaceutical application. 
 
10.1.3 Cell-type specific expression and regulation of genes involved 
lipoprotein metabolism 
 
The liver consists of different cell types, which have their specific 
localization and functions. It is of interest to see whether differences in 
localization and/or functions are associated with differences in the 
expression of genes involved in lipid metabolism. In chapter 7 the relative 
gene expression of a set of genes involved in hepatic lipid metabolism was 
investigated in rat liver parenchymal, endothelial, and Kupffer cells (tissue 
macrophages). In agreement with their metabolic phenotype, parenchymal 
cells contain high expression levels compared with endothelial and Kupffer 
cells of genes involved in the uptake of cholesterol (SR-BI), the metabolism 
of cholesterol to bile acids (CYP7A1) and the direct efflux of cholesterol to 
bile (ABCG5/G8). Strikingly, under normal conditions, the expression of a 
novel gene that has been proposed to play a role in hepatic (parenchymal) 
biliary cholesterol efflux, ABCG1, is particularly high in liver endothelial and 
Kupffer cells as compared to parenchymal cells. In addition, the expression 
level of nuclear receptors (chapter 7) and their regulation (chapter 8) in the 
specific cell types of the liver is quite different. A relatively high expression 
of PPARalpha and PPARgamma is observed in parenchymal cells, whilst 
LXRalpha, LXRbeta, and PPARdelta are equally expressed in 
parenchymal, endothelial, and Kupffer cells. Furthermore, atherogenic diet 
induced lipid loading of parenchymal and Kupffer cells results in markedly 
different responses in the specific cell types. Lipid loading of parenchymal 
cells leads to moderate gene expression changes, while Kupffer cells 
respond highly adaptive by stimulating the expression of genes involved in 
(regulation of) cholesterol metabolism and transport. These findings stress 
that is very important to determine the expression and nuclear receptor-
mediated regulation of genes involved in lipid metabolism not only in 
complete liver, but also to attribute this regulatory effect to the specific cell 
types of the liver. In parallel, in chapter 9 the effect of a Western type diet 
on gene expression patterns specifically in the parenchymal cells was 
evaluated to gain insight into the response of parenchymal cells to a rise in 
dietary lipid levels. Microarray analysis data suggest that liver parenchymal 
cells in response to an increased dietary lipid level stimulate the expression 
of genes involved in glycolysis (pyruvate kinase) and lipogenesis (ACLY, 
ACC, ME, SCD1) to maintain (intracellular) homeostasis. In addition, based 
upon the gene expression profile, it is suggested that SREBP and LXR 
transcription factors play a very prominant role in the (initial) response of 
the parenchymal cells to the increased dietary lipid levels. 
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10.2 Perspectives 
 
In this thesis it has been shown that hepatic gene expression is highly 
adaptive and can lead to significant alterations in (hepatic) lipid metabolism. 
This knowledge can lead to novel approaches to treat lipid disorders such 
as atherosclerosis and consequently cardiovascular disease. In particular 
the role of nuclear receptors in the modulation of gene expression is of 
interest, since hepatic activation of LXR and PPARalpha may prevent 
atherosclerotic lesion formation, whilst hepatic FXR activation results in a 
stimulation of atherogenesis. Based on these findings, it can be suggested 
that development of drugs that stimulate the activity of LXR and PPARalpha 
might be beneficial in the treatment of atherosclerotic lesion formation. In 
this respect, it is very promising to see that co-administration of a LXR 
agonist and a PPARalpha agonist in mice reduces concentrations of 
circulating triglycerides while simultaneously raising HDL concentrations, 
generating a more anti-atherogenic lipoprotein profile [18]. However, 
treatment with synthetic LXR ligands also induces lipogenic enzymes such 
as SREBP-1 and fatty acid synthase resulting in increased hepatic 
triglyceride synthesis, hypertriglyceridmia, and hepatic steatosis, which can 
be considered as a contraindication for pharmaceutical application. 
Interestingly, the recent finding by Miao et al. [19] that tissue and gene 
selective modulation is possible with selective LXR modulators opens up 
the possibility that selective LXR modulators will only affect genes involved 
in HDL production (e.g. ABCA1), but not lipogenesis, which offers the 
potential of anti-atherogenic applications in combination with PPARalpha 
activators. 
Importantly, in addition to its role in hepatic lipid metabolism, activation of 
PPARalpha in the vessel wall has also been associated with local inhibition 
of the progression of atherosclerosis, since PPAR activators were shown to 
inhibit the activation of inflammatory response genes (such as IL-2, IL-6, IL-
8, TNF alpha and metalloproteases) by negatively interfering with the NF-
kappa B, STAT and AP-1 signalling pathways in cells of the vascular wall 
(reviewed by Fruchart et al. [20]). Furthermore, PPARalpha activation leads 
to inhibition of the expression of monocyte-recruiting proteins such as 
adhesion molecules [21], which are very important for the initiation of 
atherosclerosis. 
In conclusion, modulation of the activity of nuclear receptors in the liver 
might provide a new tool to treat lipid disorders and consequently the 
initiation and progression of atherosclerotic lesions. It will be interesting to 
see whether indeed gene selective nuclear receptor modulators can be 
developed, opening new approaches to treat cardiovascular disease. 
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Samenvatting voor niet-ingewijden 
 
Hart- en vaatziekten zijn doodsoorzaak nummer 1 in Nederland en andere 
westerse landen en de verwachting is dat in de nabije toekomst het aantal 
sterfgevallen door hart- en vaatziekten sterk zal toenemen doordat mensen 
gemiddeld genomen minder bewegen en ongezonder eten. Een belangrijke 
oorzaak van hart- en vaatziekten is de vernauwing van de bloedvaten door 
een verdikking van de wand van het bloedvat als gevolg van een 
plaatselijke ophoping van vetten (lipiden), ook wel bekend onder de term 
“atherosclerose”. 
 
Cholesterol, een van de belangrijkste vetten in het lichaam, is een 
component van celmembranen en een precursor voor de aanmaak van 
steroïdhormonen, regulatoren van fysiologische functies, en galzouten, die 
noodzakelijk zijn voor de galvorming en opname van vetten en 
vetoplosbare vitaminen in de darm. Cholesterol en andere vetten zijn niet 
oplosbaar in bloed en worden daarom door het lichaam vervoerd in 
bolvormige deeltjes, de lipoproteïnen. Afhankelijk van de grootte, 
samenstelling en dichtheid kunnen 4 verschillende soorten lipoproteïnen 
worden onderscheiden: chylomicronen, zeer lage dichtheids lipoproteïnen 
(VLDL), lage dichtheids lipoproteïnen (LDL), en hoge dichtheids 
lipoproteïnen (HDL). Een hoog VLDL en LDL cholesterolgehalte vormt een 
belangrijke risicofactor voor het ontstaan van hart- en vaatziekten, terwijl 
een hoog HDL cholesterolgehalte beschermt tegen hart- en vaatziekten. 
In het lichaam speelt de lever een belangrijke rol in de huishouding van 
cholesterol en andere vetten. Ten eerste maakt de lever lipoproteïnen zoals 
VLDL en HDL. Echter de lever kan ook lipoproteïnen (en dus vetten) uit het 
bloed kan verwijderen om ze vervolgens uit te scheiden in de gal door 
middel van diverse eiwitten, receptoren en enzymen. 
In dit proefschrift wordt de regulatie van receptoren en enzymen die van 
belang zijn voor de vethuishouding bestudeerd, aangezien meer inzicht in 
de regulatie kan leiden tot de ontwikkeling van geneesmiddelen die het 
vetmetabolisme optimaliseren. 
 
De lever verwijdert cholesterol uit het bloed via verschillende receptoren en 
routes. De LDL receptor en LRP1 zijn voornamelijk betrokken bij de 
opname van VLDL en LDL deeltjes, terwijl scavenger receptor BI (SR-BI) 
een belangrijke receptor is voor de selectieve verwijdering van cholesterol 
uit HDL zonder opname van het gehele deeltje. Eerdere studies hadden al 
aangetoond dat SR-BI een rol speelt in de selectieve opname van 
cholesterol uit HDL, maar de kwantitatieve bijdrage van SR-BI in dit proces 
was nog onbekend. In hoofdstuk 2 worden kwantitatieve data 
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gepresenteerd die aantonen dat SR-BI het enige molecuul is dat een rol 
speelt bij de selectieve opname van HDL’s cholesterol uit het bloed. Alleen 
de lever en bijnier tonen selectieve opname van cholesterol uit HDL, de 
twee organen waar het SR-BI eiwit onder normale condities in grote 
hoeveelheid aanwezig is. Muizen die het functionele SR-BI eiwit missen, 
zogenaamde SR-BI knockout muizen, laten een zeer verminderde opname 
van HDL cholesterol in de lever en bijnieren zien wat tevens leidt tot een 
sterk geremde verwijdering van HDL cholesterol uit het bloed. Recent is 
aangetoond dat SR-BI ook een rol speelt bij de opname van andere 
lipoproteïnen dan HDL, omdat de binding van VLDL en chylomicronen aan 
levercellen sterk is geremd in SR-BI knockout muizen. Hoofdstuk 3 
beschrijft proeven om deze gepostuleerde nieuwe functie van SR-BI te 
ondersteunen. De hoeveelheid SR-BI eiwit in de lever van muizen is met 
behulp van een SR-BI bevattend adenovirus (een verkoudheidsvirus dat 
eiwitten tot expressie kan brengen) sterk verhoogd, waardoor de opname 
van VLDL en chylomicronen sterk werd verhoogd. Dit impliceert dat SR-BI, 
naast zijn rol in HDL cholesterol opname, inderdaad ook een rol speelt in de 
verwijdering van VLDL and chylomicronen uit het bloed door de lever. 
Opmerkelijk genoeg hebben SR-BI knockout muizen onder gevaste 
condities een lagere bloed glucose spiegel dan muizen die het SR-BI eiwit 
wel hebben. In hoofdstuk 4 wordt aangetoond dat dit waarschijnlijk een 
gevolg is van de lagere opname door de lever van vetzuren 
(getransporteerd in lipoproteïnen). Het blijkt dus dat SR-BI niet alleen een 
rol speelt in de huishouding van vetten, maar dat dit ook consequenties 
heeft voor de glucosehuishouding. Verstoringen van de glucosehuishouding 
zijn geassocieerd met verschillende aandoeningen zoals diabetes (door te 
veel glucose in het bloed) en coma in kinderen na vasten (door te weinig 
glucose in het bloed). 
 
In muizen kan vaatvernauwing bij de mens soms worden nagebootst door 
muizen specifieke diëten te geven met een hoog cholesterol gehalte. 
Teneinde de dieet geïnduceerde veranderingen in genetische expressie te 
analyseren werd in hoofdstuk 5 bestudeerd wat het effect was van een 
cholesterol/vet rijk (westers) dieet op de aanwezigheid van receptoren en 
enzymen in de lever van muizen. Het Westerse dieet induceerde 
significante veranderingen in de activiteit van de transcriptiefactoren: liver X 
receptor (LXR) en peroxisome proliferator-activated receptor (PPAR) alpha, 
leidend tot veranderingen in de genactiviteit van genen betrokken bij HDL 
en VLDL aanmaak, galzuur synthese en transport, en vetophoping in de 
lever. Echter, de veranderingen in genexpressie in de lever zorgden ervoor 
dat in normale muizen de pro- en anti-atherosclerotische balans in de 
concentratie van de verschillende lipoproteïnen in het bloed onveranderd 
was, wat verklaart dat de normale muizen op het Westerse dieet in 
tegenstelling tot mensen geen atherosclerose ontwikkelen. Activatie van 
een andere transcriptiefactor, farnesoid X receptor (FXR), in de lever van 
een muis model dat wel atherosclerose ontwikkelt op het Westerse dieet 
(ApoE knockout muizen) leidde tot meer vorming van atherosclerose, 
hetgeen verklaard kan worden door een 50% daling van de LDL receptor in 
de lever, (hoofdstuk 6). Activatoren van FXR zijn recentelijk aangedragen 
als mogelijke geneesmiddelen tegen galstenen. De toename in de 
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hoeveelheid atherosclerose zoals geconstateerd in muizen, en dus mogelijk 
hart- en vaatziekten, biedt geen goed perspectief dat FXR activatoren 
toepassing kunnen vinden als geneesmiddelen ter behandeling/voorkoming 
van galstenen. 
 
De lever is een complex orgaan bestaande uit verschillende soorten cellen.  
Kupffercellen (macrofagen in de lever) en endotheelcellen beschermen de 
lever tegen schadelijke stoffen en bacteriën, terwijl de lever 
parenchymcellen de opname van cholesterol uit het bloed en de daaraan 
gekoppelde uitscheiding in de gal voor hun rekening nemen. Omdat de 
verschillende celtypen zulke specifieke functies hebben, is het goed 
mogelijk er tussen de cellen ook verschillen zijn wat betreft de activiteit van 
genen/eiwitten betrokken bij de vethuishouding. In hoofdstuk 7 is de 
genexpressie van genen betrokken bij de opname en verwerking van 
cholesterol tot galzuren in de verschillende celtypen onder normale 
condities bestudeerd. In overeenstemming met hun rol in de cholesterol 
huishuishouding bevatten parenchymcellen een hoge genexpressie van 
SR-BI, cholesterol 7α-hydroxylase (CYP7A1) en de ATP-binding cassette 
transporters G5 en G8 (ABCG5/G8). Deze eiwitten zijn betrokken bij de 
opname van cholesterol uit het bloed en de daarop volgende uitscheiding in 
de gal. Opvallend genoeg was de expressie van ABCG1, een eiwit waarvan 
met aannam dat het een rol speelt in het cholesterol metabolisme, relatief 
zeer hoog in de endotheel- en Kupffercellen in vergelijking met de 
parenchymcellen. Ook de aanwezigheid van transcriptiefactoren betrokken 
bij de regulatie van cholesterol huishouding (LXR, PPAR) was zeer 
verschillend tussen de diverse cellen onder normale condities. In 
hoofdstuk 8 wordt verder bewijs geleverd dat de verschillende celtypen in 
de lever specifieke functies vervullen in het cholesterol metabolisme. 
Parenchymcellen reageren met relatief kleine veranderingen in 
genexpressie wanneer muizen een hoog cholesterol dieet ondergaan, 
terwijl in Kupffercellen de aanwezigheid van meerdere genen betrokken bij 
de verwijdering van cholesterol uit de cellen (ABCA1, ABCG5/G8, en 
CYP7A1) sterk vermeerderd wordt. Teneinde een verklaring te vinden voor 
de beperkte response van de parenchymcellen is in hoofdstuk 9 het 
tijdsafhankelijke effect van een Westers dieet op de activiteit van genen in 
de lever parenchymcellen bepaald. Grootschalige genexpressie profielen 
(>30.000 genen) werden verkregen met behulp van zogenaamde 
microarray (gen-chip) arrays. Uit de analyses blijkt dat de aanwezigheid van 
eiwitten betrokken bij de afbraak van glucose (glycolyse) en de daaraan 
gekoppelde aanmaak van vet (lipogenese) sterk verhoogd was in 
parenchym cellen op het westerse dieet. Interessant genoeg bleek verder 
dat de initiële veranderingen door het dieet voornamelijk aangestuurd 
werden door de transcriptiefactoren LXR en SREBP. Het grote 
adaptatievermogen van de complexe metabole paden in de 
leverparenchymcel verklaart de relatief kleine veranderingen in 
genexpressie van specifieke genen op een hoog cholesterol dieet. 
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Perspectief 
 
In dit proefschrift is beschreven dat de lever zich zeer snel kan aanpassen 
aan veranderingen in haar omgeving door de expressie van bepaalde 
regulatoren te veranderen, leidend tot significante aanpassingen in de 
(lever) vethuishouding. Deze kennis kan goed van pas komen bij de 
zoektocht naar nieuwe behandelingsmethoden voor aandoeningen zoals 
atherosclerose en dus hart- en vaatziekten. Vooral de identificatie van de 
transcriptiefactoren LXR en PPARalpha als cruciale eiwitten in de regulatie 
van de vethuishouding is belangrijk. Recentelijk is al veel onderzoek 
gedaan naar de effecten van activatoren van de beide transcriptiefactoren 
LXR en PPARalpha op hart- en vaatziekten in muizen, omdat deze eiwitten 
een grote rol spelen in de vethuishouding door de lever en omdat PPAR 
activatoren ook plaatselijk de ontstekingsreactie in de vaatwand kunnen 
remmen. Uit deze studies is duidelijk geworden dat het belangrijk is om 
activatoren te ontwikkelen die lokaal de aanwezigheid van specifieke 
genen/eiwitten in de lever of in de vaatwand kunnen moduleren. Hierdoor 
kunnen nadelige bijeffecten (bv. een leververvetting) worden voorkomen. 
Het zal interessant zijn om te zien of daadwerkelijk lokaalwerkende gen-
selectieve activatoren kunnen worden ontwikkeld, als nieuwe effectieve 
therapieën voor de bestrijding van hart- en vaatziekten. 
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Abbreviations 
 
18SrRNA 18S ribosomal RNA 
36B4  Acidic ribosomal phosphoprotein P0 
ABC  ATP-binding cassette transporter 
Apo  Apolipoprotein 
BSEP  Bile salt efflux pump 
CETP  Cholesterol ester transfer protein 
CYP7A1 Cholesterol 7α-hydroxylase 
EC  Endothelial cell 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
HDL  High-density lipoprotein 
HMGCR HMG-CoA reductase 
HMGCS HMG-CoA synthase 
HPRT  Hypoxanthine-guanine phosphoribosyltransferase 
FXR  Farnesoid X receptor 
KC  Kupffer cell 
KO  Knockout 
LCAT  Lecithin:cholesterol acyltransferase 
LDL  Low-density lipoprotein 
LPL  Lipoprotein lipase 
LRP1  LDL receptor-related protein 
LXR  Liver X receptor 
MTP  Microsomal triglyceride transfer protein 
PC  Parenchymal cell 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
PPAR  Peroxisome proliferator-activated receptor 
PXR  Pregnane X receptor 
SHP  Small heterodimer partner 
SR-BI  Scavenger receptor class B type I 
SREBP  Sterol regulatory element binding protein 
VLDL  Very low-density lipoprotein 
WT  Wild-type
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